MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 1of 220 Template 14.1A Phase 1/2 Study  to Evaluate the Safety , Tolerability , and 
Pharmacokinetics of MEDI4736 in Subjects With A dvanced 
Solid T umors
Sponsor Protocol Number: Protocol  CD-ON-MEDI4736-1108
Application Number: BB-IND 112249
EudraCT 2012 -002206-
52
Investigational Product: MEDI4736
Sponsor: MedImmune, LLC, a wholly -owned subsi diary of AstraZeneca
PLC, One MedImmune Way , Gai thersburg, Maryland, 20878, 
USA
Primary Medical Monitor :
 
Sponsor Medical Monitor:  
Protocol History, Date Original  Protocol , 04Apr2012
Amendment 1, 11Jul2012
Amendment 2, 24Jul2012
Amendment 3, 12Jun2013
Amendment 4, 04Nov2013

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 2of 220 Template 14.1Administrative Change 1, 10 Jan2014
Amendment 4.1 ,Germany, 08May2014
Amendment 5, 21May 2014
Amendment 6, 18Jun2014
Administrative Change 2, 21Jul2014
Amendment 6, France, 30Jul2014
Amendment 6, United States, 11Sep2014
Administ rative Change 3, 06Oct2014
Amendment 7, 17Nov2014
Amendment 8, 25No v2015
Amendment 9, 04Feb 2016
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 3of 220 Template 14.1TABLE OF CONTENTS
1 INTRODUCTION .................................................................................................... 21
1.1 Disease Background ........................................................................................ 21
1.2 Descript ion of MEDI4736 ............................................................................... 24
1.2.1 Product Derivat ion.................................................................................. 24
1.2.2 Summary  of Nonclinical Experience ....................................................... 24
1.2.3 Summary  of Clinical Experi ence ............................................................. 26
1.3 Research Hypothesis ....................................................................................... 30
1.4 Rationale for Study  Conduct ........................................................................... 30
1.5 Benefit -risk and Ethical Assessment ................................................................ 31
2 STUDY OBJECTIVES ............................................................................................. 34
2.1 Primary Object ive........................................................................................... 34
2.2 Secondary  Object ives...................................................................................... 35
2.3 Exploratory  Objectives .................................................................................... 35
3 STUDY DESIGN ...................................................................................................... 35
3.1 Overview of Study  Design .............................................................................. 35
3.1.1 Dose Escal ation....................................................................................... 39
3.1.2 Dose Expl oration..................................................................................... 40
3.1.3 Dose Expansio n....................................................................................... 40
3.2 Estimated Duration of Subject Participat ion.................................................... 43
3.3 Study -stopping Cri teria................................................................................... 43
3.4 Rationale for Study  Design and Doses ............................................................. 44
4 STUDY PROCEDURES ........................................................................................... 50
4.1 Subject Participat ion and Ident ification ........................................................... 50
4.2 Subject Selection and Wit hdrawal ................................................................... 50
4.2.1 Inclusio n Cri teria..................................................................................... 51
4.2.2 Exclusio n Cri teria.................................................................................... 55
4.2.3Withdrawal Criteria ................................................................................. 57
4.2.4 Replacement of Subjects ......................................................................... 58
4.3 Treatment Assignment .................................................................................... 59
4.4 Blinding .......................................................................................................... 59
4.5 Study  Medicat ions.......................................................................................... 59
4.5.1 Invest igational Products .......................................................................... 59
4.5.1.1 Invest igational Product Preparation ........................................ 59
4.5.2 Other Study  Medicat ions......................................................................... 62
4.5.3 Treatment Regimen ................................................................................. 62
4.5.3.1 Dose Escal ation...................................................................... 62
4.5.3.2 Dose Expl oration................................................................... 65
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 4of 220 Template 14.14.5.3.3 Dose Expansio n..................................................................... 66
4.5.4 Treatment Administration ........................................................................ 67
4.5.5 Moni toring of Dose Administration ......................................................... 68
4.5.6 Dose Escal ation....................................................................................... 69
4.5.7 Dose -limit ing Toxi city............................................................................ 70
4.5.8 Dose Modificat ion for Toxi city Management .......................................... 71
4.5.9 Treatment Compliance ............................................................................ 72
4.6 Concomitant Medications ................................................................................ 72
4.6.1 Permi tted Concomitant Medications ........................................................ 72
4.6.2 Excluded Conco mitant Medi cations........................................................ 72
4.7 Subject Com pletion......................................................................................... 73
4.8 End of the Study ............................................................................................. 73
5 STUDY PROCEDURES ........................................................................................... 73
5.1 Schedule of Study  Procedures ......................................................................... 73
5.1.1 Screening………. .................................................................................... 89
5.1.2 Treatment Period ..................................................................................... 89
5.1.3 End of Treatment ..................................................................................... 89
5.1.4 Post-treatm ent Follow -up........................................................................ 89
5.2 Descript ion of Study Procedures ..................................................................... 89
5.2.1 Medical History  and Physical Examinat ion, Electrocardi ogram , 
Weight, and Vital Signs .......................................................... 89
5.2.2 Clinical Laboratory  Tests ........................................................................ 91
5.2.3 Pharmacokinet ic Evaluat ionand Methods ............................................... 92
5.2.4 Immunogenicit y Evaluat ion and Methods ................................................ 92
5.2.5 Biomarker Evaluat ion and Methods ......................................................... 92
5.2.6 Disease Evaluat ion and Methods ............................................................. 93
5.2.6.1 RECIST v 1.1 ......................................................................... 95
5.2.6.2 Revised RANO Criteria .......................................................... 98
5.2.7 Archival Tumor Samples and Tumor Biopsies ....................................... 100
5.2.7.1 Archival Tumor Samples ...................................................... 100
5.2.7.2 Tumor Bi opsies.................................................................... 101
5.2.8 Patient-reported Outcomes Assessments ................................................ 102
5.2.8.1 Pain Quest ionnaire ............................................................... 102
5.2.8.2 EORTC QLQ -C30 and Cancer -specific Modul es................. 102
5.2.8.3 FACT -BL............................................................................ 105
5.2.9 Estima te of Volume of Bl ood to be Collected ........................................ 106
6 ASSESSMENT OF SAFETY .................................................................................. 106
6.1 Safety Param eters .......................................................................................... 106
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 5of 220 Template 14.16.1.1 Adverse Events ..................................................................................... 106
6.1.2 Serious Adverse Events ......................................................................... 107
6.1.3 Other Events of Special Interest ............................................................. 108
6.1.3.1 Pneumo nitis......................................................................... 109
6.1.3.2 Hypersensi tivity Reacti ons................................................... 109
6.1.3.3 Hepati c Funct ion Abnormalit ies (Hepatotoxicit y)................. 109
6.2 Assessment of Safety  Parameters .................................................................. 110
6.2.1 Assessment of Severit y.......................................................................... 110
6.2.2 Assessment of Relat ionship................................................................... 111
6.2.2.1 Relationship to Invest igational Product ................................ 111
6.2.2.2 Relationship to Protocol Procedures ..................................... 112
6.3 Recording of Safet y Param eters ................................
.................................... 112
6.3.1 Recording of Adverse Events and Serious Adverse Events .................... 112
6.3.2 Recording of Other Events of Special Interest ....................................... 113
6.4 Reporting Requirements for Safet y Parameters ............................................. 113
6.4.1 Study  Reporting Period and Fo llow-up for Adverse Events ................... 113
6.4.2 Reporting of Serious Adverse Events .................................................... 113
6.4.2.1 Study  Reporting Period and Fo llow-up for Serious Adverse 
Events .................................................................... 113
6.4.2.2 Notifying the Sponsor of Serious Adverse Events ................ 114
6.4.2.3 Safety Reporting to Invest igators, Institutional Review 
Boards or Independent Ethics Co mmit tees, and 
Regulatory  Authori ties........................................... 115
6.4.3 Other Events Requiring Immediate Reporting ....................................... 115
6.4.3.1 Overdose .............................................................................. 115
6.4.3.2 Hepati c Funct ion Abnormalit y............................................. 116
6.4.3.3 Pregnancy ............................................................................ 116
6.4.3.4 Events Mee ting Study -stopping Cri teria............................... 117
6.5 Safety Management During the Study ........................................................... 117
7 STATISTICAL CONSIDER ATIONS ..................................................................... 118
7.1 General Considerations ................................................................................. 118
7.2 Analysis Populat ions..................................................................................... 118
7.3 Endpoints ...................................................................................................... 119
7.3.1 Primary Endpo ints................................................................................. 119
7.3.2 Secondary  Endpo ints............................................................................. 121
7.3.2.1 Pharmacokinet ics.................................................................121
7.3.2.2 Immunogenicit y................................................................... 122
7.3.2.3 Antitumor Activit y............................................................... 122
7.3.3 Exploratory  Endpo ints........................................................................... 123
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 6of 220 Template 14.17.4 Subgroup Analysis ........................................................................................ 124
7.5 Interim Analysis ............................................................................................ 124
7.6 Sample Si ze and Power Calculations ............................................................. 125
8 DIRECT ACCESS TO SOU RCE DOCUMENTS ................................................... 130
9 QUALITY CONTROL AND QUALITY ASSURANCE ........................................ 130
9.1 Data Collect ion............................................................................................. 130
9.2 Study  Moni toring .......................................................................................... 131
9.3 Audit and Inspecti on of  the Study .................................................................131
10 ETHICS .................................................................................................................. 132
10.1 Regulatory  Considerat ions............................................................................ 132
10.2 Institutional Review Board or Independent Ethics Committee ....................... 132
10.3 Inform ed Consent .......................................................................................... 133
10.4 Withdrawal o f Consent for Continued Study  Parti cipat ion............................. 134
11 DAT A HANDLING AND RE CORD KEEPING .................................................... 135
12 FINANCING AND INSURA NCE .......................................................................... 135
13 PUBLICATION POLICY ................................
....................................................... 135
14 REFERENCES ....................................................................................................... 136
15 SUMMARY OF PROTOCOL AMENDMENTS AND ADMIN ISTRATIVE 
CHANGES TO THE PROTOCOL .................................................................. 147
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 7of 220 Template 14.1LIST OF IN -TEXT TABL ES
Table 1. Number of Subjects Enrolled by Tumor Type in Dose -expansio n Cohorts ............. 14
Table 2. Probabilit y of Escalating for Different True Underlying Dose -limit ing Toxi city Rate 
at a Given Dose Level ....................................................................... 18
Table 3. ..................................................... 19
Table 4. ..................................................... 19
Table 5. .................................................................................. 20
Table 1.2.3 -1  
................................................................................... 29
Table1.5-1  
....................................... 33
Table 3.1-1 Number of Subjects Enrolled by Tumor Ty pe in Dose -expansio n 
Cohorts ............................................................................................. 38
Table 3.1.3 -1 NSCLC Dose -expansio n Cohort PD -L1 Expression Requirements ....41
Table 4.2.1 -1 Highly Effective Methods of Contraception (< 1% Failure Rate) ......55
Table 4.5.1.1 -1 Preparati on of  MEDI4736 Doses Less Than 1.0 mg/kg to Dose for 
Administrati on by Sy ringe................................................................ 60
Table 5.1-1 Schedule of Study  Procedures: Screening and Treatment Period ....... 75
Table 5.1-2 Q4W Schedule of Study  Procedures: Screening and Treatment 
Period............................................................................................... 83
Table 5.1-3 Schedule of Study  Procedures: Follow -up for Subjects Who Have 
Com pleted MEDI4736 Treatm ent and Achieved Disease Control 
(Until Confirmed Progressive Disease) and Subjects Who Have 
Discontinued MEDI4736 Due to Toxicit y in the Absence of 
Confirmed Prog ressive Disease ......................................................... 86
Table 5.2.6.1 -1 Evaluat ion of Overall Response ........................................................ 97
Table 7.6-1 Probabilit y of Escalat ion for Different True Underlying Dose -limiting 
Toxicit y Rate at a Given Dose Level ............................................... 126
Table 7.6-2 .............................. 126
Table 7.6-3 .............................. 127
Table 7.6-4 Estimated ORR and 95% CI in Squamous NSCLC Subjects with 
Tumoral PD-L1 Expression ............................................................ 128
Table 7.6-5 ........................................................... 129
LIST OF IN -TEXT FIGURES
Figure 3.1-1 Study  Flow Diagram ......................................................................... 37
Figure 4.5.3.1 -1 Dosing Schema for MEDI4736 Q2W Dose -escalatio n Cohorts ......... 63
Figure 4.5.3.1 -2 Dosing Schema for MEDI4736 Q3W Dose -escalatio n Cohorts ......... 65
Figure 4.5.3.2-1 Dosing Schema for MEDI4736 Q4W Dose -exploration Cohort ........ 66
Figure 4.5.3.3 -1 Dosing Schema for MEDI4736 Q2W Dose -expansio n Cohorts ......... 67

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 8of 220 Template 14.1LIST OF APPENDICES
Appendix 1 Signatures ....................................................................................... 170
Appendix 2 Pain Quest ionnaire .......................................................................... 172
Appendix 3 Patient-reported Outcome Quest ionnaire EORTC QLQ -C30........... 173
Appendix 4 Patient-reported Outcome Quest ionnaire EORTC QLQ -BR23 ........ 175
Appendix 5 Patient-reported Outcome Quest ionnaire EORTC QLQ -LC13 ........ 177
Appendix 6 Patient-reported Outcome Quest ionnaire EORTC QLQ -STO22 ......178
Appendix 7 Patient-reported Outcome Quest ionnaire EORTC QLQ -PAN26 .....179
Appendix 8 Patient-reported Outcome Quest ionnaire EORTC QLQ -HCC18 .....181
Appendix 9 Patient-reported Outcom e Quest ionnaire EORTC QLQ -H&N35 .....182
Appendix 10 Patient-reported Outcome Quest ionnaire EORTC QLQ -BN20 ........ 185
Appendix 11 Patient-reported Outcome Quest ionnaire EORTC QLQ -OV28 ........ 186
Appendix 12 Patient-reported Outcome Quest ionnaire FACT -BL........................ 188
Appendix 13 Schedule of Study  Procedures for Subjects in Retreatment of 
MEDI4736...................................................................................... 192
Appendix 14 Schedule of Study  Procedures in Fo llow-up for Subjects Who Have 
Discontinued MEDI4736 Treatment Due to Confirmed Progressive 
Disease ........................................................................................... 196
Appendix 15 ..................... 199

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 9of 220 Template 14.1List of A bbreviations
Abbreviation or 
Specialized TermDefinition
ADA anti-drug antibody
ADCC antibody -dependent cell -mediated cytotoxicity
AE adverse event
AESI adverse event of special interest
ALK anaplastic lymphoma kinase
ALT alanine aminotransferase
APC antigen presenting cells 
AST aspartate aminotransferase
BICR blinded independent central review
BoR best overall response
CD cluster of differentiation
CI confidence interval
Cmax maximum observed concentration
CNS central nervous system
CR complete response
CRC colorectal cancer
CRF case report form
CT computed tomography
CTC circulating tumor cells
CTCAE Common Terminology Criteria for Adverse Events
CTLA -4 cytotoxic T -lymphocy te antigen 4
cynoPD -L1 cynomolgus monkey programmed death ligand 1
DC disease control
DCR disease control rate
DCR -24w disease control rate at 24 weeks
DLT dose-limiting toxicity
DNA deoxyribonucleic acid
DR duration of response
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
EGFR epidermal growth factor receptor
EORTC QLQ -C30European Organisation for Research and Treatment of Cancer quality -of-life 
questionnaire
EU European Union
FACT -BL Functional Assessment of Chronic Illness Therapy -bladder
FACT -G Functional Assessment of Chronic Illness Therapy -general
FAS full analy sis set
Fc fragment crystallizable
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 10of 220 Template 14.1Abbreviation or 
Specialized TermDefinition
FFPE formalin fixed paraffin embedded
FLAIR fluid attenuated inversion recover y
FTIH first-time-in-human
GBM glioblastoma multiforme
GCP Good Clinical Practice 
GGT gamma glutamyl transferase
GLP Good Laboratory Practice
HCC hepatocellular carcinoma
HCV hepatitis C virus
HIPAA Health Insurance Portability and Accountability Act
HIV human immunodeficiency virus
hPD-L1 human programmed death ligand 1
HPV human papilloma virus
ICF informed consent form
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
IFN interferon
IgG1 immunoglobulin G1
IgG1κ immunoglobulin G1 kappa
IHC immunohistochemistry 
IL interleukin 
IM immunogenicity
irAE immune -related adverse event
IRB Institutio nal Review Board
irRC immune -related response criteria
IV intravenous(ly)
IVRS interactive voice response system
IWRS interactive web response system
MAb monoclonal antibody
MedDRA Medical Dictionary for Regulatory Activities
miRNA micro ribonucleic acid
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
MRSD maximum recommended starting dose
MSI microsatellite instability
MTD maximum tolerated dose
NCI Natio nal Cancer Institute
NK natural killer
NOAEL no-observed adverse -effect -level

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 11of 220 Template 14.1Abbreviation or 
Specialized TermDefinition
NSCLC non-small cell lung cancer
OBD optimal biological dose
OR objective response
ORR objective response rate
OS overall survival
PBMC peripheral blood mononuclear cell
PD progressive disease
PD-1 programmed death 1
PD-L1 programmed death ligand 1
PFS progression -free survival
PK pharmacokinetic
PR partial response
PRO patient -reported outcome
Q2W every 2 weeks
Q3W every 3 weeks
Q4W every 4 weeks
RANO Response Assessment in Neuro -oncology
RCC renal cell carcinoma
RECIST Response Evaluation Criteria in Solid Tumors 
RNA ribonucleic acid
SAE serious adverse event
SCCHN squamous cell carcinoma of the head and neck
SCLC small -cell lung cancer
SD stable disease
SID subject identification
sPD-L1 soluble programmed death ligand 1
SRT Safety Review Team
SUSAR suspected unexpected serious adverse reaction
TIL tumor -infiltrating lymphocyte
TKI tyrosine kinase inhibitor
TNBC triple negative breast cancer
TNF -α tumor necrosis factor alpha
UBC urothelial bladder cancer
ULN upper limit of normal
USA United States of America
US FDA United States Food and Drug Administration
WFI water for injection
w/v weight/volume
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 12of 220 Template 14.1Study  Abstract
TITLE
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With 
Advanced Solid Tumors
OBJECTIVES
Primary Objectives
Dose -escalation phase
The primary objective of the dose -escalation phase is to determine the maximum tolerated dose (MTD) or 
optimal biological dose (OBD), and the safety profile of MEDI4736 in subjects with advanced melanoma, 
renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) refractory to 
standard therapy or for which no standard therapy exists. 
Dose -exploratio n coho rt
The primary objective of the dose -exploration cohort is to determine the safety profile of MEDI4736 using an 
every 4 weeks (Q4W) dosing schedule in subjects with advanced cutaneous melanoma, uveal melanoma, 
hepatocellular carcinoma (HCC), squamous cell carcinoma of the head and neck (SCCHN), NSCLC 
squamous histology, NSCLC non -squamous histology, ga stroesophageal cancer, triple negative breast cancer 
(TNBC) and pancreatic adenocarcinoma.
Dose -expansio n phase
The primary objectives of the dose -expansio n phase are: 
1. To determine the safety profile of MEDI4736 in subjects with advanced cutaneous mela noma, uveal 
melanoma, HCC, SCCHN, NSCLC squamous histology, NSCLC non -squamous histology, 
gastroesophageal cancer, TNBC, pancreatic adenocarcinoma, urothelial bladder cancer (UBC), glioblastoma 
multiforme (GBM), ovarian cancer, soft tissue sarcoma, small -cell lung cancer (SCLC), microsatellite 
instability (MSI) -high cancers, human papilloma virus (HPV) -positive cancers, and nasopharyngeal 
carcinoma.
2. To evaluate the antitumor activity of MEDI4736 in subjects with non -squamous NSCLC who have received 
2 or more prio r lines of therapy and subjects with squamous NSCLC who have received 1 prior lines of 
therapy  and 2 or mo re prio r lines of therapy as assessed by Response Evaluation Criteria in Solid Tumors 
(RECIST) v1.1 guidelines .
3. To evaluate the antitumor activity of MEDI4736 in subjects with progr ammed death ligand 1 ( PD-L1)-
positive UBC as assessed by RECIST v1.1 .
Secondary Objectives
1. To describe the pharmacokinetics (PK) of MEDI4736.
2. To determine the immunogenicity (IM) of MEDI4736 .
3. To evaluate the antitumor activity of MEDI4736 (except for subgroups of UBC and NSCLC subjects where 
this is considered a primary objective )as assessed by RECIST v1.1 .
4. To evaluate the antitumor activity of MEDI4736 in subjects with UBC, regardless of PD -L1 status as 
assessed by RECIST v1.1 .
5. To evaluate the antitumor activity of MEDI4736 in subjects with PD -L1-negative UBC as assessed by 
RECIST v1.1 .
6. To evaluate the antitumor activity of MEDI4736 as assessed by RECIST v1.1 in subjects with PD -L1-
positive UBC a s compared to PD -L1-negative UBC .
Exploratory Objectives
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 13of 220 Template 14.1STUDY DESIGN 
This is a multicenter, open -label, first -time-in -human (FTIH) dose -escalatio n, dose -exploration, and 
dose-expansion study of MEDI4736 to evaluate the safety, tolerability, PK, IM, and antitumor activity of 
MEDI4637 in adult subjects with solid tumors. The dose -escalatio n phase will be conducted i n subjects with 
advanced melanoma, RCC, NSCLC, or CRC followed by a dose -expansion phase in subjects with advanced 
cutaneous melanoma, uveal melanoma, HCC, SCCHN, NSCLC squamous histology, NSCLC non -squamous 
histology, gastroesophageal cancer, TNBC, pancr eatic adenocarcinoma, UBC, GBM, ovarian cancer, soft 
tissue sarcoma, SCLC, MSI -high cancers, HPV -positive cancers, or nasopharyngeal carcinoma. In addition, a 
dose -exploratio n cohort will examine MEDI4736 at an alternative dosing schedule in subjects wit h advanced 
cutaneous melanoma, uveal melanoma, NSCLC, HCC, SCCHN, gastroesophageal cancer, TNBC, or 
pancreatic adenocarcinoma.
Dose Escalation
In the dose -escalatio n phase of the study, MEDI4736 will be administered every 2 weeks (Q2W), in sequential 
cohorts of 3 -6subjects each receiving one of 5 doses of MEDI4736 (0.1, 0.3, 1.0, 3.0,  or 10 mg/kg) via 
intravenous (IV) infusion. Dose escalation will be considered completed once an MTD or OBD is identified or 
the top dose of 10 mg/kg is reached. Provided the MTD is not exceeded at the 10 mg/kg dose level, additional 
cohorts of 3 -6 subjects using doses above 10 mg/kg of MEDI4736 Q2W may be explored based on emerging 
PK or pharmacodynamic data suggesting maximal suppression of soluble programmed death lig and 1 (sPD -
L1) is not being maintained throughout the dosing interval or T -cell activation has not plateaued, respectively. 
Intermediate doses may be evaluated at the discretion of the sponsor based on available data. A total of 
20subjects were enrolled i n the Q2W dose -escalation phase including 4 subjects in each of the 0.1 and 
0.3mg/kg cohorts, 3 subjects in each of the 1.0 and 3.0 mg/kg cohorts and 6 subjects in the 10 mg/kg cohort. 
The planned Q2W dose -escalation phase of the study is complete. 
Upon completion of dose escalation for the MEDI4736 Q2W dose -escalatio n arm, a separate dose -escalation 
arm of MEDI4736 administered ever y 3 weeks (Q3W) will be initiated. This arm will be conducted in parallel 
with the dose -expansion phase. The first cohort of 3-6 subjects will receive MEDI4736 Q3W at the highest 
dose level that has not exceeded the MTD or the OBD in the Q2W dose -escalatio n arm. MEDI4736 Q3W 
dose escalation may proceed with sequential cohorts of 3 -
6 subjects dependent upon acceptable safety, 
PK/pharmacodynamic, and clinical data . A total of 7 subjects have been enrolled in the 15 mg/kg Q3W 
dose-escalation arm and the planned Q3W dose -escalation phase of the study is complete.
Dose Exploration
Approximately 20 subjects with advanced cutaneous me lanoma, uveal melanoma, NSCLC, HCC, SCCHN, 
gastroesophageal cancer, TNBC or pancreatic adenocarcinoma are being enrolled into the dose -exploration 
cohort at select sites in the United States. MEDI4736 will be administered Q4W, at a dose of 20 mg/kg 
MEDI473 6 via IV infusion. 
Dose Expansion
The dose -expansio n phase of the study will be conducted following completion of dose escalation for the 
MEDI4736 Q2W dose -escalation arm and in parallel with the MEDI4736 Q3W dose -escalation arm. The 
10mg/kg dose adminis tered Q2W was chosen to take into expansion. A minimum of 20 subjects each with 
advanced cutaneous melanoma, uveal melanoma, HCC, gastroesophageal cancer, TNBC, UBC, SCCHN, 
GBM, ovarian cancer, soft tissue sarcoma, SCLC, MSI -high cancers, and HPV -positive cancers will be 
enrolled (Table 1). In addition, a minimum of 10 subjects with pancreatic adenocarcinoma or nasopharyngeal 
carcinoma will be enrolled. Additional subjects, up to a total of 60 subjects in any of these dose -expansio n 
cohorts may be enrolled if promising clinical activity is observed in that cohort. Approximately 110 -140 
subjects with non -squamous histology NSCLC will be enrolled including approximately 10 -30 subjects who 
are treatment naive, approximately 20 -30 subjects who have received 1 pr ior line of therapy, and 
approximately 80 subjects who have received at least 2 prior lines of therapy. Approximately 170 -190 subjects 
with squamous histology NSCLC will be enrolled including approximately 10 -30 subjects who are treatment -
naive, approximat ely 80 subjects who have received 1 prior line of therapy, and approximately 80 subjects 
who have received at least 2 prior lines of therapy. 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 14of 220 Template 14.1Table 1. Number of Subject sEnrolled by Tumor Type in Dose -expansion Cohorts
Tumor TypeTotal Planned 
Enrollm entSubjects Enrolled 
as of 20Nov 2015Planned Enrollment Under 
Amendment 8 and Beyond
Advance dcutaneous melanoma 20 21 0
Uveal melanoma 20-60 24 Up to 36
HCC 20-60 41 Up to 19
SCCHN 20-60 63 0
Squamous NSCLC (Total)
     1L
     2L
     ≥ 3L170-190
     10-30
     80
     
80151
29
51
70Up to 39
Non-squamous NSCLC (Total)
     1L
     2L
     ≥ 3L110-140
     10-30
     20-
30
     80143
30
34
790
Gastroesophageal 20-60 51 Up to 9
TNBC 20-60 40 Up to 20
Pancreatic adenocarcinoma 10-60 31 Up to 29
UBC (Total)
     Initial UBC subjects
     Amendment 8 and beyond
   PD-L1 positive
        PD-L1 negative
        Non-evaluable for PD -L120-192
20-60
132
≥ 70
50
1260
60
0
0
0
0Up to 132
0
Up to 132
≥ 70
50
12
GBM (Total)
     MGMT negative20-60
≥ 1020 Up to 40
Ovarian cancer (Total)
     Platinum sensitive20-60
≥ 1046 Up to 14
Soft tissue sarcoma 20-60 20 Up to 40
SCLC 20-60 21 Up to 39
MSI-high cancers 20-60 57 Up to 3
HPV -positive tumors (Total)
     Cervical cancer20-60
≤ 10 a22
10Up to 38
Nasophary ngeal carcinoma 10-60 10 Up to 50
Total 692-1,322 821 Up to 508
GBM = glioblastoma multiforme; HCC = hepatocellular carcinoma; HPV = human papilloma virus; 
L =line; MGMT = O6 -methy lguanine -deoxyribonucleic acid methyltransferase promoter methylation; MSI 
= microsatellite instability; NSCLC = non -small cell lung cancer; PD-L1 = programmed death ligand 1; 
SCCHN = squamous cell carcinoma of the head and neck; SCLC = smal l-cell lung cancer; TNBC = triple 
negative breast cancer ; UBC = urothelial bladder cancer .
aA maximum of 10 cervical cancer subjects will be enrolled out of the initial 20 subjects in the 
HPV -positive tumors cohort. If the cohort is expanded beyond 20 subje cts based on clinical activity, 
additional cervical cancer subjects may be enrolled.
An evaluation of a possible correlation between clinical activity of MEDI4736 and potential biomarkers (eg, 
PD-L1 expression on tumor or sPD -L1) will be ongoing throughout the study. Initially, tumoral PD -L1 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 15of 220 Template 14.1expression will be assessed on screening samples after enrollment on an ongoing basis. After the first 
20-40 subjects in the HCC, gastroesophageal cancer, TNBC, UBC, GBM, ovarian cancer, soft tissue sarcoma, 
SCLC, HPV -positive cancers, pancreatic adenocarcinoma, and nasopharyngeal carcinoma dose -
expansion 
cohorts are enrolled, additional subjects in the applicable cohorts may be required to have tumoral PD -L1 
expression as determined by prospective testing prio r to enrollment. 
Under previous amendments of this protocol, a minimum of 5 -10 subjects in the SCCHN dose expansion 
cohort were required to have tumoral PD -L1 expression. That requirement has been met and enrollment into 
the SCCHN cohort is complete. 
Under Amendment 7, all remaining subjects in the non -squamous NSCLC dose - expansion cohort were
required to have tumoral PD -L1 expression as determined by prospective testing prior to enrollment. In the 
squamous NSCLC dose -expansion cohort, a minimum of 10 sub jects in the first -line therapy cohort, and a 
minimum of 35 subjects in each of the second -line therapy and third -line o r greater therapy cohorts will be 
required to have tumoral PD -L1 expression as determined by prospective testing prior to enrollment.
Under Amendment 8 and beyond of this protocol, theUBC cohort will be expanded to evaluate the antitumor 
activity  of MEDI4736 in subjects with PD -L1-positive UBC and validate the potential of PD-L1 expression 
(determined by immunohistochemistry [IHC]) to pre dict response to MEDI4736 treatment. Approximately 
132additio nal UBC subjects will be enrolled in this cohort in order to include a minimum of 70 PD-L1-
positive subjects and 50 PD-
L1-negative subjects, and approximately 12 subjects with non -evaluable PD -L1 
status.  
 
 
 
To ensure that all of the additional UBC subjects contribute to the biomarker validation, subjects must hav e 
measurable disease at baseline by blinded independent central review (BICR). PD -L1 status will be 
determined by a central testing laboratory and will be derived from a fresh tumor biopsy taken during 
screening or an available tumor sample taken from ≤ 6months prior to study entry. The tumor sample (fresh 
and/or recent [within 6months prior to study entry ])used for PD -L1 analysis must be shipped to ,and 
confirmed as received by, the Sponsor or central vendor prior to the first dose of MEDI4736. It is highly 
recommended that efforts are taken to ensure presence of tumor cells within the tumor sample prior to 
shipping for PD -L1 analysis. The tumor PD -L1 status will be determined by IHC with PD -L1-positive 
samples defined as ≥ 25% tumor cell or immu ne cell staining and PD -L1-negative samples defined as < 25% 
tumor cell and immune cell staining. In cases where subjects have more than one tumor sample from 
≤ 6months prior to study entry available for testing, PD -L1 status will be derived from the most recent 
evaluable sample. PD -L1 status determined by IHC testing from tumor samples evaluated for screening into 
MedImmune Study D4190C00010 may be used if derived from a sample taken ≤ 6 mo nths prio r to study  
entry . Additional archival tumor tissue, from beyond 6 months prior to study entry is also required , if 
available .
All subjects will be evaluated regularly and their clinical status classified according to RECIST 
v1.1(
Eisenhauer et al, 2009 ) with modification except for subjects with GBM who will have their clinical 
status classified according to the Response Assessment in Neuro -oncology (RANO) guidelines ( Wen et al, 
2010). Modification of RECIST as described may discourage the early discontinuation of MEDI4736 and 
provide a more complete evaluation of its antitumor activity than would be seen with conventional response 
criteria. Nonetheless, the efficacy analysis will be conducted primarily based on RECIST v1.1. All subjects 
will be followed indefinitely for survival until the sponsor closes the study.

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 16of 220 Template 14.1SUBJECT POPULATION 
The subjects in this study will be adults 18 years of age or older. Subjects in the dose -escalation phase will 
have advanced melanoma, RCC, NSCLC, or CRC refractory to standard therapy or for which no standard 
therapy  exists. Subject s in the dose -expansion phase will have advanced cutaneous melanoma, uveal 
melanoma, HCC, SCCHN, NSCLC squamous histology, NSCLC non -squamous histology, gastroesophageal 
cancer, TNBC, pancreatic adenocarcinoma, UBC, GBM, ovarian cancer, soft tissue sarcoma , SCLC, 
MSI-high cancers, HPV -positive cancer, or nasopharyngeal carcinoma. Subjects in the dose -exploratio n 
cohort will have advanced cutaneous melanoma, uveal melanoma, HCC, SCCHN, NSCLC squamous 
histology, NSCLC non -squamous histology, gastroesophageal cancer, TNBC or pancreatic adenocarcinoma. If 
approved first -line standard therapy is available, subjects must have failed, be intolerant to, be ineligible for, 
or have refused treatment. 
TREATMENT REGIMEN
Subjects will be treated in either a dose -escalation or a dose -expansion phase of the study or a dose -
exploration cohort. 
Dose Escalation
Subjects enrolled in the Q2W dose -escalation arm will receive one of 5 doses of MEDI4736 (0.1, 0.3, 1.0, 3.0, 
or 10mg/kg) via IV infusion Q2W ± 3days. Provided the MTD is not exceeded at the 10 mg/kg dose level, 
additional cohorts of 3 -6 subjects using d oses above 10 mg/kg of MEDI4736 Q2W may be initiated based on 
PK or pharmacodynamic data suggesting maximal suppression of sPD -L1 is not being maintained throughout 
the dosing interval or T -cell activation has not plateaued, respectively. Intermediate dose s may  be evaluated at 
the discretion of the sponsor based on available data. 
Upon the completion of dose escalation for the Q2W dose -escalation arm, a separate dose -escalatio n arm of 
MEDI4736 administered Q3W will be initiated. This Q3W dose -escalation ar m will be carried out in parallel 
to the dose -expansio n phase. The first cohort of subjects will receive MEDI4736 Q3W ± 3 days at the highest 
dose level that does not exceed the MTD or the OBD in the Q2W dose -escalatio n arm. Higher doses of 
MEDI4736 may be explored based upon acceptable safety, PK/pharmacodynamic, and clinical data. 
Treatment in the Q2W or Q3W dose -escalation arm will continue for 12 months or until confirmed 
progressive disease (PD), initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of 
consent, or other reasons to discontinue treatment occur. In the event of confirmed PD, subjects may continue 
to receive MEDI4736 in the absence of clinical deterioration and if investigators consider that subjects 
continue to recei ve benefit from treatment. Subjects who have achieved and maintained disease control (DC; 
ie, complete response [CR], partial response [PR], or stable disease [SD]) or clinical benefit through to the end 
of the 12- month treatment period will enter follow -up. Upon evidence of PD during follow -up, subjects will 
be re -administered MEDI4736 at the dose previously received or at 10 mg/kg, the dose chosen for the 
expansion phase via IV infusion Q2W or Q3W as appropriate. Subjects may continue MEDI4736 retreatment
for up to 12 months with the same treatment guidelines followed during the initial 12 -month treatment period. 
Only one round of retreatment with MEDI4736 will be allowed. Subjects who have confirmed PD during the 
12-month initial treatment or retreatment period and cannot continue to receive MEDI4736 will enter follow -
up for 90- day safety  assessments and survival follow -up.
Dose Exploration
MEDI4736 will be administered Q4W, at a dose of 20 mg/kg MEDI4736 via IV infusion. Treatment in the 
dose exploration cohort will continue on a Q4W schedule for 12 months or until confirmed PD, initiation of 
alternative cancer therapy, unacceptable toxicity, withdrawal of consent or other reasons to discontinue 
treatment occur. In the event of confirmed PD, subjects may c ontinue to receive MEDI4736 in the absence of 
clinical deterioration and if investigators consider that subjects continue to receive benefit from treatment. 
Subjects who have achieved and maintained DC (ie, CR, PR, or SD) or clinical benefit through to the end of 
the 12 -month treatment period will enter follow -
up. Upon evidence of PD during follow -up, subjects will be 
re-administered MEDI4736 at 20 mg/kg via IV infusion Q4W. Subjects may continue MEDI4736 retreatment 
for up to 12 months with the same treatm ent guidelines followed during the initial 12 -month treatment period. 
Only one round of retreatment with MEDI4736 will be allowed. Subjects who have confirmed PD during the 
12-month Q4W initial treatment or retreatment period and cannot continue to receive MEDI4736 will enter 
follow -up for 90-
day safety  assessments and survival follow -up.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 17of 220 Template 14.1Dose Expansion
The dose -expansio n phase of the study will be conducted following completion of dose escalation for the 
MEDI4736 Q2W dose -escalation arm and in parallel wit h the MEDI4736 Q3W dose -escalation arm. Subjects 
will receive MEDI4736 Q2W via IV infusion at the MTD/OBD or the highest dose evaluated during Q2W 
dose escalation if no MTD or OBD is determined.
Treatment in the dose -expansion phase will continue on a Q2W schedule for 12 months or until confirmed 
PD, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent or other reasons to 
discontinue treatment occur. In the event of confirmed PD, subjects may continue to receive MEDI4736 in the 
absence of clinical deterioration and if investigators consider that subjects continue to receive benefit from 
treatment. Subjects who have achieved and maintained DC (ie, CR, PR, or SD) or clinical benefit through to 
the end of the 12- month treatment period will enter follow -up. Upon evidence of PD during follow -up, 
subjects will be re -administered MEDI4736 at the dose previously received via IV infusion Q2W. Subjects 
may continue MEDI4736 retreatment for up to 12 months with the same treatment guidel ines followed during 
the initial 12 -month treatment period. Only one round of retreatment with MEDI4736 will be allowed. 
Subjects who have confirmed PD during the 12 -month initial treatment or retreatment period and cannot 
continue to receive MEDI4736 will enter follow -up for 90 -day safety assessments and survival follow -up. 
ASSESSMENT OF ENDPOINTS
MTD or OBD : Endpoints related to the primary objective of determining MTD or OBD include evaluation of 
dose-limiting toxicities ( DLTs ), overall safety, and parameters related to the OBD. The MTD evaluation will 
be based on data from subjects who completed the DLT evaluation period. The OBD will be determined based 
upon analysis of all available subject data, including safety, PK, pharmacodynamic, biomarker, a nd response 
data.
Safety : Endpoints include assessments of adverse events (AEs), serious adverse events (SAEs), laboratory 
evaluations, vital signs, electrocardiograms (ECGs; digital and central read at selected sites), and physical 
examinations. 
Pharmaco kinetics : Individual MEDI4736 concentrations will be tabulated by dose cohort
Immunogenicity : The immunogenic potential of MEDI4736 will be assessed by summarizing the number and 
percentage of subjects who develop detectable anti -drug antibodies (ADAs). 
Antitumor activity : Assessments of antitumor activity will be based on the objective response rate (ORR), 
disease control rate (DCR), duration of response (DR), progression -free survival (PFS), and overall survival 
(OS). Response Evaluation Criteria in Soli d Tumors v1.1 guidelines will be used to determine tumor response 
and to guide treatment decisions. The primary endpoint of antitumor activity in the NSCLC and UBC cohorts 
is objective response (OR), which is defined as a best overall response (BoR )of CR or PRaccording to 
RECIST v1.1 as determined by BICR . BoR is defined as the best response (in the order of CR, PR, SD, PD, 
and not evaluable) among all overall responses recorded from the start of treatment until objective 
documentation of PD (per RECIST v 1.1 as assessed by BICR ), or the last evaluable disease assessment in the 
absence of PD prior to initiation of subsequent anticancer therapy or discontinuation from the study, 
whichever occurs first. The best overall response of CR or PR must be confirmed. The ORR is defined as the 
proportion of subjects with OR. The 95% confidence interval (CI) of ORR will be estimated using the exact 
probability method . 
The ORR (based on RECIST v1.1 by BICR) along with its 95% CI will be provided for all NSCLC subjects i n 
each line by histology and for the subpopulation in the ≥second -line squamous NSCLC subjects who have 
tumoral PD -L1 expression as determined by prospective testing prior to enrollment.
For UBC, the primary analysis of ORR based on RECIST v1.1 by BICR will be performed for all UBC 
subjects (second -or greater line of therapy ) in the PD -L1-positive full analysis set ( FAS) enrolled in the entire 
study. The FAS include all subjects who have been treated, have measurable disease at baseline per BICR, and 
have opportunity to be followed for at least 24 weeks. The primary  endpoint for UBC cohort in PD -L1-
positive subgroup is considered to be met if the lower -limit of the exact 2 -sided 95% CI for ORR excludes a 
historical response rate of 10% or less (Bellmunt et al, 2009 ). An analysis of ORR for all UBC subjects in the 
PD-L1-positive FAS enrolled under Amendment 8 and beyond will be conducted as a supportive analysis. 
If the primary endpoint for the PD -L1-positive subgroup of the UBC cohort is met, the ORR based on 
RECIST v1.1 by BICR along with its 95% CI will be also provided for all UBC subjects (second or greater 
lineof  therapy )in the FAS (regardless of PD -L1 status) enrolled in the entire study. The primary endpoint 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 18of 220 Template 14.1for UBC cohort in all -comers is cons idered to be met if the lower -limit of the exact 2 -sided 95% CI for ORR 
excludes a historical response rate of 10% or less (Bellmunt et al, 2009) . In addition, the ORR based on 
RECIST v1.1 by BICR along with its 95% CI will be provided for all UBC subjects (second -or greater line of 
therapy) in the PD -L1-negative FAS enrolled in the entire study and in the PD -L1-negative FAS enrolled 
under Amendment 8 and beyond .The primary analysis for UBC cohort will occur at least 24 weeks after the 
last PD -L1-positive UBC subject’s first dose of study treatment. The analyse s of ORR per BICR described 
above for the UBC cohort will be repeated for the UBC subjects (second -or greater lineoftherapy) in the PD -
L1-positive FAS, t he PD -L1-negative FAS ,and the FAS (regardless of PD -L1 status )enrolled in the entire 
study. 
INTERIM ANALYSIS
For the UBC cohort, the first interim analysis will be conducted after approximately 30 PD -L1-positive UBC 
subjects are enrolled and followed for at least 12 weeks. The efficacy analysis will be based on investigator 
RECIST data .
The second interim analysis for the UBC cohort will be conducted after a minimum of 60 PD -L1- positive 
second -or greater line UBC subjects are enrolled in the entire study and followed for at least 16 weeks. The 
primary  efficacy  analy sis population for this analysis will be bas ed on the treated PD -L1-positive UBC 
subjects (second -or greater line ) with measurable disease at baseline per BICR who have had an opportunity 
of being followed up for at least 16 weeks by the interim analysis. The analysis will be primarily based on 
RECIST v1.1 by BICR, and add itional analysis based on investigator RECIST data will be conducted as 
supportive.  
 
The enrollment will not be interrupted or 
terminated for efficacy based on the interim analysis.
SAMPLE SIZE AND POWER CALCULATIONS 
 
 
Dose -escalation phase: The number of subjects required will depend upon the toxicities observed as the study 
progresses. Up to approximately 50 evaluable subjects could be required if the separate Q3W dose escalation 
is implemented upon completion of dose escalation for the MEDI4736 Q2W dose -escalation arm. More 
subjects may be enrolled to investigate intermediate doses for MTD evaluation if DLTs are observed in either 
the 3.0 or 10 mg/kg dose cohort. In addition, more subjects may be enrolled if doses higher than 10 mg/kg 
Q2W are evaluated during dose escalation. Table 2 provides the probability of dose escalation to the next 
higher level for each underlying true DLT rate. For example, for a common toxicity that occurs in 10% of 
subjects, there is a greater than 90% probability of escalating to the next higher dose level. Conversely, for a 
toxicity that occurs at a rate of 60%, the probability of escalating to the next higher dose level is less than 
10%.
Table 2. Probability of Escalating for Different True Underlying Dose -limiting Toxicity Rate at a 
Given Dose Level
True underlying dose -
limiting toxicity rate10% 20% 30% 40% 50% 60% 70% 80% 90%
Probability of escalating dose 0.91 0.71 0.49 0.31 0.17 0.08 0.03 0.009 0.001
Dose -exploratio n coho rt: Approximately 20 subjects will be enrolled in the dose -exploration cohort of the 
study to determine the safety of 20 mg/kg Q4W dose schedule. 
 
Dose -expansio n phase: A minimum of approximately 692subjects will be enrolled in the dose -expansion 
phase as described below . Additio nal subjects, described in each cohort below, may be enrolled if promising 
clinical activity is observed in any of these cohorts.
•Advanced cutaneous melanoma, uveal melanoma, HCC, gastroesophageal cancer, TNBC, SCCHN, UBC
(initial cohort enrolled prior to Amendment 8) , GBM, ovarian cancer, soft tissue sarcoma, SCLC, 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 19of 220 Template 14.1MSI-high cancers, and HPV -positive cancers cohorts: A minimum of 20 subjects will be enrolled in each 
of these 13 disease cohorts. The sample size is chosen to obtain a preliminary assessment of antitumor 
activity  in terms of DCR for each disease cohort. The DCR will be estimated by the proportion of subjects 
with CR, PR, or SD ≥ 12 weeks in each disease cohort and i ts 80% CI will be estimated by the exact 
probability method
 
Table 3. 
 
 
•Pancreatic adenocarcinoma and nasopharyngeal carcinoma cohorts: A minimum of 10 subjects will be 
enrolled in each of these cohorts. The DCR will be estimated by the proportion of subjects with CR, PR, 
or SD ≥ 12 weeks in each cohort and its 80% CI will be estimated by the exact probability method  
. Additional su bjects, up to a total of 60 subjects in either of these 2 cohorts may be enrolled if 
promising clinical activity is observed in that cohort.
Table 4. 
 
 
control rate; PR = partial response; SD = stable disease.
•NSCLC: Preliminary data from the dose -escalation phase of this study as well as data from other 
antibodies targeting the PD1/PD -L1 pathway suggest that subjects with NSCLC may benefit from 
treatment with an agent such as ME DI4736. As a result, a minimum of approximately 110 subjects in the 
non-squamous histology NSCLC cohort and 170 subjects in the squamous histology NSCLC cohort will 
be enrolled from among specific subpopulations of NSCLC as outlined below. 
◦For the non-squamous NSCLC cohort, the enrollment will include approximately 10 subjects who are 
treatment -naïve, approximately 20 subjects who have received 1 prior line of therapy, and 
approximately 80 subjects who have received at least 2 prior lines of therapy . Additional subjects, up 
to 30 each for first -line and second -line therapy groups, may be enrolled. 
◦For the squamous NSCLC cohort, the enrollment will include approximately 10 subjects who are 
treatment -naïve, approximately 80 subjects who have received 1prior line of therapy, and 
approximately 80 subjects who have received at least 2 prior lines of therapy. Additional subjects, up 
to 30 for first -line therapy group, may be enrolled. 
◦The minimum sample sizes of 10 and 20 subjects were chosen to provide a preliminary assessment of 
the ORR for MEDI4736 as first -line therapy for both squamous and non -squamous NSCLC and 
second -line therapy for non -squamous NSCLC, respectively, similar to the aforementioned cohorts in 
other tumor types. 
◦The sample size of 80 subjects for MEDI4736 in ≥ third -line therapy in non -squamous NSCLC and 
as second -line therapy as well as ≥ third -line therapy for squamous NSCLC, respectively, was chosen 
to provide a formal statistical testing of the following hypothesis
H0: ORR ≤10% v s H 1: ORR > 10%

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 20of 220 Template 14.1 
•UBC: Under Amendment 7, approximately 60 UBC subjects were enrolled. Under Amendment 8 and 
beyond , approximately 1 32additional UBC subjects with inoperable or metast atic disease (second- or 
greater line) will be enrolled, which includes a minimum total of 70 PD -L1-positive and 50 PD -L1-
negative subjects, and approximately 12 subjects with tumor samples non -evaluable for PD -L1, assuming 
a PD -L1-positive prevalence of 60% and approximately 10% of subjec ts with tumor sample snot 
evaluable for PD -L1(based on preliminary data from the initial UBC cohort of this study).
Of 192UBC subjects enrolled in the study , it is expected that there will be approximately 100PD-
L1-positive 
subjects in the second -or greater line of treatment (approximately 30 enrolled under Amendment 7 and 
approximately 70 enrolled under Amendment 8 and beyond ). As shown in Table 5, when the ORR is expected 
to be in the 17% to 33% range (Plimack et al, 2015; Rosenberg et al, 2015), a total of 100 subjects wou ld 
provide a width of < 9% between the observed ORR and its lower limit of the exact 95% C  
Table 5. 
 
 
 
 
 
  
The prevalence of PD -L1 status for UBC subjects will be monitored through the study. After a total of 
approximately 1 32subjects are enrolled under Amendment 8 and beyond , the enrollment of only PD -L1-
positive subjects may continue to ensure a minimum total of 70 PD -L1-positive subjects are enrolled.
With 70 PD -L1-positive and 50 PD -L1-negative UBC subjects enrolled under Amendment 8 and beyond to 
validate the potential of PD -L1 expression to predict response to MEDI4736 treatment, 
 
The response ra te for the PD -L1-negative group is assumed to be similar to that 
observed with chemotherapy in a second-line UBC population ( Bellmunt et al, 2009 ).

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 21of 220 Template 14.11INTRODUCTION
1.1 Disease Background
Cancer continues to be a major global healt h burden. In the United States of America (USA), 
it is the second most commo n cause of death after heart disease, accounting for nearly one in 
every 4 deaths ( American Cancer Society , 2011 ). The 5- year survival rate for all cancers 
diagnose d between 1999 and 2006 is 68%, which is 18% higher than the rate reported 
between 1975 and 1977, likely reflect ing progress in diagnosing certain cancers earlier and 
improvements in treatment ( Amer ican Cancer Society , 2011 ). Unfortunately, despite 
indisputable progress in the treatment of cancer, there continues to be an unmet medical need 
for more effect ive and less toxic therapies, especially for those patients with advanced 
disease that do not respond or hav e beco me resistant to exist ing therapies.
Recent advances in the treatment of advanced melano ma using ipilimumab (YERVOY™) 
have led to improvements in overall survival (OS) in both the first -and second -line setting 
(Robert et al, 2011 ; Hodi  et al , 2010 ). Despi te these im provements, there rem ains a need for 
new therapies as only  a small proporti on of  melanom a pat ients attain durable responses and a 
survival benefit. In addit ion, treatm ent w ith ant i-cytotoxi c T-lymphocy te ant igen 4 (CTLA -4) 
antibodies has been shown to result in significant immune -related toxi city that coul d lead to 
serious com plicat ions if not properly  managed. The development of novel approaches to 
treatm ent m ay lead to imp roved outcom es in these popul ations.
The immune system is capable o f ident ifying tumor -associated antigens and eliminat ing the 
cancerous cells expressing them. This process of tumor immune surveillance plays an 
important rol e in prevent ing and combating th e growth of tumors. The process of immune 
surveillance is believed to result in a co- evolution of the tumor andimmune response termed 
immunoedi ting, which is thought to follow 3 stages ( Swann and Smyth, 2007 ). During th e 
initial phase of eliminat ion, the innate and adaptive immune systems detect and eliminate 
tumor cells. Eliminat ion can result in co mplete cl earance o f tumor cells as is seen in rare 
cases o f spontaneous regression of melano ma (Kalialis et al, 2009 ). However, if eliminat ion 
is incomplete, the immune system and tumor may enter a state of equilibrium. During this 
second phase of immunoedit ing, the immune response select ively eliminates susceptible 
tumor cells and may  prevent tum or progressi on. As the equilibrium phase persists, the tumor 
may evo lve mechanisms to avoid or attenuate the immune response. The emergence of tumor 
cells wit h reduced immunogenicit y (IM) or enhanced immunosuppressive mechanisms leads 
to the escape phase o f immunoedit ing. During escape, many factors may contribute to the 
failure of the immune system to control tumor growth including expressio n of T -cell 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 22of 220 Template 14.1inhibitory  molecules, downregulat ion of tum or antigens, and presence of immunosuppressive 
regul atory T cells or immunosuppressive cy tokines wi thin the tum or microenvironment.
Enhancing the immune response may  provide a m eans to regain control of tumors that have 
progressed to the escape phase during immunoediting. A number of mechanisms to stimulate 
the ant itumor immune response have been successfully emplo yed. Interleukin (IL) -2 and 
interferon (IFN) al pha have shown object ive response rates (ORRs) of 12% to 23% in renal 
cell carcino ma (RCC), with durable complete responses (CRs) and partial responses (PRs) 
insome patients ( Motzer et al, 2009 ; McDermott et al, 2005 ). High-dose IL -2 
hasalso ledtosurvival benefit, but only in subjects with durable CRs (6%) in melano ma 
(Atkins et al, 1999). Recently sipuleucel -T, an immunotherapy  consist ing of act ivated 
autol ogous anti gen-present ing cells, was granted United States Food and Drug 
Administrati on (US FDA) approval for treatment of metastatic hormone re fractory  prostate 
cancer ( Madan and Gulley, 2011 ). Blockade of negative regulatory  signals to T cells such as 
CTLA -4 and programmed death ligand 1 (PD-L1) has also shown promising clinical act ivity. 
Ipilimumab, which bi nds to CTLA -4 and prevents the interaction of CTLA -4 with cluster of 
different iation 80 (CD80) and CD86, results in enhanced T- cell act ivation and proliferat ion 
(Lipson and Drake, 2011 ). Ipilimumab was granted US FDA approval  in 2011 for the 
treatm ent of m etastati c melanom a and is current ly under invest igation for several other 
malignancies.
PD-L1 (B7- H1, CD274) is part of a complex system o f receptors and ligands that are 
involved in controlling T -cell act ivation. In normal tissue, PD -L1 is expressed on T cells, 
Bcells, dendrit ic cells, macrophages, mesenchymal stem cells, bone marrow -derived mast 
cells, as well as various nonhematopoiet ic cells ( Keir et al , 2008 ). Its norm al functionis to 
regul ate the balance between T -cell act ivation and tol erance through interaction with its 
2 receptors, programmed death 1 (PD- 1, CD279) and CD80 (B7 -1). PD -L1 is also expressed 
by tum ors and acts at m ultiple si tes to hel p tum ors evade detection and eliminat ion by the 
host immune system . In the lymph nodes, PD -L1 on antigen presenting cells (APC) binding 
to PD -1 (CD279) or CD80 (B7- 1) on activated T cells delivers an inhibitory  signal to the 
Tcell ( Keir et al , 2008 ;Park J et al, 2010 ). Likewise, binding of CD80 on APCs to PD -L1 on 
Tcells leads to inhibitory  signaling in the T cell. These and bidirect ional interact ions 
between CD80 and PD -L1, expressed on both APCs and T cells, lead to further inhibit ion of 
T-cell act ivation. These interact ions result in reduced T -cell act ivation and fewer activated 
Tcells inthe circulat ion. In the tumor microenvironment, PD -L1 expressed on tumor cells 
binds to PD -1 on activated T cells reaching th e tumor. Thi s delivers an inhibitory  signal to 
those T cells, preventing them fro m killing target tumor cells, and protecting the tumor from 
immune eliminat ion (Zou and Chen, 2008 ).
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 23of 220 Template 14.1PD-L1 is expressed in a broad range of c ancers with a high frequency, up to 88% in 
some types of  cancer. In a number of these cancers, including lung ( Mu et al , 2011 ), 
renal (Thompson et al , 2005 ; Thompson et al, 2006; Krambeck et al , 2007 ), pancreat ic
(Nomi et al, 2007 ; Loos et al, 2008 ; Wang et al, 2010), and ovarian ( Hamanishi et al, 2007 ), 
the expression o f PD-L1 is associated with reduced survival and unfavorable 
prognosi s.Inovari an cancer, for example, the 5 -year survival rate in pat ients with low 
levels ofPD-L1was 80.2%, compared to 52.6% in patients with high levels of PD -L1 
(Ham anishi et al , 2007 ). In l ung cancer, only  20% of  patients wi th tumors expressing 
PD-L1survived for more than 3 years, compared to 49% of patients with tumors lacking 
PD-L1 (Mu et al, 2011). Based on these data, and on assessments of expressio n of PD -L1 on 
the surface of human tumors using proprietary  immunohistochemistry  methods for 
assessment, MEDI4736 has the potential to affect mult iple ty pes of  solid tum ors, including 
those wi th a high inci dence rate and som e less commo n types wi th limited treatm ent opti ons 
and poor outcomes.
The l evels o f tumor-infiltrating lymphocy tes (TILs), and more specificall y cytotoxi c T cells, 
have been correlated to improved prognosis in a number of cancers including colorectal, 
melano ma, and lung ( Pages et al, 2010), suggesting that an ant itumor immune response is 
beneficial to patients. It has been shown in vitro that an antibody  that bl ocks the interacti on 
between PD -L1 and its receptors can relieve PD -L1-dependent immunosuppressive effects 
and enhance the cy totoxic activi ty of antitumor T cells ( Blank et al, 2006 ). Based on these 
findings, an ant i-PD-L1 ant ibody  coul d be used therapeutically to enhance ant itumor immune 
responses in pat ients with cancer. Results of several preclinical studies using mouse 
tumormodels support this hypothesis. In these studi es, antibodies directed against PD -L1, 
oritsreceptor PD -1, showed antitumor activit y (Hirano et al , 2005 ; Iwai et al , 2002 ; 
Okudai ra et al , 2009 ; Zhang et al, 2008).
Blocking PD -L1 is a similar approach to that taken by  ipilimumab, but has some potential 
advantages. First ly, the expressio n of CTLA -4 and i ts ligands i s restri cted to the 
hematopoiet ic system; thus the site of action for mol ecules targeting CTLA -4 is solely the 
peripheral  lymphoi d organs. In contrast, PD -L1 is expressed not only on cells o f the 
hematopoiet ic system but also on a range of tumor types. Targeting of PD -L1 coul d therefore 
have addit ionaleffects wi thin the tum or microenvironment. Secondly  CTLA -4 plays an early 
and crit ical role in controlling T -cell activation. This is reflected in the phenoty pe of CTLA -4 
knockout mice, which die at an age of between 3 and 4 weeks due to lymphoproliferat ive 
disease and tissue destruction. In contrast PD -L1, via binding to PD -1, acts later in the 
process of T -cell activation (Fife and Bluestone, 2008 ) and i s considered more dispensable 
for the con trol of initial T-cellactivation. This is reflected in the phenoty pe of PD -L1 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 24of 220 Template 14.1knockout mice, which are viable and have normal T -cell numbers and activation levels, but 
which have increased T -cell act ivation in response to antigen andincreased suscept ibilit y in 
certain autoimm unity models (Dong et al, 2004; Latchm an et al , 2004 ). Similarly, PD -1 
knockout mice show strain -specific phenoty pes milder than those seen in CTLA -4 knockouts 
(Nishimura et al , 1998 ; Nishimura and Honjo, 2001 ). Based on these data, inhibit ion of 
PD-L1 woul d be expected to have reduced toxicit y relative to inhibit ion of CTLA -4. In 
support of this, recent Phase 1 cl inical studies testing the tolerabilit y of agents targeting 
PD-1have shown a more favorable toxicit y profile than i pilimumab ( Brahmer et al, 2010 ; 
Berger et al 2008 ; Wolchok et al, 2010 ).
1.2 Description of MEDI4736
MEDI4736 is briefly described below. Refer to the current Invest igator’s Brochure for 
details.
1.2.1 Product Derivation
MEDI4736 is a human immunoglobulin G1 kappa (IgG1κ) monoclonal ant ibody  (MA b) 
directed against human PD -L1. MEDI4736 has an overall mo lecular weight of approximately 
149kDa, including N -linked oligosaccharides. The antibody is co mposed of 2 identical 
heavy chains o f approximately  49,670 Da each, and 2 i dentical light chains o f approximately  
23,390 Da each. The fragment crystallizable (Fc) domain o f MEDI4736 contains a triple 
mutati on in the constant domain of the immunoglobulin G1 ( IgG1 )heavy chain that reduces 
binding to the complement component C1q and the Fcγ receptors respon sible for m ediat ing 
antibody -dependent cell -mediated cy totoxi city (ADCC) ( Oganesyan et al, 2008 ). Subsequent 
to this tri ple m utation, the anticipated lack o f MEDI4736- mediated ADCC and 
complement -dependent cy totoxi city were confirmed using cell -based funct ional assays. 
MEDI4736 is select ive for recombinant PD -L1 and blocks the binding of recombinant PD -L1 
to the PD -1 and CD80 receptors.
1.2.2 Summary of Nonclinical Experience
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 25of 220 Template 14.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 26of 220 Template 14.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.3 Summary of Clinical Experience
 
 
 
 
 
 
, 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 27of 220 Template 14.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
 
 
 
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 28of 220 Template 14.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 29of 220 Template 14.1 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 30of 220 Template 14.1 
 
 
 
1.3 Research Hypothesis
The primary  object ives of this Phase 1/2, first-time-in-human ( FTIH) , dose -escalation and 
dose-expansio n study are t o determine the maximum tol erated dose ( MTD) or optimal 
biological  dose ( OBD ), and safety  profile of MEDI4736 in subjects with advanced solid 
malignancies and the antitumor activit y of subjects wi th NSCLC and UBC . Secondary  
objectives include evaluat ion ofthe PK, IM, and ant itumor activit y of MEDI4736. The 
exploratory  object ives are to evaluate bio markers that may correlate with act ivity or 
prospectively ident ify pat ients likely  to respond to MEDI4736 and to evaluate the effect of 
MEDI4736 on patient -repor ted outcom es (PROs).
The research hypothesis is that MEDI4736 will be adequately  tolerated fo llowing 
administration in ascending doses to subjects with refractory  solid tum ors and that such 
administration may result in clinical benefit.
1.4 Rationale for Study Conduct
Current ly available therapies for the advanced so lid malignancies included in this study  resul t 
in poor outcomes and there is a significant unmet medical need for addit ional treatm ent 
options in these patient populat ions. MEDI4736, an antibody  that blocks the interacti on 
between PD -L1 and its receptors, may relieve PD -L1-dependent immunosuppressive effects 
and enhance the cy totoxic activi ty of antitumor T cells. Given the preliminary clinical 
activit y observed in all tum or types in the dose -expansi on phase of this study , the recent ly 
available data fro m similar agents and the immunomodulatory  mechanism  of an ant i-PD-L1 
MAb, MEDI4736 may  offer benefi t to pati ents wi th a broad range of cancers. Rationale for 
the selection of specific tumor ty pes is pr ovided in Secti on 3.4.
This study  is intended to establish the MTD or OBD and the safet y profile of MEDI4736, as 
well as the preliminary  antitumor activit y in subgroups of NSCLC and UBC . Other data to be 
evaluated include the PK, pharmacodynamics, IM, antitumor activit yin addit ional tumor 
types, and potential bio markers, which may correlate with response to MEDI4736 treatment. 
Specifically , the dose -expansio n phase of this study will evaluate the antitumor activit y of 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 31of 220 Template 14.1MEDI4736 in several advanced so lid malignancies where historical outcomes are poor and 
scientific rationale suggests that treatment with an ant i-PD-L1 MAb m ay be beneficial. 
Potenti al biomarkers, including PD -L1 expressio n, will be evaluated on an ongo ing basis. 
The results from this study  will form  the basis for decisio ns applied to ongoi ng and future 
studi es.
1.5 Benefit-risk and Ethical Assessment
Subjects with advanced so lid tumors refra ctory  to standard treatm ent or for which no 
standard therapy  exists represent a patient population with unmet medical needs. MEDI4736, 
a human MAb directed against hPD -L1, m ay offer benefit to this patient populat ion. 
MEDI4736 has a high affinit y for hPD -L1 and i s able to com pletely bl ock the interacti on of  
recombinant hPD -L1 wi th both recombinant hPD -1 and recombinant human CD80 in a 
biochemical assay. In vitro, MEDI4736 enhances the proliferat ion and act ivation of primary  
human T cells cultured in the pre sence of recombinant PD -L1.
Nonclinical studies demonstrate that MEDI4736 inhibits tumor growth in mouse xenograft 
models. This act ivity is shown to be dependent upon the presence of human T cells, 
supporting the hypothesis that PD -L1 blockade can enhance antitumor immune response. No 
MEDI4736- associ ated ri sks have been reported in nonclinical safet y studi es in cyno molgus 
monkeys.
Promising evidence of clinical act ivity has been observed for molecules similar to 
MEDI4736, including other MAbs targeting the PD-1/PD -L1 pathway (Topalian et al , 2012 ; 
Hamid et al, 2013 ; Brahmer et al , 2012 ; Herbst et al, 201 3). In these studies, encouraging 
response rates and durable responses have been observed across a range of tumor ty pes. The 
experience to date with anti -PD-1/PD -L1 MAbs suggests that these agents can provide 
significant clinical activit y with a manageable safety  profile that i s superior to that of the 
anti-CTLA -4 class.
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 32of 220 Template 14.1 
 
 
 
 
Clinically significant risks of interest with MEDI4736 and related molecules include 
immune -mediated reactions and their associated signs and symptoms, risks due to IMand 
other potential risks. Immune -mediated reactions/ immune -related AEs ( irAEs), also 
considered to be AEs of special interest (AESIs), are important risks of immune checkpo int 
inhibitors, and are being closely monitored in clinical studies with MEDI4736 monotherapy  
and co mbinat ion therapy . 
Under previous versio ns of this protocol, inclusio n criteria requi red that subjec ts have a 
creatinine clearance of ≥ 50 mL/min. Under Amendment 9, UBC subjects will be permitted 
to enroll with a creat inine clearance of ≥ 30 m L/min. In the UBC populat ion, impaired renal 
funct ion is commo n due to age, urinary  tract obstructi on, sm oking -related vascular disease, 
or pri or treatm ents including nephrectomy , cystectomy , and pri or nephrotoxi c chem otherapy  
(ie,commo nly used pl atinum -based chemotherapy; Galsky et al, 2011). As such, lowering 
the creatinine clearance requirement for these subjec ts will allo w for eval uation of 
MEDI4736 in a broader UBC patient populat ion that m ay be more representative of a real 
world popul ation. Giv en that MEDI4736 is an IgG1 MAb, and MAbs are not expected to be 
cleared through renal mechanisms, it is anticipated that exposure will not be significant ly 
altered in subjec ts wi th impai red renal  function. This is supported by  popul ation PKanalysis 
of patients treated wi th MEDI4736, whi ch dem onstrated that creatinine clearance was not a 
significant covariate for drug clearance ( Song et al, 2015 ). 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 33of 220 Template 14.1 
 
 
In the overall study  popul ation, the most frequently reported MEDI4736 -related renal AESIs
of all grades were acute ki dney injury and blood creatinine increased (2subjects each; 0.2%).
In the UBC populat ion, MEDI4736- related renal AESIs were reported in 1 subject ( Grade 3 
acute kidney injury; 1.6%).
Table 1.5-1  
)
  
     
     
     
     
     
     
     
     
 
     
     
     
     
 
Given the available PK,clinical act ivity, and safety  data observed in UBC subjec ts treated 
with MEDI4736 and the limited treatment options after failure of st andard plat inum -based 
regimens, allowing subjec ts wi th creat inine clearance ≥ 30 mL/min to be treated with 
MEDI4736 is justified. 
In order to mit igate potential risks to patients, this study ha s incorporated toxicit y 
management guidelines developed for use across the broader MEDI4736 clinical 
development program. These guidelines are based on evidence and experience from ongo ing 
studi es of  MEDI4736 and similar immune -modulating agents and are fo cused on frequent 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 34of 220 Template 14.1monitoring for and early identificat ion of potenti al immune -mediated events . Management 
principles include interruption of dosing and/or treatment with corticosteroids or more potent 
immunosuppressive agents as needed. In addit ion, the st udy has incorporated eligibilit y 
criteria to ensure patients that may be at risk woul d not be included ( ie,by excluding those 
with prior autoimmune disease, inflammatory  bowel  disease, unreso lved toxicit ies from prior 
therapi es, or i nadequate hematologic or organ function). 
2STUDY OBJECTIVES
2.1 Primary Objective
Dose -escalation Phase
The primary  object ive of the dose -escalat ion phase is to determine the MTD or OBD, and the 
safet y profile of MEDI4736 in subjects with advanced melanoma, RCC, NSCLC, and 
colorectal  cancer ( CRC) refractory  to standard therapy  or for whi ch no standard therapy  
exists. 
Dose -exploration Cohort
The primary  object ive of the dose -exploration cohort is to determine the safet y profile of 
MEDI4736 using an every  4 weeks (Q4W) dosing schedule in subjects with advanced 
cutaneous melano ma, uveal melano ma, HCC, SCCHN, NSCLC squamous histology, 
NSCLC non -squamous histology , gastroesophageal cancer, TNBC or pancreatic 
adenocarcino ma.
Dose -expansion Phase
The primary  object ives of the dose -expansio n phase are: 
1.To determine the safet y profile of MEDI4736 in subjects with advanced cutaneous 
melano ma, uveal melano ma, HCC, SCCHN, NSCLC squamous histology, NSCLC 
non-squamous histology , gastroesophageal cancer, TNBC, pancreatic adenocarcinoma, 
UBC, GBM, ovarian cancer, soft tissue sarco ma, SCLC, MSI -high cancers, HPV -positive 
cancers, or nasopharyngeal carcino ma.
2.To evaluate the ant itumor activit y of MEDI4736 in subjects with non -squamous NSCLC 
who have received 2 or more prior lines of therapy an d subjects wi th squam ous NSCLC 
who have received 1 prior lines of therapy  and 2 or m ore pri or lines of therapy  as 
assessed by  RECIST v1.1. 
3.To evaluate the ant itumor activit y of MEDI4736 in subjects with PD
-L1-positive UBC as 
assessed by  RECIST v1.1.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 35of 220 Template 14.12.2 Seco ndary Objectives
The secondary  objectives of this study  are:
1. To describe the PK of MEDI4736.
2.To determine the immunogenicit y of MEDI4736 .
3.To evaluate the ant itumor activit y of MEDI4736 (except for subgroups of UBC and 
NSCLC subjects where this is considere d a primary  objective )as assessed by RECIST 
v1.1.
4.To evaluate the ant itumor activit y of MEDI4736 in subjects with UBC, regardless of 
PD-L1 status as assessed by RECIST v1.1 .
5.To evaluate the ant itumor activit y of MEDI4736 in subjects with PD- L1-negative UB C
as assessed by RECIST v1.1 .
6.To evaluate the ant itumor activit y of MEDI4736 as assessed by RECIST v1.1 in subjects 
with PD-L1-positive UBC as compared to PD -L1-negat ive UBC .
2.3 Exploratory Objectives
 
 
 
3STUDY DESIGN
3.1 Overview of Study Design
This is a mult icenter, open -label, FTIH dose -escalation, dose -exploration, and 
dose-expansio n study  of MEDI4736 to evaluate the safet y, tolerabili ty, PK, IM, and 
antitumor activit y of MEDI4637 in adult subjects with solid tumors. A dose -escalat ion phase 
in subjects wi th advanced melanom a, RCC, NSCLC, or CRC using a Q2W  (at doses up to 
10mg/kg) schedule has co mpleted enrollment without ident ificat ion of an MTD. In addition, 
a dose -escalat ion cohort using a Q3W schedule at a dose of 15 mg/kg has fully enrolled 
without identificat ion of an MTD. A dose -expansion phase us ing a dose and schedule of 
10mg/kg Q2W is current ly enrolling. A dose -explorati on cohort using an alternat ive dose 
and schedule of 20 mg/kg Q4W is ongoing at select si tesin the USA in parallel to the 
ongoing dose -expansio n cohorts. 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 36of 220 Template 14.1The dose -escalation phase will include subjects with advanced melanoma, RCC, NSCLC, or 
CRC fo llowed by  a dose -expansio n phase in subjects with advanced cutaneous melano ma, 
uveal melano ma, HCC, SCCHN, NSCLC squamo us histology , NSCLC non -squamous 
histol ogy, gastroesophageal can cer, TNBC, pancreati c adenocarcino ma, UBC, GBM, ovarian 
cancer, soft tissue sarco ma, SCLC, MSI -high cancers, HPV -posit ive cancers, or 
nasopharyngeal carcino ma. In addit ion, a dose -explorat ion cohort will include subjects with 
advanced cutaneous melano ma, u veal melano ma, HCC, SCCHN, NSCLC squamous 
histol ogy, NSCLC non -squamous histology , gastroesophageal cancer, TNBC or pancreatic 
adenocarcino ma. Therapeutic response criteria for these tumor ty pes are defined in 
Secti on4.2.1 . 
Up to approximately  1,392 subjects could be required for the dose -escalat ion (n = 50), 
dose-exploration (n = 20), and dose -expansio n (n = 692 – 1,322based on emerging safet y 
and clinical activit y data) phases o f the study . Subject swill be enro lledat approximately  
100sites globally . A study  flow diagram of the study  design is shown in Figure 3.1-
1.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 37of 220 Template 14.1Figure 3.1-1 Study Flow Diagram
CRC = colorectal cancer; HCC = hepatocellular carcinoma; MTD = maximum tolerated dose; NSCLC = non -
small cell lung cancer; OBD = optimal biological dose; PK = pharmacokinetic; Q 2W = every 2 weeks; Q3W = 
every 3weeks; Q4W = every 4 weeks; RCC = renal cell carcinoma; SCCHN = squamous cell carcinoma of the 
head and neck; TNBC = triple negative breast cancer.
A minimum of approximately 750subjects are to be enrolled in this study, including approximately 50subjects 
in the dose -escalation phase, 20 subjects in the Q4W dose -exploratio n cohort, and 692subjects in the dose -
expansion phase, with the possibility of enrolling more subjects in the expansion phase, if necessary, up to a 
maximum of 1,322subjects based on the emerging safety and clinical activity profile (total study 
populatio n =1,392).
The Q3W MEDI4736 dose -escalation arm, the Q4W dose -exploration cohort, and the MEDI4736 dose -
expansion phase will be conducted in parallel. 
aIf 2 or more dose -limiting toxicities are observed in the first cohort, the starting dose may be de -escalated 
to 0.05 mg/kg given Q3W. Provided the MTD is not exceeded at the 10 mg/kg dose level, higher doses 
may be further explored based on clinical, safety, and PK/pharmacodynamic data. Intermediate doses may 
also be explored at the discretion of the sponsor based on available data.
bThe first cohort of 3 -6 subjects will receive MEDI4736 at a dose equivalent to the highest dose level that 
has not exceeded the MTD or the OBD in the Q2W dose -escalation arm. Dose escalation may proceed with 
sequential cohorts of 3 -6 subjec ts dependent upon acceptable safety, PK/pharmacodynamic, and clinical 
data.
MEDI4736 Dose -escalation Arm, Q2W Dosing a
(Melanoma, RCC, NSCLC, and CRC tumors)
Cohort 1 Q2W 0.1 mg/kg (n = 4)
Cohort 2 Q2W 0.3 mg/kg (n = 4)
Cohort 3 Q2W 1
.0mg/kg (n = 3)
Cohort 4 Q2W 3.0mg/kg (n = 3)
Cohort 5 Q2W 10 mg/kg (n = 6)
MEDI4736 Dose -escalation Arm, Q3W 
Dosing b
(Melanoma, RCC, NSCLC, and CRC 
tumors)
Q3W Cohort 15 mg/kg MEDI4736
(n= 7)
MTD/OBD Identified
MEDI4736 Dose -expansion Arms, Q2W Dosing
See Table 3.1-1for tumor type details
MEDI4736 Dose -exploration Arm, 
Q4W Dosing 
(Melanoma, pancreatic, HCC, SCCHN, 
NSCLC, gastroesophageal, and TNBC 
tumors)
Q4W Cohort 20 mg/kg MEDI4736
(n = 20)
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 38of 220 Template 14.1Table 3.1-1 Number of Subject sEnrolled by Tumor Type in Dose -
expansion Cohorts
Tumor TypeTotal 
Planned 
EnrollmentSubjects Enrolle d 
as of 20Nov2015Planned Enrollment Under 
Amendment 8 and Beyond
Advance dcutaneous melanoma 20 21 0
Uveal melanoma 20-60 24 Up to 36
HCC 20-60 41 Up to 19
SCCHN 20-60 63 0
Squamous NSCLC (Total)
     1L
     2L
     ≥ 3L170-190
     10-
30
     80
     
80151
29
51
70Up to 39
Non-squamous NSCLC (Total)
     1L
     2L
     ≥ 3L110-140
     10-
30
     20-
30
     80143
30
34
790
Gastroesophageal 20-60 51 Up to 9
TNBC 20-60 40 Up to 20
Pancreatic adenocarcinoma 10-60 31 Up to 29
UBC (Total)
     Initial UBC subjects
     Amendment 8 and beyond
        PD-L1 positive
        PD-L1 negative
        Non-evaluable for PD -L120-192
20-60
132
≥ 70
50
1260
60
0
0
0
0Up to 132
0
Up to 132
≥ 70
50
12
GBM (Total)
     MGMT negative20-60
     ≥ 1020 Up to 40
Ovarian cancer (Total)
     Platinum sensitive20-60
     ≥ 1046 Up to 14
Soft tissue sarcoma 20-60 20 Up to 40
SCLC 20-60 21 Up to 39
MSI-high cancers 20-60 57 Up to 3
HPV -positive tumors (Total)
     Cervical cancer20-60
     ≤ 10 a22
10Up to 38
Nasophary ngeal carcinoma 10-60 10 Up to 50
Total 692-1,322 821 Up to 508
GBM = glioblastoma multiforme; HCC = hepatocellular carcinoma; HPV = human papilloma virus; L = line; 
MGMT = O6 -methy lguanine -deoxyribonucleic acid methyltransferase promoter methylation; MSI = 
microsatellite instability; NSCLC = non -small cell lung cancer; PD-L1 = programmed death ligand 1; 
SCCHN = squamous cell carc inoma of the head and neck; SCLC = small -cell lung cancer; TNBC = triple 
negative breast cancer ; UBC = urothelial bladder cancer .
aA maximum of 10 cervical cancer subjects will be enrolled out of the initial 20 subjects in the HPV -
positive tumors cohort. If the cohort is expanded beyond 20 subjects based on clinical activity, additional 
cervical cancer subjects may be enrolled.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 39of 220 Template 14.13.1.1 Dose Escalation
MEDI4736 Dose -escalation Arm, Q2W Dosing
In the dose -escalat ion phase of the study , MEDI4736 will be administered Q2W, in 
sequent ial cohorts of 3 -6subjects each receiving one of 5 doses of MEDI4736 (0.1, 0.3, 1.0, 
3.0, or 10 mg/kg) via intravenous ( IV)infusio n. Dose escalat ion will be considered 
completed once an MTD or OBD is ident ified or the top dose of 10 mg/kg is reached. 
Provi ded the MTD is not exceeded at the 10 mg/kg dose level, addit ional cohorts of 3 -6 
subjects using doses above 10 mg/kg of MEDI4736 Q2W may be explored based on 
emerging PK or pharm acodynamic data suggesting maximal suppressio n of sPD -L1 is not 
being maintained throughout the dosing interval or T- cell activation has not plateaued, 
respectively . The first cohort will enroll a minimum of 3 subjects, according to a standard 
3+3design. Subjects in the first cohort will receive a dose of 0.1 mg/kg MED4736. The first 
IV infusio n for subjects in this cohort will be 4 hours in durat ion; subsequent infusions for 
subjects in this cohort and all infusio ns for the remaining cohorts will be approximately  
60minutes in duration. Subsequent cohorts will re ceive 0.3, 1.0, 3.0, or 10 mg/kg IV Q2W 
unless an MTD or OBD is ident ified before all dose -escalat ion cohorts are completed. 
Provi ded the MTD is not exceeded at the 10 mg/kg dose level, higher doses may be further 
explored based on clinical, safet y, and PK /pharmacodynamic data generated from the study . 
Interm ediate doses m ay be evaluated atthe discretion of the sponsor based on available data. 
If ≥ 2 DLTs, as defined in Sect ion 4.5.7 , are observed in the first dose cohort, the starting 
dose will be de -escalated to half o f the previous dose given (0.05 mg/kg) and will be 
administered Q3W. Refer to Section 4.5.6 for detailed dose -escalat ion procedures. A total of 
20 subjects have been enro lled in the Q2W dose -escal ation phase of the study , including 
4subjects in each of the 0.1 and 0.3 mg/kg cohor ts, 3 subjects in each of the 1.0 and 3.0 
mg/kg cohorts and 6 subjects in the 10 mg/kg cohort. The planned Q2W dose -escalation 
phase of the study  is complete.
MEDI4736 Dose -escalation Arm, Q3W Dosing 
Upon com pletion of dose escalat ion for the MEDI4736 Q2W dose-escalation arm, a separate 
dose-escalat ion arm  of MEDI4736 administered Q3W will be init iated. Thi s arm  will be 
conducted in parallel wit h the dose -expansio n phase (see below for descript ion of dose 
expansio n). The first cohort of 3 -6subjects will r eceive MEDI4736 via IV infusio n Q3W at 
the highest dose level that has not exceeded the MTD or the OBD in the Q2W 
dose-escalat ion arm . MEDI4736 Q3W dose escalation may proceed with addit ional cohorts 
of 3-6 subjects dependent upon acceptable safet y, PK/pha rmacodynamic, and clinical data 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 40of 220 Template 14.1according to the dose -escalat ion procedures described in Sect ion 4.5.6 .A total of 7 subjects 
have been enrolled in the 15 m g/kg Q3W dose -escal ation arm  and the pl anned Q3W dose -
escalat ion phase of the study  is com plete.
3.1.2 Dose Exploration 
A total o f approximately  20 subjects wi th advanced cutaneous m elano ma, uveal melano ma, 
pancreat ic adenocarcino ma, NSCLC squamous hist ology , NSCLC non -squam ous histol ogy 
HCC, SCCHN, gastroesophageal cancer, or TNBC are being enrolled into the dose -
explorat ion cohort at select sites in the United States. MEDI4736 will be administered Q4W, 
at a dose of 20 mg/kg MEDI4736 via IV infusio n. 
3.1.3 Dose Expansion
The dose -expansio n phase of the study  will be conducted following complet ion of dose 
escalat ion for the MEDI4736 Q2W dose -escalat ion arm  and in parallel wit h the MEDI4736 
Q3W dose -escalat ion arm . The 10 m g/kg dose administered Q2W was chosen to take into 
expansio n. 
A minimum of 20 subjects each wit h advanced cutaneous melano ma, uveal melano ma, HCC, 
SCCHN, gastroesophageal cancer, TNBC, UBC, GBM, ovarian cancer, soft tissue sarco ma, 
SCLC, MSI -high cancers, and HPV -positive cancers will be enrolled into tum or-specific 
expansio n cohorts . In addition, a minimum o f 10 subjects each with pancreat ic 
adenocarcino ma or nasopharyngeal carcino ma will be enro lled. No more than 10 subjects 
with cervical  cancer will  be enrolled out of the 20 subjects in the HPV -positive cancers 
dose-expansio n cohort. A minimum of 10 subjects without O6-methylguanine -deoxynucleic 
acid (DNA) m ethyl transferase prom oter methylat ion will be enrolled in the GBM cohort. 
Similarly, a minimum of 10 subjects with plat inum sensit ivity will be enrolled in the ovarian 
cancer cohort. Additional subjects, up to a total of 60 subjects in any o f these dose -expansion 
cohorts m ay be enrolled if promising clinical act ivity is observed in that cohort. If the 
HPV -positive cancers, MSI -high can cers, GBM, ovarian cancer, or soft tissue sarco ma 
cohorts are expanded beyo nd 20 subjects each, enrollment may be prioritized to tumor sub-
type(s) that showed promising clinical act ivity, at the sponsor’s di scret ion. Approximately  
110-140 subjects with non -squamous histology  NSCLC will be enrolled including 
approximately  10-30 subjects who are treatment -naive, approximately 20-
30subjects who 
have received 1 prior line of therapy , and approximately 80 subjects who have received at 
least 2 prior lines of the rapy. Approximately  170-190 subjects wi th squam ous histol ogy 
NSCLC will be enrolled including approximately 10 -30 subjects who are treatment -naive, 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 41of 220 Template 14.1approximately  80 subjects who have received 1 prior line of therapy , and approximately 
80subjects who have received at l east 2 pri or lines of therapy . 
An evaluat ion of a possible correlat ion between clinical act ivity of MEDI4736 and potential 
biomarkers (eg, PD-L1 expressio n on tumor or sPD -L1) will be ongoing throughout the 
study . Initially, tum oral PD-L1 exp ression will be assessed on screening samples after 
enrollment on an ongoing basis. After the first 20 -40subjects in each of HCC, 
gastroesophageal cancer, TNBC, UBC, GBM, ovarian cancer, soft tissue sarco ma, SCLC, 
HPV -positive cancers, pancreatic adenocar cinoma, and nasopharyngeal carcino ma dose -
expansio n cohorts are enrolled, addit ional subjects in the applicable cohorts may be required 
to have tumoral PD -L1 expressio n as determined by prospect ive testing prior to enrollment.  
Under previous amendments of this protocol , a minimum o f 5-10 SCCHN subjects were 
requi red to have tumoral PD -L1 expressio n. That requirement has been met and enrollment 
into the SCCHN cohort is complete. Tumoral PD- L1 expressio n as determined by 
prospective testing prior to enrollme nt will be required for the squamous and non -squamous 
NSCLC cohorts as described below in Table 3.1.3 -1.
Table 3.1.3 -1 NSCLC Dose -expansion Cohort PD -L1 Expression 
Requirements
CohortTotal Planned Enrollment 
(n)Tumoral PD -
L1 Requirement 
(Under Amendment 7)
Squamous NSCLC (Total)
     1L
     2L
     ≥ 3L170-190
     10-30
     80
     
80Minimum of 80 PD-L1-positive
     Minimum of 10 PD -L1-positive
     Minimum of 35 PD -L1-positive
     Minimum of 35 PD -L1-positive
Non-squamous NSCLC (Total)
     1L
     2L
     ≥ 3L110-140
     10-30
     20-
30
     80All remaining subjects PD -L1-postive
     All remaining subjects PD -L1-positive
     All remaining subjects PD -L1-positive
     All remaining subjects PD -L1-positive
L = line; NSCLC = non -small cell lung cancer; PD -L1 = programmed death ligand 1.
Under Amendment 8 and beyond of this protoco l, the UBC cohort will be expanded to 
evaluate the ant itumor activit y of MEDI4736 in subjects with PD- L1-positive UBC and 
validate the potential of PD-L1 expressio n (determined by  IHC) to predict response to 
MEDI4736 treatment. Approximately  132additional UBC subjects will be enrolled in this 
cohort in order to include a minimum o f 70PD-L1-positive subjects and 50 PD-L1-negat ive 
subjects, and approximately 12 subjects with non -evaluable PD -L1 status.  
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 42of 220 Template 14.1 
In 
addition to validat ing the currently proposed PD -L1 select ion criteria (≥ 25% PD -L1 staining 
on tum or or immune cells), inclusion of patients wit h PD- L1 staining above and below this 
cutoff will enable exploratory  analyses potentially  leading to a refinement of PD -L1 status 
definit ions or tothe qualificat ion of alternative bio markers for select ion of UBC subjects
most likely to benefi t from treatm ent wi th MEDI4736 in future clinical studies.
To ensure that all o f the addi tional UBC subjects contri bute to the bio marker validat ion, 
subjects must have measurable disease at baseline by blinded independent central  review 
(BICR). PD -L1 status will be determined by a central testing laboratory and will be derived 
from a fresh tum or biopsy  taken during screening or an available tumor sample taken fro m 
≤ 6months pri or to study  entry . The tum or sam ple(fresh and /or recent wi thin 6 m onths prior 
to study  entry )used for PD-L1 analysis must be shipped to ,and confirmed as received by, 
the Sponsor or central vendor prior to the first dose of MEDI4736. It is highly recommended 
that efforts are taken to ensure presence of tumor cells wi thin the tum or sam ple pri or to 
shipping for PD -L1 analysis. The tum or PD -L1 status will be determined by IHC with 
PD-L1-positive samples defined as ≥ 25% tum or cell or immune cell staining and PD -L1-
negat ive samples defined as < 25% tum orcell and immune cell staining. In cases where 
subjects have more than one tumor sample fro m ≤ 6months pri or to study  entry  available for 
testing, PD -L1 status will be derived fro m the most recent evaluable sample. PD -L1 status 
determined by IHC testing f rom tumor sam ples eval uated for screening into MedImmune 
Study  D4190C00010 m ay be used if derived fro m a sam ple taken ≤ 6 m onths pri or to study  
entry . Addi tional archival tum or tissue, from  beyond 6 m onths pri or to study  entry  is also 
requi red, if availabl e.
As of 20Nov 2015, 821subjects have been treated in the dose -expansio n phase o f the study . 
Enrollment into dose -expansio n cohorts may be discontinued at the discretion o f the sponsor 
shoul d emerging clinical or preclinical data suggest that continued tr eatment may not be 
beneficial to a given cohort.
All subjects will be evaluated regularly and their clinical status classified 
according toRECIST guidelines (v1.1; Eisenhauer et al, 2009) wi th modificat ions (see 
Secti on 5.2.6 for a descript ion of disease evaluat ion) except for subjects with GBM who will 
have their clinical status c lassified according to the Response Assessment in Neuro -oncol ogy 
(RANO) guidelines ( Wen et al , 2010 ). Modificat ion of RECIST as described may  discourage 
early  discontinuat ion of MEDI4736 and provide a more complete evaluat ion ofits anti tumor 
activit y than woul d be seen wi th convent ional response criteria. Nonetheless, the efficacy  

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 43of 220 Template 14.1analysis will be conducted primarily based on RECIST v1.1. All subjects will be fo llowed 
indefinit ely for survival unt il the sponsor closes the study  or for the m aximum  durati on per 
institutional standards. Adverse events and SAEs will be followed as per Section 6.4.
The endpo ints to be measured in this study  are described in Sect ion 7.3.
3.2 Estimated Duration of Subject Participation
Subjects in the dose -escalat ion, dose -exploration, and dose -expansion phases will be treated 
for up to 12 m onths unt il confirmed progressive disease ( PD), initiation of alternat ive cancer 
therapy , unacceptable toxicit y, wi thdrawal  of consent, or other reasons to discont inue 
treatm ent occur. In the event of PD, subjects may continue to receive MEDI4736 in the 
absence of clinical deterioration (see Section 5.2.6 ) and if invest igators consider that subjects 
continue to receive benefit from treatment. Subjects who achieve and maintain disease 
control  (DC; ie, CR, PR, or SD) or clinical benefit through to the end of the 12 -month 
MEDI4736 treatment period will enter fo llow-up. Upon evidence of PD during follow -up, 
subjects will be re -administered MEDI4736 for up to another 12 months. Only one round of 
retreatm ent wi th MEDI4736 will be allowed. All subjects will be followed for survival and 
anticancer therapy  indefinitely  unless the sponsor decides to end the study .
3.3 Study -stopping Criteria
If the fo llowing occurs, administration of investigational product will be stopped and no 
additional subjects will  be entered into the study :
•Any safet y finding assessed as related to invest igatio nal product that, in the opinio n of 
the sponsor in consul tation wi th a MedImmune safety  review committee (or equivalent), 
contraindicates further dosing of study  subjects.
If any such safet y findings occur, further administration of the investigational product will be 
stopped and no further subjects will be entered into the study . Thereafter the regulatory  
authori ties and Inst itutional Review Boards (IRBs)/Independent Ethics Committees (IECs) 
will be n otified and a prom pt cum ulative review of safet y data and the circumstances of the 
event in quest ion will be conducted (see Section 6.5). The findi ngs will  be shared wi th the 
regul atory  authori ties and the IRBs/IECs. If it is deemed appropriate by the sponsor after 
review by  a MedImmune safet y review co mmittee (or equivalent), just ification for stopping 
the study  will be sent to the regulatory  author ities and the IRBs/IECs as required.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 44of 220 Template 14.1Any subjects who have already  received investi gational product and are currently in the 
study  at the time study -stopping cri teria are met will cont inue to be fo llowed by the 
investigator for safet y (see Section 6.4.1 ).
Withdrawal criteria for individual subjects are provided in Sect ion 4.2.3 .
3.4 Rationale for Study Design and Doses
An open -label dose -escalat ion study  with a dose -expansio n arm  is a commo n study  design in 
early -phase onco logy studi es and is considered appropriate for a FTIH study .
The primary  obje ctive of the dose -escalat ion phase of this study  is to determine the MTD or 
OBD of MEDI4736 in subjects with advanced melano ma, CRC, NSCLC, or RCC refractory 
to standard therapy  or for whi ch no standard therapy  exists. Thi s study  populati on is 
appropriate for testing a FTIH compound with potent ial for significant toxi cities. An unmet 
medical need exists for these patient populations given that they  have exhausted alternat ive 
treatm ent opti ons or available therapies. Moreover, subjects with less advanced dis ease still 
have opti ons for life -prolonging therapy , and administrati on of  an agent wi thout proven 
benefit would be inappropriate.
The tum or types included in the dose -escalat ion phase are of interest for several reasons. 
There i s a hi gh unmet need for new treatm ent options in each of these diseases. 
Melano ma,NSCLC, and RCC are known to respond to immunotherapy  (Hodi etal, 2010 ; 
Rosenblatt and McDermott, 2011 ; Topalian et al, 2012 ). Taken together with the proposed 
immuno modulatory  mechanism of MEDI4736, there may be a greater chance of seeing 
antitumor activit y in these malignancies.
The primary  object ive of the dose -expansion pha se of this study  is to determine the safet y 
profile of MEDI4736 in subjects with advanced cutaneous melano ma, uveal melano ma, 
HCC, SCCHN, NSCLC squamous histology, NSCLC non -squam ous histol ogy, 
gastroesophageal cancer, TNBC, pancreat ic adenocarcino ma, UBC, GBM, ovari an cancer, 
soft tissue sarcoma, SCLC, MSI -high cancers, HPV -positive cancers, and nasopharyngeal 
carcino ma. The dose -expansio n phase will further evaluate the safet y and preliminary  
antitumor activit y of MEDI4736 at the MTD or OBD as assessed by RECIST v1.1 
guidelines. In addit ion, under Amendment 8 of this protocol, theUBC cohort will be 
expanded to evaluate the ant itumor activit y of MEDI4736 in subjects with PD- L1-positive 
UBC and validate the potential for PD -L1 expression to predict response to MEDI4736 
treatm ent.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 45of 220 Template 14.1The m alignancies included in the dose -expansio n phase were based on the greatest unmet 
medical need, tumoral expressio n of PD -L1, and underlying bio logy in these tum or types. 
Although, these tumor ty pes have approved first -line trea tments, further therapeutic options 
are limited wit h second -and third -line treatments generally providing short OS. These tumor 
types present an opportunit y for an ant i-PD-L1 antibody to demonstrate benefit. 
Preliminary data from this study  as well  as em erging data from other antibodies targeting the 
PD-1/PD -L1 pathway suggest that subjects with mult iple tumor ty pes m ay benefi t from 
treatm ent wi th an agent such as MEDI4736. Cancers that have historically  shown 
responsiveness to immunotherapy  may be likely to benefit from  immune checkpo int 
blockade. Treatment of melano ma with immunotherapy is well established, with 
improvements in OS shown with ant i-CTLA -4 (Hodi  et al , 2010 ). Similarly , treatm ent of 
early  stage bladder cancer wi th Bacillus Calmette -Guerin is well established and reduces the 
risk of recurrence ( Sheley et al, 2000 ). While no longer considered to be a standard 
treatm ent, sarcom a was one of the first cancers to show response to immunoth erapy  with 
Coley’s toxins ( McCarthy , 2006 ) and recent reports suggest sarcoma may  be responsive to 
PD-L1 targeting ant ibodies ( Sagiv -Barfi  et al , 2014 ). In addit ion to this early clinical 
appro ach, unpublished data from syngeneic mouse models of sarco ma suggest that PD -1/ 
PD-L1 targeting ant ibodies may have activit y in this disease. 
Cancers with viral and bacterial et iologies are known to express cell surface ant igens which 
may be recognized by the immune system and immune checkpo int blockade m ay be 
advantageous in these diseases. Included in the expansio n phase are cohorts designed to 
evaluate this hypothesis. The HPV - posit ive cancers cohort and nasopharyngeal carcino ma 
cohort will enroll subj ects wi th HPV or Epstein bar virus associated cancers, respect ively. 
Similarly, both SCCHN (HPV) and HCC (hepat itis B vi rus and hepat itis C virus [HCV]) 
have subpopulat ions wi th viral et iologies. Last ly, gastroesophageal cancer is associated with 
bacteri alinfect ion and m ay benefi t from immunotherapy. For example, in a Phase 2 study  in 
HCC, treatm ent wi th the ant i-CTLA -4 ant ibody  tremelimumab resulted in radiographic 
responses in 18% of subjects while demo nstrating a decline in HCV load and an increase in 
anti-HCV immune response ( Sangro et al, 2012). Tremelimumab has also demonstrated 
antitumor activit y as monotherapy  in gastroesophageal cancer and in co mbinat ion with 
gemcitabine in pancreatic adenocarcinoma ( Ralph et al , 2010 ; Aglietta et al, 2012 ).
Recent data suggest that NSCLC patients with a history  of heavy smoking m ay be m ore 
prone to respond to an ant i-PD-1/PD -L1 antibody.  Specifically, higher ORR following 
treatm ent wi th MPDL3280A were observed in NSCLC subjects with a history  of smoking as 
compared to those wi thout a hi story  of smoking ( Soria et al , 2013 ). One potential explanat ion 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 46of 220 Template 14.1for this observat ion is that heavy smoking m ay lead to a greater frequency  of mutations 
within the tum or and subsequently a greater diversit y of tumor associ ated anti gens that are 
recogni zable by  the immune system . Considering the preliminary  data presented by  
Soria etal, it is reasonable to extend the exploration of this hypothesis into addit ional 
tumortypes known to be associated with smoking (NSCLC, SCLC, SCCHN, and 
bladder cancer). These same tumor ty pes, al ong with m elano ma, cervical cancer, MSI -high 
cancers, and gastroesophageal canc er are al so known to have a high mutational burden 
(Alexandrov et al, 2013 ).
Based on early ant itumor activit y signals in this study  as well  as from similar agents, the 
dose-expansio n phase of the study  will further explore the safet y and clinical act ivity of 
MEDI4736 in specific subpopulat ions of NSCLC to support future studies planned in this 
tumor type. Specifically , the expansi on phase will  test the hy pothesis that MEDI4736 will 
resul t in at least a 10% ORR in sub jects with squamous NSCLC who have received 1 prior 
line of therapy  and wi th squam ous and non -squamous NSCLC who have received at least 
2prior lines of therapy . In addi tion, the clinical activit y of MEDI4736 will be explored in 
subjects who are treatment -naïve as a basis for potent ial future studies.
Tumor infiltrating lymphocy tes are found in many  tumors and are thought to be a marker of 
an immune response against the tumor. Cancers with high levels o f infiltrat ing lymphocy tes 
may benefit fro m checkpo int blockade. In TNBC and ovarian cancer, lymphocyt ic 
infiltrat ionhas been shown to be a strong prognostic factor ( Loi et al , 2013 ; Sato et al, 2005 ; 
Leffers et al, 2009 ). Similarly, cancers with MSI are also known to harbor high 
levels ofinfiltrating lymphocytes targeting frame -shift pepti des associ ated wi th MSI 
(Schwitalle et al, 2008 ). Ult imately, even in those patients with high levels of TILs, the 
underlying malignancy will usually recur and lead to death. This may suggest that although 
an immune response to the tumor has begun, there may be immune regulatory  mechanisms 
hindering the ant itumor response. These tumors may  represen t popul ations that coul d benefit 
from anti-PD-L1 therapy . 
Preclinical evidence suggests that anti -PD-1/PD -L1 therapy may be beneficial in GBM, 
particularly in co mbinat ion with radiotherapy  (Zeng et al, 2013). Clinical data als o show that 
immune checkpo int blockade wi th an ant i-CTLA -4 MAb is act ive in pat ients with brain 
metastases, suggest ing that immune recognit ion of cancer within the central nervous system 
(CNS) i s possible. ( Quei rolo et al , 2014). 
Current experience with immunotherapies suggests that only a subset of any given patient 
popul ation is likely to benefit from treatment and that it might be beneficial to enrich the 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 47of 220 Template 14.1patient popul ation by  select ing pat ients likely to respond to ther apy. Independent data from 
multiple sources using different assays and scoring methods suggest that PD -L1 expressio n 
on tum or cells and/or tum or-infiltrat ing cells may be associated with greater clinical benefit 
in response to treatment with single agent a nti-PD-1/PD -L1 agents: 
•PD-L1 expression has been shown to correlate with clinical outcomes (ORR, 
progression -free survival [ PFS], OS) in subjects with NSCLC treated with ant i-
PD-1/PD -L1 antibodies including pembro lizumab, nivo lumab, atezolizumab, or 
MEDI4 736 ( Garon et al, 2015; Borghaei et al, 2015 ; Vansteenkiste et al, 2015; 
Besse etal, 2015 ; Rizvi  et al , 2015 ). 
•Similarly, PD -L1 expression has been shown to correlate with ORR, PFS, and OS in 
subjects wi th UBC treated with atezolizumab ( Rosenberg et al, 2015 ). 
 
-L1 expression may correlate with ORR in subjects treated with 
 
The totalit y of the em erging data suggest that PD-L1 expressio n may improve the probabilit y 
and/or qualit y of response to single agent PD -1/PD -L1 pathway  inhibitors, and therefore may  
have merit as an enrichment tool. The tumor ty pes included in the expansio n phase are 
thought to express PD- L1 over a b road range of frequencies and will allow for an exploration 
of the correl ation between tumor expressio n of PD -L1 and the clinical act ivity of MEDI4736. 
Access to fresh tumor biopsies and archival tumor tissue in the dose -expansio n phase will 
support explor ation of  potenti al biomarkers of response, including PD- L1, f or MEDI4736. 
Based on current ly available data fro m patients treated with MEDI4736 and similar 
molecules, clinical outcomes in UBC appear to correlate with PD -L1 expressio n. Data from 
the recent ly presented Phase 2 study  of atezolizumab in previously treated UBC suggest that 
patients wi th tumors defined as IC 2/3 by  the Ventana SP142 IHC assay  (ie, ≥ 5% of immune 
cells staining posit ive for PD -L1) , achieved higher ORR (27%) and improved OS compar ed 
to those patients with tumors defined as IC 1 ( ≥ 1% but < 5% immune cell staining; 
ORR =10%) or IC 0 (< 1% immune cell staining; ORR = 9%). In this study populat ion, 
100of 311 subjects (32%) were defined as IC 2/3, while 211 of 311 subjects (68%) were
defined as IC 0 or IC 1. The data available fro m Study  1108 also support the hypothesis that 
PD-L1 expression may be useful as a selection strategy  to identify UBC patients most likely 
to benefit fro m treatm ent wi th MEDI4736. Based on init ial prevale nce d ata fro m the study , it 
is est imated that approximately 60% of UBC subjects may be classified as PD -L1-positive as 
defined by ≥25% staining in eit her tum or cells or i mmune cells. Validat ion of a PD -L1 
expressio n bio marker cutoff is warranted to allow for s electi on of  UBC patients most likely  
to benefit fro m treatm ent wi th MEDI4736 alone and will inform ongo ing registrational 
studi es in this indication.

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 48of 220 Template 14.1The study  will also allow for retreatment with MEDI4736 upon evidence of PD. 
Dem onstrati on of  any clinical benefit with reinduction in the absence o f significant AEs 
woul d suggest that future studies should include a similar treatment option.
The secondary  endpoint of ant itumor activit y will be assessed according to RECIST v1.1 
guidelines wit h modificat ions. R esponse to immunotherapy  may differ 
fromtypical responses observed with cy totoxi c chem otherapy  including the foll owing 
(Wolchok et al, 2009 ):
1.Response to immunotherapy  may be delayed
2.Response to immunotherapy  may occur after PD by  conventi onal criteria
3.The appearance of new lesio ns may not represent PD with immunotherapy
4.Stabl e disease while on immunotherapy  may be durable and represent clinical benefit
To accoun t for these differences, the RECIST criteria will be modi fied so that PD must be 
confirmed at least 4 weeks after the init ial assessment of PD in the absence of clinical 
deteri oration. Treatm ent wi th MEDI4736 will continue between the init ial assessment of 
progression and confirmat ion for progression. In addit ion, subjects may cont inue to receive 
MEDI4736 bey ond confi rmed PD in the absence of clinical deterioration (see Sect ion 5.2.6 ) 
and if invest igators consider that subjects continue to receive benefit fro m treatm ent. In the 
absence of clinical deterioration, RECIST criteria with such modificat ions may discourage 
the early discontinuat ion of MEDI4736 and provide a more complete evaluat ion of its 
antitumor activit y than woul d be seen wi th conventi onal response cri teria.
The starting dose of 0.1 mg/kg to be evaluated in this FTIH study  was selected to provide a 
potenti ally pharmacol ogically act ive dose with transient PD -L1 suppressio n and was 
approximately  1/30 of the m aximum recommended starti ng dose (MRSD).  
 
 
 
The dose -escalation scheme of 0.1, 0.3, 1.0, 3.0, and 10 mg/kg MEDI4736 was designed to 
rapidly achieve dose l evels at whi ch clinical act ivity may be obse rved while m aintaining an 
adequate safety  margin. The range of doses selected was based on predicted PD -L1 
suppressio n and considerable safet y margins in relation to the NOAEL.

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 49of 220 Template 14.1While both Q2W and Q3W dosing schedules are supported based on PK modeling data
derived fro m the nonclinical and clinical studies performed to date, the Q2W dosing schedule 
will be taken into the dose -expansio n phase first.
 
 
This dosing regimen is expected to 
offer the opportunity  to observe a clinical response in subjects with a variet y of solid tum or 
malignan cies.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 50of 220 Template 14.14STUDY PROCE DURES
4.1 Subject Participation and Identification
Study  parti cipat ion begins once written informed consent is obtained (see Section 10.3 for 
details). Once informed consent is obtained, a subject ident ification (SID) number will be 
assigned by  a central  system  (eg, an interactive voice/web response system [IVRS/IWRS]), 
and the screening evaluat ions may begin to assess study  eligibilit y (inclusio n/exclus ion) 
criteria. The SID number will be used to identify  the subject during the screening process and 
throughout study  partici pation, if applicable.
A master log of all consented subjects will be maintained at the site and will document all 
screening failure s (ie, subjects who are consented but do not meet study  eligibilit y criteria) 
including the reason(s) for screening failure (see Section 9.1for details).
4.2 Subject Selection and Withdrawal
The subjects in this study  will be adults 18 y ears of age or ol der. Subjects in the 
dose-escalat ion phase will have advanced melanoma, RCC, NSCLC, or CRC refractory  to 
standard therapy  or for whi ch no standar d therapy  exists. Subjects in the dose -exploration 
cohort will be adults with advanced cutaneous melano ma, uveal melano ma, HCC, SCCHN, 
NSCLC squamous histology , NSCLC non -squamo us histology , gastroesophageal cancer, 
TNBC, or pancreat ic adenocarcino ma. Subj ects in the dose -expansio n phase of the study  will 
be adults with advanced cutaneous melano ma, uveal melano ma, HCC, SCCHN, NSCLC 
squamous histo logy, NSCLC non -squamous histology , gastroesophageal cancer, TNBC, 
pancreat ic adenocarcino ma, UBC, GBM, ovarian c ancer, soft tissue sarcoma, SCLC, MSI-
high cancers, HPV -positive cancers, or nasopharyngeal carcino ma. If approved first -line 
standard therapy  is available, subjects in the dose -expansio n phase must have failed, be 
intolerant to, be ineligible for, or have refused treatment.
The invest igator (physician) or qualified designee will discuss the study with a subject/the 
legal representative of a subject who is considered a potential candidate for the study  and 
provi de the subject/legal representative wit h the s tudy-specific informed consent form(s) 
(ICF[s]) approved by  the IRB/IEC. The invest igator or designee will address any questions 
and/or concerns that the subject/legal representative may  have and, if there is cont inued 
interest, will secure written informe d consent for participat ion in the study. Written informed 
consent and any locally -required authori zation (eg, Heal th Insurance Portabilit y and 
Accountabilit y Act [HIPAA] authorizat ion in the USA, European Unio n [EU] Data Privacy  
Directive authorizat ion inthe EU), will be obtained prior to conducting any protocol -specific 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 51of 220 Template 14.1procedures, including screening evaluat ions or m edication washouts. See Section 10.3 for 
additional details concerning informed consent.
4.2.1 Inclusion Criteria
Subjects m ust m eet allof the fo llowing cri teria:
1.Written inform ed consent and any  locally-required authori zation (eg, HIPAA in the USA, 
EU Data Privacy  Direct ive in the EU) obtained from the subject/legal representative prior 
to performing any protocol -related procedures, including screening evaluat ions
2.In the dose -escalat ion phase: histologically- or cy tologically -confirmed advanced 
melano ma, RCC, NSCLC, or CRC that is refra ctory  to standard therapy  and for which no 
standard therapy  exists
3.In the dose -expansio n phase: histo logically or cy tologically  confirmed advanced 
cutaneous melano ma, uveal melano ma, HCC, SCCHN, NSCLC squamous and non -
squamous histo logy, gastroesophageal c ancer, TNBC, pancreat ic adenocarcino ma, UBC, 
GBM, epi thelial ovari an cancer, soft ti ssue sarcoma (excluding gastrointestinal stromal 
tumor), SCLC, MSI -high cancers, HPV -positive cancers, or nasopharyngeal carcino ma 
4.HCC subjects must be of Child -Pugh class A (not am enable to or refractory  to 
locoregi onal therapy). Subjects wi th HCC associ ated wi th hepat itis B virus must be 
receiving adequate ant iviral therapy
5.UBC cohort: Subjects must have histologically or cy tologically  confirmed inoperable or 
metastati c transit ional cell (including transit ional cell and mixed transit ional cell/non -
transi tional cell histol ogies) carcinom a of the urothelium (including the urinary  bladder, 
ureter, urethra, and renal pelvis). 
a.Subjects m ust have received and have progressed or are refractory  to at l east 1 but not 
more than 2 pri or lines o f systemic therapy  for inoperable or m etastati c disease, 
including a standard plat inum -based regimen. Interval progression between 2 lines of 
therapy  defines separate lines of therapy . Prior de finitive chemoradiation for locally 
advanced disease, adjuvant treatment, or neoadjuvant treatment will be considered a 
prior line of therapy , provi ded that progression has occurred < 12 months fro m 
therapy  [for chem oradi ation and adjuvant treatment] or < 12 months from surgery [for 
neoadj uvant treatm ent].
6.Subjects with histologically or cy tologically documented NSCLC must present with 
Stage IIIB/ Stage IV disease (according to version 7 of the Internat ional Associ ation for 
the Study  of Lung Cancer Staging Manual in Thoracic Onco logy), or wi th recurrent or 
progressive disease fo llowing mul timodal therapy  (radiati on therapy , surgical  resecti on, 
or definit ive chemoradiat ion therapy ) for locally  advanced di sease
a.For advanced stage NSCLC, maintenance therapy  following plat inum doublet -based 
chemotherapy is not considered as a separate regimen of therapy .
b.Prior platinum containing neoadjuvant chemotherapy  for operabl e disease, adj uvant 
chemotherapy for completely  resected disease or definit ive chemoradiat ion thera py 
given for locally advanced disease is not considered a separate regimen of therapy.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 52of 220 Template 14.1c.For first -line therapy NSCLC cohorts: Subjects must not have received prior 
chemotherapy or systemic ant i-neopl astic therapy  (eg, ty rosine kinase inhibitor [TKI], 
MAb th erapy ) for advanced di sease. Pri or surgery  and/or l ocalized irradiati on are 
permitted. 
d.For second- line therapy NSCLC cohorts: Subjects without known sensit izing 
epidermal  growth factor receptor (EGFR) mutations or anaplast ic lympho ma kinase 
(ALK) rearrang ements m ust have experienced disease progression or recurrence 
following one prior plat inum based doublet chemo therapy  for advanced disease. 
Subjects with sensit izing EGFR mutations or ALK rearrangements must have 
experienced disease progression or recurre nce fo llowing either a TKI therapy or prior 
platinum based doublet chemotherapy  for advanced disease.
e.For thi rd-line or greater therapy  NSCLC cohorts: Subjects must have experienced 
disease progressi on or recurrence after both a plat inum -doublet based chem otherapy  
regimen and at least 1 addit ional systemic therapy for advanced disease. For subjects 
with sensit izing EGFR mutations or ALK rearrangements, the addit ional therapy  
must include a TKI therapy . Addi tional therapies are defined as agents that are US 
FDA - or European Medicine Agency-approved for use after a prior regimen, given as 
monotherapy  or in co mbinat ion; or vinorelbine -or gem citabine -containing regimens 
given as part of locally accepted standard -of-care, for subjects who are not candidates 
for docetaxel. 
f.For subjects in the Q4W dose -exploration cohort, subjects are eligible if they meet 
any of the criteria for first -line, second -line, or third- line or greater therapy as 
described in 5c, 5d, or 5e above.
7.Subjects with SCCHN must have disease tha t is ei ther metastati c or recurrent and deemed 
to be incurable by  the invest igator (subjects who refuse radical resect ion for recurrent 
disease are eligible). 
8.MSI-high cancers must have defect ive DNA mismatch repair by eit her: 
a.High-frequency microsatelli te instabili ty with changes detected in 2 or more panels of 
microsatellite markers (BAT -25, BAT -26, NR -21, NR -24 and MONO -27); OR, 
b.Immunohistochemical analysis demonstrating absence o f protein expressio n of any  1 
or more of the following proteins: MLH1, M SH2, MSH6, PMS2.
9.Subjects with HPV -positive cancers are eligible if they  have a confirmed HPV -positive 
tumor by  local laboratory . Subjects wi th HPV -positive SCCHN are only eligible for the 
SCCHN specific cohort. No more than 10 subjects with cervical cance r will  initially be 
enrolled in this cohort
10.GBM cohort: Subjects with GBM must not have significant edema or shift fro m midline 
by intracranial imaging, or be symptomatic due to edema. A minimum of 10 subjects 
without O6-methylguanine -DNA m ethyl transferase prom oter methylat ion will  be enrolled 
in the GBM cohort
11.Epithelial ovarian cancer cohort: A minimum of 10 subjects with platinum sensit ivity will 
be enrolled in the ovarian cancer cohort
12.If an approved first -line standard therapy  is available, subjects must have failed, be 
intolerant to, be ineligible for, or have refused treatment
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 53of 220 Template 14.113.Progressive disease as assessed by  the invest igator or treatment naïve at the time of study 
entry
14.Tumoral PD-L1 expressio n requirements are as fo llows:
a.HCC, gastroesophageal c ancer, TNBC, GBM, ovarian cancer, soft tissue sarco ma, 
SCLC, HPV- positive cancers, pancreat ic adenocarcino ma, and nasopharyngeal 
carcino ma dose -expansio n cohorts: after the first 20 -40subjects in each cohort are 
enrolled, addit ional subjects in the applic able cohorts may  be requi red to have 
tumoral PD-L1 expression as determined by prospective testing prior to enrollment
b.Under previous versio ns of this protocol, a minimum o f 5-10 SCCHN subjects were 
requi red to have tumoral PD -L1 expressio n. That requireme nt has been met, and 
enrollment into this cohort is complete
c.NSCLC (squamous and non -squamous) dose -expansio n cohorts:
▪Non-squamous NSCLC: all remaining subjects to be enrolled will be required to 
have tum oral PD-L1 expressio n as determined by prospective testing pri or to 
enrollment
▪Squam ous NSCLC: A minimum of 10 subjects in the first -line therapy cohort, 
and a minimum o f 35 subjects in each o f the second -line therapy and third- line or 
greater therapy  cohorts will be required to have tumoral PD -L1 expressi on as 
determined by prospective testing prior to enrollment
d.UBC cohort:
▪S
ubjects must consent to provide an archived tumor specimen fro m within 
6months pri or to study  entry  (ie, from subject si gning consent to participate in the 
study ) for PD -L1 IHC analy sis. If not available, subjects must have at least 
1lesio n amenable to biopsy  and consent to provide a pre -treatm ent fresh bi opsy ; 
tumor lesions pl anned f or biopsy  shoul d not be lesions used as RECIST target 
lesions. Tum or tissue for PD -L1 analysis must be shipped to , and confirmed as 
received by ,the Sponsor or designated central vendor prior to the first dose of 
investigat ional product. However, subjects may be dosed before PD -L1 results are 
known. It is highly  recommended that efforts are taken to confirm presence of 
tumor cells wit hin the tum or sam ple pri or to shi pping for PD -L1 analysis. In 
addition to the tum or tissue requi red for PD -L1 analysis, subjects in the UBC 
cohort must also provide addit ional older archival tis sue regardl ess of age, if 
available.
15.Age ≥ 18 y ears at time of study  entry
16.Females of childbearing potential who are sexually active with a nonsterilized male 
partner m ust use 2 m ethods of contracepti on, at least one of which must be highly  
effect ive,fromscreening, and must agree to continue using such precaut ions for 90 day s 
after the final dose of MEDI4736; cessation o f birth control after this point should be 
discussed wi th a responsible physician. Not engaging in sexual act ivity for the total  
durati on of  the drug treatm ent and the drug washout period is an acceptable practice; 
however, peri odic abst inence, the rhythm method, and the withdrawal method are not 
acceptable methods of birth control
a.Females of childbearing potential are defined as those who are not surgically sterile 
(ie, bilateral tubal ligat ion, bilateral oophorectomy, or complete hysterectomy ) or 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 54of 220 Template 14.1postm enopausal (defined as 12 months with no menses without an alternative medical 
cause)
b.Subjects m ust use 2 acceptable methods of effective con tracepti on, at least one of 
which is highly effective, as described in Table 4.2.1 -1
c.Female subjects should also refrain fro m breastfeeding throughout this peri od
17.Nonsterilized males who are sexually  active wi th a female partner of childbearing 
potenti al must use a male condom  with spermicide and another highly effective method 
of contracepti on (see Table 4.2.1 -1) from Day  1 and for 90 day s after recei pt of the final  
dose of invest igational product . Not engaging in sexual act ivity is an acceptable pract ice; 
however, occasional abst inence, the rhyt hm method, and the withdrawal method are not 
acceptable methods of contraception.  Male subjec ts should refrain fro m sperm  donat ion 
throughout this period
18.Eastern Cooperative Oncology  Group (ECOG) status of 0 or 1
19.Adequate organ and marrow funct ion as defined below(without growth factor or 
transfusio n support within 28 days prior to first dose of invest igational product) :
a.Hem oglobin ≥ 9 g/dL
b.Absolute neutrophil count ≥ 1,500/mm3
c.Platelet coun t ≥ 100,000/mm3
d.AST and ALT ≤2.5×institutional upper limi t of norm al (ULN); for subjects wi th 
HCC or liver metastases, AST or ALT ≤5 × ULN 
e.Bilirubin ≤ 1.5 × ULN; for subjects with HCC or subjects with documented/suspected 
Gilbert’s disease, bilirubin ≤ 3 × ULN 
f.Creat inine clearance ≥ 50 mL/min (or ≥ 30 mL/min for subjects with UBC) as 
determined by the Cockcroft -Gault equation ( Cockcroft and Gault, 1976 ) or by  
24-hour urine co llection for determinat ion of creat inine clearance
20.Subjects m ust have at l east 1 m easurable lesio n per RECIST v1.1 guidelines or per 
RANO gui delines ( Wen et al, 2010 ) for subjects wit h GBM
a.A previously  irradiated l esion can be considered a target lesio n if the lesio n is well 
defin ed, m easurable per RECIST v1.1, and there is object ive evidence of interval 
increase in size
b.For subjects in the UBC cohort, measurable disease per RECIST v1.1 must be 
confirmed by BICR prior to enrollment
21.Available unstained archived tumor tissue sample in sufficient quant ity to allow for 
pharmacodynamic analyses. Note: a biopsy  must be perform ed for all subjects for which 
suitable archived tumor sample is not available (eg, recently  diagnosed subjects or 
diagnosed wi th fine needle aspirat ion). In addit ion to the tumor tissue requirements 
specified in inclusio n criterion 14d, subjects in the UBC cohort must also provide
additional older archival  tissue regardl ess of age , if available . (See inclusio n criterion 14d 
for tissue requi rements for the UBC cohort. )
22.Life expectancy  ≥ 16 weeks
23.At least 1 lesio n amenable to biopsy (dose -expansion phase only, excluding GBM 
subjects) as described in Sect ion 5.2.7 .2. See inclusion criterion 14d for tissue 
requi rements for the UBC cohort . 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 55of 220 Template 14.124.Willingness to provide consent for biopsy  samples (dose -expansio n phase only). Tumor 
biopsies will be required for all subjects as described in Section 5.2.7.2 . Tum or lesions 
planned for biopsy  should not be l esions used as RECIST target lesio ns. N ote: biopsies 
are opti onal for subjects wi th GBM. If a biopsy is not performed for GBM subjects, an 
archival t issue sample will be required for study  entry . Note: for subjects in the UBC 
cohort, this requirement does not apply if an archival tumor sample fro m within 6 m onths 
prior to study  entry  has been provi ded
25.In the dose -explorat ion cohort: histologically or cytologically confirmed advanced 
cutaneous melano ma, uveal melano ma, HCC, SCCHN, NSCLC squamous and non -
squamous histo logy, gastroesophageal cancer, TNBC, or pancreatic adenocarcino ma
Table 4.2.1 -1 Highly Effective Methods of Contraception ( < 1%  Failure 
Rate )
Barrier /Intrauterine Methods Hormonal Methods
•Copper T intrauterine device
•Levonorgestrel -releasing intrauterine system 
(eg, Mirena®) aEtonogestrel implants; eg, Implanon or Norplan
•Intravaginal device; eg, ethinylestradiol and 
etonogestrel
•Medroxy progesterone injection: e.g. Depo -Provera 
•Normal and low dose combined oral contraceptive pill
•Norelgestromin/ethinylestradiol  transdermal system
•Cerazette (desogestrel)
Note: A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 
1% per y ear) w hen used consistently and co rrectly . Note that some contraception methods are not c onsidered 
highly  effective (eg, male or female c ondom with or without spermicide; female cap, diaphragm, or sponge with 
or without spermicide; non -copper containing intrauterine device; progestogen -only  oral ho rmonal contraceptive 
pills where inhibition of ovulation is not the primary mode of action [ex cluding Cerazette/desogestrel which is 
considered highly effective]; and triphasic combined oral contraceptive pills).
aThis is also considered a hormonal method.
4.2.2 Exclusion Criteria
Any of the fo llowing woul d exclude the subject from participat ion in the study :
1.Concurrent enrollment in another clinical study , unless i t is an observat ional 
(non-intervent ional) clinical study  or the follow -up period of an intervent ional study
2.Receipt of any  immunotherapy , BRAF inhibitor (in cutaneous melano ma and uveal 
melan oma subjects), or i nvest igational anticancer therapy within 4 weeks prior to the first 
dose of MEDI4736; in the case o f MAbs (for investigat ional use or immunotherapy ), 
6weeks prior to the first dose of MEDI4736
3.Any pri or Grade ≥ 3 irAE while receiving immunotherapy , including ant i-CTLA -4 
treatm ent, or any  unresolved i rAE > Grade 1.
4.For all subjects, pri or exposure to any  anti-PD-1 or anti -PD-L1 ant ibody . For subj ects in 
the UBC cohort, prior treatment with immunotherapy  agents including, but not limited to, 
tumor necrosis factor receptor superfamily agonists or checkpo int inhibitors or natural 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 56of 220 Template 14.1killer ( NK)cell inhibitors including agents targeting KIR, PD -1, PD -L1, CTLA -4, OX40, 
CD27, CD137 (4 -1BB), CD357 (GITR), and CD40. Prior treatment with Bacillus 
Calmette -Guerin therapy is permitted.
5.Any concurrent chemotherapy, immunotherapy , biol ogic or horm onal therapy  for cancer 
treatm ent. Concurrent use of hormones for non -cancer -related condit ions (eg, insulin for 
diabetes and hormone replacement therapy ) is acc eptabl e. 
Note: Local treatment of isolated lesio ns for palliative intent is acceptable (eg, by  local 
surgery  or radi otherapy )
6. Current or prior use of immunosuppressive medication within 28 days before the first 
dose of MEDI4736, with the exceptions of intranasal, topical, and inhaled corticosteroids 
or sy stemic corti costeroi ds at phy siologic doses not to exceed 10 mg/day of prednisone or 
equivalent (2 mg/day  of dexamethasone or equivalent for subjects with GBM). Subjects 
with GBM must be on a stable dose o f steroi ds for ≥ 7days prior to study  entry  and pri or 
to baseline imaging
7.Active or prior documented autoimmune disease wit hin the past 2 y ears 
Note: Subjects with vit iligo, Grave’s disease, Hashimoto’s disease, or psoriasis not 
requi ring systemic treatm ent (wi thin the past 2 years) are not excluded
8.Active or prior documented inflammatory bowel disease (eg, Crohn’s disease, ulcerat ive 
colitis)
9.History  of primary  immunodeficiency
10.History  of organ transplant that requires use of immunosuppressives
11.Known all ergy or reacti on to any  com ponent of the MEDI4736 formulat ion.
12.Untreated CNS metastatic disease, leptomeningeal disease, or cord compressio n. Note: 
Subjects previously treated for CNS metastases that are radiographically and 
neuro logically  stable for at l east 42 days and do not require corticosteroids (of any dose) 
for symptom atic management for at least 14 day s prior to the first dose of MEDI4736 are 
not excluded.
13.Other invasive malignancy  within 2 years except for noninvasive malignancies such as 
cervical carcino ma in situ, non -melano matous carcino ma of the skin or ductal carcino ma 
in situ of  the breast that has/have been surgically  cured . Cancer subjects with incidental 
histol ogic findings of prostate cancer that, in the opinio n of the investigator, is no t 
deemed to requi re act ive therapy (eg, incidental prostate cancer ident ified fo llowing 
cystoprostatectomy  that i s tumor/node/m etastasi s stage ≤ pT2N0 ) may be enrolled, 
pending discussio n and approval  with the study  physician.
14.Unreso lved toxicit ies from prior anti cancer therapy , defined as having not resolved to 
National Cancer Inst itute’s (NCI’s) Commo n Termino logy Criteria f or Adverse Events 
(CTCAE) ( NCI CTCAE v4.03) Grade 0 or 1, or to levels dictated in the 
inclusio n/exclusion criteria with the except ion of alopecia. Subjects with irreversible 
toxicity that i s not reasonably expected to be exacerbated by  MEDI4736 m ay be included 
(eg, hearing loss) after consultat ion with the MedImmune medical mo nitor.
15.Major surgi cal procedure (as defined by the investigator) within 30 days prior to the first 
dose of MEDI4736 or still recovering fro m prior surgery
16.Females who are pregnant or lactating 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 57of 220 Template 14.117.Uncontrolled intercurrent illness including, but not limited to, ongoing or active infect ion, 
symptom atic congestive heart failure, uncontrolled hypertensio n, unstable angina 
pectori s, cardi ac arrhy thmia, severe act ive peptic ulcer disease or gastritis, or psychiatric 
illness/social situat ions that would limit co mpliance wi th study  requi rement or 
compromise the abilit y of the subject to give written informed consent 
18.Any condit ion that, in the opinio n of the invest igator, would interfere with evaluat ion of 
the invest igational product or interpretation of subject safet y or study resul ts
19.Known history  of tubercul osis
20.Subjects who are known to be human immunodeficiency virus (HIV) posit ive
21.Subjects who are known to be hepat itis B or C posit ive, except for subje cts wi th HCC
22.Receipt of live attenuated vaccinat ion within 30 days pri or to study  entry  or wi thin 
30days of receiving MEDI4736
23.Subjects with pancreatic adenocarcinoma must not have more than 50% of the liver 
parenchyma replaced by  tumor
24.Subjects with HCC must not have a history  of bleeding from  esophageal varices, unless 
the varices have been treated with no active bleeding within 30 days prior to the first dose 
of MEDI4736
25.Prior parti cipat ion in clinical studi es that incl ude MEDI4736 al one or in combinati on, 
where the study  has regi strati onal intent and the analyses for the primary  endpoint have
not yet been completed
4.2.3 Withdrawal Criteria
Permanent discontinuation of investigational product: An individual subject will not 
receive any further investigat ional product if any of the fo llowing occur in the subject in 
question:
1.Withdrawal o f consent or l ost to foll ow-up
2.Adverse event that, in the opinio n of the invest igator or the sponsor, con traindicates 
further dosing
3.Subject is determined to have met one or more of the exclusio n criteria for study  
participat ion at study  entry  and continuing invest igational therapy  might const itute a 
safet y risk
4.Pregnancy or intent to beco me pregnant
5.Any AE that meets criteria for discontinuation as defined in Appendix 15
6.Adverse event related to MEDI4736 that is Grade ≥ 3, wi th the except ion of toxi cities 
that do not meet criteria for discont inuat ion as defined in Appendix 15
7.Dose -limit ing toxicit y (See Sect ion 4.5.7 for definit ion of DLT)
8.Grade ≥ 3 infusio n reaction
9.Subject nonco mpliance that, in the opinio n of the investigator or sponsor, warrants 
withdrawal; eg, refusal to adhere to scheduled visit s
10.Initiation of  alternative anticancer therapy  including another invest igational agent
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 58of 220 Template 14.111.Confirmation o f PD and investigator determinat ion that the subject is no longer 
benefit ing from treatment with MEDI4736
Subjects who are permanent ly discont inued fro m further receipt of invest igational product, 
regardl ess of the reason (withdrawal of consent, due to an AE, other), will be ident ified as 
having permanently discont inued treatment. Subjects who permanently discontinue treatment 
may eit her be considered to have co mpleted the study  or not to have completed the study  
(seeSecti on4.7).
Subjects who are permanent ly discont inued fro m receiving invest igational product will be 
followed for safet y per Secti on 6.4, including the collect ion of any  protocol -specified blood 
specimens, unless consent is wit hdrawn or the subject is lost to follow -up or enrolle d in 
another clinical study . All subjects will be followed for survival. Subjects who decline to 
return to the site for evaluat ions will be offered fo llow-up by phone every  3 months as an 
alternat ive.
Withdrawal of consent: If consent is withdrawn, the sub ject will not receive any further 
investigat ional product or further study  observat ion. Note that the subject may be offered 
additional tests or tapering of treatment to withdraw safely .
Lost to follow -up: Subjects will be considered lost to follow -up only if no con tact has been 
established by  the time the study  is com pleted (as defined in Sect ion 4.8) such that there is 
insufficient informat ion to determine the subject’s status at that time.
•Note: Subjects who refuse cont inuing participat ion in the study , including phone contact, 
shoul d be docum ented as “wit hdrawal o f consent” rather than “lost to follow -up.” 
Invest igators should document attempts to re -establish contact with missing subjects 
throughout the study  period. If  contact wi th a missing subject is re -established, the 
subject should not be considered lost to fo llow-up and any  evaluat ions should resume 
according to the protocol.
4.2.4 Replacement of Subjects
Subjects in the dose -escalat ion cohorts are considered evaluable if they receive 2 doses of 
MEDI4736 or they  discont inue MEDI4736 due to DLTs. Nonevaluable subjects in the 
dose-escalat ion cohorts will be replaced in the same dose cohort. Subjec ts enrolled in the 
dose-expansio n or dose -exploration cohorts will not be replaced.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 59of 220 Template 14.14.3 Treatment Assignment
Each subject who meets the eligibilit y criteria will be assigned open -label invest igational 
product. Invest igational product (MEDI4736) must be adminis tered wi thin 1 business day  
after the invest igational product is assigned. If there is a delay in the administration of 
investigat ional product such that it will not be administered within the specified timeframe, 
the study  monitor m ust be notified immediately .
4.4 Blinding
This study  is not blinded.
4.5 Study Medications
4.5.1 Investigational Products
MedImmune will provide the invest igator(s) with adequate quantit ies of investigational 
product using designated distribut ion centers. MEDI4736 will be stored at 2- 8°C (36 -46°F) 
in a secure area with restricted access.
MEDI4736:  
 
 
The invest igator’s or site’s designated invest igational product manager is required to 
maintain accurate invest igational product accountabilit y records. Upon com pletion of the 
study , copies of invest igational product accountabilit y records will  be returned to 
MedImmune. All unused invest igational product will be returned to a MedImmune -
authori zed depot or disposed of upon authorizat ion by MedImmune according to the 
investigational site po licy.
4.5.1.1 Investigational Product Preparation
The dose of invest igational product for administratio n must be prepared by  the invest igator’s 
or site’s designated invest igational product manager using asept ic technique. Commercially 
available WFI and 0.9% (w/v) saline will be supplied by each site. Total in -use storage time 
from reconst itution of  MEDI4736 to start of administration should not exceed 4 hours at 
room  temperature or 24 hours at 2 -8°C (36 -46°F). If in -use storage time exceeds these limits, 
a new dose must be prepared fro m new vials. MEDI4736 does not contain preservatives and 
any unused portion must be discarded.

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 60of 220 Template 14.1Reconstitution of investigational product 
MEDI4736 requires reconst itution pri or to use. The reconstitution should be pe rformed wi th 
4.0 m L sterile WFI for each vial wit h the liquid added gent ly to the side of the vial to 
minimize product foaming. The vial should be gently rotated or swirled for 5 minutes or un til 
dissolution is com plete. The vi al shoul d not be shaken or vi gorously  agitated. Reconsti tuted 
MEDI4736 should stand undisturbed at room temperature for a minimum of 5 minutes or 
until the so lution clarifies. The reconst ituted sol ution shoul d appear cl ear or slight ly 
opalescent. A thin layer of bubbles on the liquid surface is considered normal.
Preparation of doses less than 1.0 mg/kg MEDI4736 for administration with a 
syringe
For IV doses less than 1.0 mg/kg, administration will be performed using a polypropylene 
syringe and IV administration set. Each dose will be administered as an admixture of 
MEDI4736 and 0.9% (w/v) saline prepared to a set volume. The delivery vo lume for each 
dose l evel is listed in Table 4.5.1.1 -1. The preparatio n volume will include addit ional volume 
of admixture to allow for purging the lines of the administration set. 
Table 4.5.1.1 -1 Preparation of MEDI4736 Doses Less Than 1.0 mg/kg to 
Dose for Administration by Syringe
Dose (mg/kg) Delivery Volume (mL)
0.05 2
0.10 to 0.29 4
0.30 to 0.89 12
0.90 to 0.99 30
The dose preparation procedure is as fo llows:
1.Determine fro m Table 4.5.1.1 -1the correct delivery  volume needed.
2.Calculate the amount of admixture to prepare using the formula below:
3.Preparati on Vol ume (mL) = 
4.Delivery  Volume (mL) + Hol d-up Vol ume of Administrati on Set (mL)
5.Calculate the concentration of MEDI4736 in the admixture using the formula below:
6.Final Dose Concentration (mg/mL) =
7.Dose (m g/kg) × Subj ect Wei ght (kg) ÷ Delivery Volume (mL)
8.Determine the vo lume of reconst ituted MEDI4736 (mL) to be prepared in 0. 9% (w/v) 
saline required for the calculated concentration: 
9.Volume of MEDI4736 to be Diluted (mL) =
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 61of 220 Template 14.110.Final Dose Concentration (mg/mL) × Preparation Volume (mL) ÷ Drug Product 
Concentration (no minal 50 mg/mL)
11.Determine the vo lume of 0.9% (w/v) saline (mL) us ed to dil ute MEDI4736:
12.Volume of 0.9% (w/v) Saline (mL) =
13.Preparati on Vol ume (mL) -Volume of MEDI4736 to be Diluted (mL)
The admixture should be prepared in a separate sterile container. Fo llowing preparation, the 
admixture must be mixed by gentle swirli ng or inversi on. The admixture should then be 
inspected to ensure the solution is clear and then drawn up into the sy ringe. Intravenous lines 
are then purged and the specified delivery  volume is administered, using a 0.2 -μm in-line 
filter. Subj ects in the first cohort will receive the init ial infusio n over approximately  4hours. 
All remaining infusions for these subjects and other study  subjects will be approximately 
60minutes in duration. Disconnect the IV line when the correct volume has been delivered.
Example:
1.For a dose of 0.3 mg/kg, the Delivery Vo lume will be 12 mL.
2.The administration lines to be used have a ho ld-up vo lume of approximately 10 mL. The 
volume of admixture to prepare is 22 mL (12 mL + 10 mL)
3.The Final Dose Concentration of MEDI4736 for a subject weighing 100 kg and dosed at 
0.3 m g/kg will be 2.5 mg/mL. 
4.(0.3 m g/kg × 100 kg ÷ 12 mL)
5.The vo lume of reconst ituted MEDI4736 required will be 1.1 mL.
6.(2.5 m g/mL × 22 mL ÷ 50 mg/mL)
7.The vo lume of 0.9% (w/v) saline required to dilute MEDI4736 will be 20.9 m L.
8.(22 mL -1.1 mL)
After gent le mixing of the admixture in the syringe by  gent le inversio n the lines are purged 
and 12 mL is administered over the specified infusio n time.
Preparation of MEDI4736 doses greater than or equal to 1.0 mg/kg and less
than or equal to 30 mg/kg for administration with an IV bag
No incompat ibilities have been observed between MEDI4736 and polyethylene, polyo lefin 
copolymers, or polyvinylchloride. Doses greater than or equal to 1.0 mg/kg will be 
administered using a 250 m L IV bag containing 0.9% (w/v) saline and delivered through an 
IV administration set. The volume of reconst ituted MEDI4736 to add to the IV bag is 
calculated as follows:
Volume of MEDI4736 (mL) =
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 62of 220 Template 14.1Dose (m g/kg) × Subj ect Wei ght (kg) ÷ MEDI4736 Concentration (nominal 50 mg/mL)
Subject wei ght at baseline should be used for dosing calculat ions unless there is a ≥10% 
change in weight in which case the dosing day weight should be used. Dosing day weight can 
be used for dosing calculat ions instead of baseline weig ht per inst itutional standard. An 
additional volume of  0.9% (w/v) saline equal to the calculated volume of MEDI4736 to be 
added to the IV bag must be removed fro m the bag pri or to addi tion of  MEDI4736. The 
calculated vol ume of MEDI4736 i s then added to the IV bag, and the bag is mixed by gent le 
inversio n to ensure ho mogeneit y of the dose in the bag. Fo llowing preparati on of  the dose, 
the ent ire contents of the IV bag should be administered as an IV infusio n over 
approximately  60 minutes, using a 0.2 -μm in-line fil ter. Fl ush the IV line with a vo lume o f 
norm al saline equal  to the priming vol ume of the infusio n set used after the contents of the 
IV bag are fully  administered, or com plete the infusi on according to inst itutional policy to 
ensure the full dose is administered and document if the line was not flushed.
Example: For a subject weighing 80 kg and dosed at 10 mg/kg, 16 mL [10 mg/kg × 80 kg 
divided by 50 mg/mL] of MEDI4736 is to be diluted in a 250 mL IV bag containing 0.9% 
(w/v) saline. First, 16 mL of saline is removed from the IV bag, and then 16 mL of 
MEDI4736 is added to the bag. The bag is mixed by gentle inversio n to ensure ho mogeneit y 
of the dose in the bag and the diluted MEDI4736 is administered as described above.
4.5.2 Other Study Medications
No oth er study  medicat ions are specified for use in this clinical protocol.
4.5.3 Treatment Regimen
Subjects will be treated in a dose- escalat ion phase, dose -exploration cohort, or a dose -
expansio n phase of the study .
4.5.3.1 Dose Escalation
MEDI4736 Q2W Dose -escalation Arm
Subjects enrolled in the Q2W dose -escalat ion arm  will receive one of 5 doses of MEDI4736 
(0.1, 0.3, 1.0, 3.0, or 10 mg/kg) via IV infusio n Q2W ± 3days. Provided the MTD is not 
exceeded at the 10 mg/kg dose level, addit ional cohorts of 3 -6 subjects using do ses above 
10mg/kg of MEDI4736 Q2W may be init iated based on PK or pharmacodynamic data 
suggest ing maximal suppressio n of sPD -L1 is not being maintained throughout the dosing 
interval  or T -cell activation has not plateaued, respectively. The rules for dose escalat ion 
described in Section 4.5.6 would apply in this setting. Intermediate doses may be evaluated at 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 63of 220 Template 14.1the discret ion of the sponsor based on av ailable data. Dose modificat ion for toxi cities will  be 
allowed as described in Appendix 15 . 
Subjects will cont inue MEDI4736 Q2W treatment for 12 months or until confirmed PD, 
initiation of alternat ive cancer therapy, unacceptable toxicit y, withdrawal of consent, or other 
reasons to discont inue treatment occur ( Figure 4.5.3.1 -1). In the event of confirmed PD, 
subjects may  cont inue to receive MEDI4736 in the absence of clinical deterioration (see 
Secti on 5.2.6 ) and if invest igators consider that subjects continue to receive benefit from 
treatm ent.
Subjects who have achieved and maintained DC (ie, CR, PR, or SD) or clinical benefit 
through to the end of the 12 -month Q2W treatment period will enter fo llow-up and be 
assessed according to the procedures outlined in Table 5.1-3. Upon evidence of PD during 
follow-up, subjects will be re -administered MEDI4736 at t he dose previously received or at 
10 m g/kg, the dose chosen for the expansio n phase via IV infusio n Q2W ( Appendix 13 ). 
Subjects may continue MEDI473 6 Q2W retreatment for up to 12 months with the same 
treatm ent gui delines foll owed during the init ial 12 -month treatment period. Only one round 
of retreatm ent wi th MEDI4736 will  be allowed. Subjects who have confirmed PD during the 
12-month Q2W init ial trea tment or retreatment period and cannot continue to receive 
MEDI4736 will enter follow -up for 90 -day safet y assessments and survival fo llow-up (see 
Appendix 14 for schedule of procedures).
Figure 4.5.3.1 -1 Dosing Schema for MEDI4736 Q2W Dose -escalation 
Cohorts
Q2W = every 2 weeks.

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 64of 220 Template 14.1MEDI4736 Q3W Dose -escalation Arm 
Upon the complet ion of dose escalat ion for the Q2W dose- escalat ion arm , a separate 
dose-escalat ion arm  of MEDI4736 administered Q3W will be init iated. Thi s Q3W 
dose-escalat ion arm  will be carried out in parallel to the dose -expansio n phase. The first 
cohort of subjects will receive MEDI4736 Q3W ± 3 day s at the highest dose level that does 
not exceed the MTD or the OBD in the Q2W dose- escalat ion arm . Higher doses of 
MEDI4736 may be explored based upon acceptable safet y, PK/pharmacodynamic, and 
clinical data fo llowing the rules for dose escalation described in Sect ion4.5.6 . 
Subjects will cont inue MEDI4736 Q3W treatment for 12 months or until confirmed PD, 
initiation of alternat ive cancer therapy , unacceptable toxicit y, withdrawal of consent, or other 
reasons to discont inue treatment occur ( Figure 4.5.3.1 -2). In the event of confirmed P D, 
subjects may  cont inue to receive MEDI4736 in the absence of clinical deterioration (see 
Secti on 5.2.6 ) and if invest igators consider that subject s continue to receive benefit from 
treatm ent.
Subjects who have achieved and maintained DC (ie, CR, PR, or SD) or clinical benefit 
through the end of the 12 -month Q3W treatment period will enter follow -up and be assessed 
according to the procedures outlined in Table 5.1-3
. Upon evidence of PD during fo llow-up, 
subjects will be re -administered MEDI4736 at the highest dose previously received via 
IVinfusio n Q3W ( Appendix 13 ). Subj ects m ay cont inue MEDI4736 Q3W retreatment for up 
to 12 m onths wi th the same treatm ent gui delines foll owed during the init ial 12 -mont
h 
treatm ent peri od. Only  one round of retreatm ent wi th MEDI4736 will be allo wed. Subjects 
who have confirmed PD during the 12 -month Q3W init ial treatm ent or retreatm ent peri od 
and cannot continue to receive MEDI4736 will enter fo llow-up for 90 -day safety  assessments 
and survival fo llow-up (see Appendix 14 for schedul e of procedures).
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 65of 220 Template 14.1Figure 4.5.3.1 -2 Dosing Schema for MEDI4736 Q3W Dose -escalation 
Cohorts
Q3W = every 3 weeks.
4.5.3.2 Dose Exploration 
The dose -exploration cohort of the study  will be conducted in parallel with the MEDI4736 
Q2W dose -expansio n phase.
Subjects with advanced cutaneous melano ma, uveal melano ma, HCC, SCCHN, NSCLC 
squam ous histol ogy, NSCLC non -squamous histology , gastroesophageal cancer, TNBC or 
pancreat ic adenocarcino ma, will receive MEDI4736 Q4W via IV infusio n at 20 m g/kg.
Treatment in the dose -exploration cohort will cont inue on a Q4W schedule for 12 months or 
until confirmed PD, init iation of alternat ive cancer therapy, unacceptable toxicit y, 
withdrawal  of consent, or other reasons to discont inue treatment occur ( Figure4.5.3.2 -1). In 
the event of confirmed PD, subjects may continue to receive MEDI4736 in the absence of 
clinical deterioration (see Section 5.2.6 ) and if investigators consider that subjects continue to 
receive benefit from treatment.
Subjects who have achieved and maintained DC (ie, CR, PR, or SD) or clinical benefit 
through the end of the 12 -month Q4W treatment period will enter follow
-up and be assessed 
according to the procedures outlined in Table 5.1-3. Upon evidence of PD during fo llow-up, 
these subjects will be re -administered MEDI4736 at 20 mg/kg via IV infusion Q4W 
(Table5.1-2). Rebaseline will be required using the screening visit a ssessments with the 
exception of consent, collect ing the pathology report, and collecting an archival tumor 
sample. In addit ion subject must not have met discontinuat ion criteria. Subjects m ay cont inue 
MEDI4736 Q4W retreatment for up to 12 months with the same treatment guidelines 
followed during the init ial 12 -month treatm ent period. Only  one round of retreatment wi th 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 66of 220 Template 14.1MEDI4736 will be allowed. Subjects who have confirmed PD during the 12 -month Q4W 
initial treatment or retreatment period and cannot continue to receive MEDI4736 will enter 
follow-up for 90 -day safet y assessments and survival fo llow-up (see Appendix 14 for 
schedule of procedures).
Figu re4.5.3.2 -1 Dosing Schema for MEDI4736 Q4W Dose- exploration 
Cohort
Q4W = every 4 weeks.
4.5.3.3 Dose Expansion
The dose -expansio n phase of the study  will be conducted following complet ion of the 
MEDI4736 Q2W dose -escalation arm  and in parallel  with the MEDI4736 Q3W 
dose-escalat ion arm  and Q4W dose -exploration cohort.
Subjects with advanced cutaneous melano ma, uveal melano ma, HCC, SCCHN, NSCLC 
squamous histo logy, NSCLC non -squamous histology , gastroesophageal cancer, TNBC, 
pancreat ic adenocarcino ma, UBC, GBM, ovarian cancer, soft tissue sarcoma, SCLC, MSI -
high cancers, HPV -positive cancers, or nasopharyngeal carcino ma will receive MEDI4736 
Q2W via IV infusion at the 10 m g/kg Q2W, the dose selected for the expansion pha se of the 
study .
Treatment in the dose -expansio n phase will cont inue on a Q2W schedule for 12 months or 
until confirmed PD, init iation of alternat ive cancer therapy, unacceptable toxicit y, 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 67of 220 Template 14.1withdrawal  of consent, or other reasons to discont inue treatment oc cur (Figure 4.5.3.3 -1). In 
the event of confirmed PD, subjects may continue to receive MEDI4736 in the absence of 
clinical deterioration (see Section 5.2.6 ) and if investigators consider that subjects continue to 
receive benefit from treatment. 
Subjects who have achieved and maintained DC (ie, CR, PR, or SD) or clinical benefit 
through the end of the 12 -month Q2W treatment period will enter follow -up and be assessed 
according to the procedures outlined in Table 5.1-3. Upon evidence of PD during fo llow-up, 
these subjects will be re -administered MEDI4736 at the dose previously received via IV 
infusio n Q2W ( Appendix 13 ). Subjects m ay cont inue MEDI4736 Q2 W retreatment for up to 
12 m onths wi th the same treatment gui delines fo llowed during the init ial 12 -month treatment 
period. Only  one round of retreatment with MEDI4736 will be allowed. Subjects who have 
confirmed PD during the 12 -month Q2W init ial treatmen t or retreatment period and cannot 
continue to receive MEDI4736 will enter fo llow-up for 90 -day safet y assessments and 
survival fo llow-up (see Appendix 14 for schedule of procedures).
Figure 4.5.3.3 -1 Dosing Schema for MEDI4736 Q2W Dose -expansion 
Cohorts
Q2W = every 2 weeks.
4.5.4 Treatment Administration
The first day  of dosing is considered Day 1. Subj ects in the first dose-escalat ion cohort will 
receive the first dose of MEDI4736 as an IV infusion over 4 hours and subsequent doses as 
an IV infusio n over approximately 60 minutes (± 5 minutes). In the rema ining 
dose-escalat ion and expansio n cohorts, MEDI4736 will be administered as an IV infusio n 
over approximately 60 minutes (± 5 minutes). When a syringe is used for the infusio n, the 
syringe shoul d be disconnected when the correct volume has been infused. When an IV bag 

MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 68of 220 Template 14.1is used for the infusio n, the IV line will be flushed with a vo lume of normal saline equal to 
the priming vo lume of the infusion set used after the contents of the IV bag are fully 
administered (unless prohibited by inst itutional practi ce).
Since the compat ibilit y of MEDI4736 wi th other IV medicat ions and so lutions, other than 
norm al saline (0.9% [w/v] Sodium Chloride for Injection), is not known, the MEDI4736 
solution shoul d not be infused through an IV line in which other solutions or medic ations are 
being administered. The date, start time, interruption, and complet ion time of MEDI4736 
administration must be recorded in the source documents.
4.5.5 Monitoring of Dose Administration 
Subjects will be mo nitored during and after the first infusio n ofMEDI4736 wi th assessment 
of vital signs wi thin an hour prior to the start of the infusio n, every  15 minutes (± 5 minutes) 
during the infusion, at the end of infusio n (+ 5 minutes) and at 30 minutes (± 5 minutes) and 
60minutes (± 5minutes) postinfusio n, followed by  a 3-hour (± 15 minutes) period of 
observat ion. For subsequent doses (at dose levels of 10 mg/kg or less), the 3- hour 
observat ion peri od will  not be requi red unless a subject experiences an infusio n-related 
reacti on or a hi gher dose l evel is being tested. The 3 -hour observat ion peri od, however, will 
be required for the first 4 doses for any  dose l evel > 10m g/kg (Q2W or Q3W) and for 
subjects in the 20 mg/kg Q4W dose -exploration cohort.
Acetaminophen and/or an ant ihistamine (eg, diphenhydramine) or equivalent medicat ions per 
institutional standard m ay be administered prior to infusio n at the discret ion of the 
investigator for primary  prophylaxis against infusion -related reactions. In the event of Grade 
≤2 infusio n-related reacti on, the infusio n rate of MEDI4736 may be decreased by 50% or 
interrupted until reso lution of the event (up to 4 hours) and re -initiated at 50% of the init ial 
rate until co mpletion o f the infusio n. In subjects experiencing Grade ≤2 infusion -related 
reacti on, subsequent infusi ons may  be administered at 50% of the initial rate. If a subject 
experiences an infusio n-related reaction, acetaminophen and/or an ant ihistamine (eg, 
diphenhydramine) and/or corticosteroid or equivalent medicat ions per inst itutional standard 
may be adminis tered pri or to subsequent infusio ns at the discretion of the invest igator for 
secondary  prophylaxis of infusio n-related reacti ons. If the infusio n-related reacti on is Grade 
3 or hi gher in severit y, treatm ent wi th MEDI4736 will be discont inued.
As wi th any antibody , allergic reactions to dose administration are possible. Appropriate 
drugs and medical equipment to treat acute anaphylact ic react ions must be immediately 
available, and study  personnel must be trained to recognize and treat anaphylaxis. The study
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 69of 220 Template 14.1site must have immediate access to emergency  resusci tation team s and equipment in addit ion 
to the abilit y to admi t subjects to an intensive care unit if necessary .
4.5.6 Dose Escalation
In the dose -escalat ion phase, the first dose of MEDI4736 will be administer ed to all subjects 
in the first cohort as a 0.1 mg/kg infusio n given over 4 hours. Subsequent infusio ns (2nd and 
3rd doses, etc) for the first cohort will be given over approximately 60 minutes Q2W. The 
doses for subsequent cohorts will be 0.3, 1.0, 3.0, o r 10mg/kg, administered over 
approximately  60 minutes as an IV infusion Q2W unless an MTD or OBD is ident ified 
before all dose -escalat ion cohorts are completed. Higher doses may be further explored based 
on clinical, safet y, and PK/pharmacodynamic data ge nerated fro m the study . If 2 or m ore 
DLTs are observed in the first dose cohort, the dose will be de -escalated to half of the 
starting dose (0.05 mg/kg) and will be given Q3W.
Upon com pletion of dose escalat ion for the MEDI4736 Q2W dose -escalation arm, a s eparate 
Q3W dose -escalat ion arm  will be init iated in parallel with the dose- expansio n phase. The 
dose pl anned for the first Q3W escalat ion cohort i s the dose that i s the equivalent dosing rate 
(in average mg/kg/week) to the OBD or highest dose tested if an OBD was not i dentified. A 
lower dose may  be used pending review of available data. For example, if dose escalat ion 
proceeds to 10 mg/kg Q2W, the planned starting dose in the Q3W dose escalat ion will be 
15mg/kg Q3W.
If an MTD is reached prior to complet ing the Q2W dose escalat ion, the Q3W starting dose 
will be the equivalent dosing rate to the Q2W MTD. For example, if an MTD is identified at 
3.0mg/kg Q2W, the starting dose in the Q3W dose escalat ion will be approximately 
4.5mg/kg Q3W. The Q3W dose escala tion will proceed based upon on available data. 
Addit ional MEDI4736 Q3W cohorts wi th 3-6subjects each may be init iated based on 
acceptable clinical, safet y, and PK/pharmacodynamic data fo llowing the rul es for dose 
escalat ion described below . Because the DLT evaluation period for this study  includes 
2doses of MEDI4736, the timing of any toxicit ies observed during the Q2W escalat ion will 
be important in determining the maximum dose level to be evaluated in the Q3W escalat ion. 
If DLTs defining the Q2W MTD a re observed prior to the second dose of MEDI4736, the 
Q3W dose escalat ion may not proceed past the Q2W MTD dose level. However, if the DLTs 
defining the Q2W MTD are observed after the second dose of MEDI4736, the Q3W dose 
escalat ion may proceed bey ond the Q2W MTD.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 70of 220 Template 14.1Rules for dose escal ation are as fo llows:
1.The MTD will be determined based on the assessment of DLT (as defined in 
Secti on4.5.7 ) during t he DLT evaluat ion peri od, which is defined as the period fro m 
administration of the first dose of MEDI4736 until the planned administration of the third 
dose. Subjects are considered evaluable for assessment of DLT if they receive 2 full 
assigned doses of MEDI4736, or the subject experiences any  DLT. Nonevaluable 
subjects will be replaced in the same dose cohort.
2.A minimum of 3 subjects will be enrolled in each dose cohort. 
3. The administration of MEDI4736 to the first and second subjects of each cohort will be 
separated by  at least 24 hours.
4.Dose escalat ion to the next dose level is permitted only  after the subject(s) enrolled in the 
current dose cohort have competed the DLT observat ion peri od and all safet y data have 
been reviewed by  a study -specific dose -escalat ion committee.
5.If 1 of the 3 subjects in any  dose cohort experiences a DLT, that dose cohort will be 
expanded to a total of 6 subjects. If no m ore than 1 of 6 subjects in the cohort experiences 
a DLT, dose escalat ion may proceed.
6.If 2 or more subject s in a dose cohort experience a DLT during the DLT evaluat ion 
period, the MTD will be exceeded and no further subjects will be enro lled into that dose 
cohort. If this occurs, the preceding dose cohort will be evaluated for the MTD and a total 
of 6subjects will be treated at the preceding dose. If no more than 1 of 6 subjects 
experiences a DLT at the preceding dose, then that dose level will be the MTD.
7.At the di screti on of  the sponsor, dose escalat ion may be stopped before an MTD is 
reached. In this case, the OBD m ay be chosen based on an assessment of PK, 
pharmacodynamic, bio marker, safet y, and response data. An MTD does not have to be 
reached to expand a dose cohort if the available data demonstrate that a lower dose level 
may provide ant itumor activit y while minimizing potential risk.
8.Upon com pletion of the Q2W dose escalat ion, the cohort with eit her the highest dose 
level shown to be well tolerated or the OBD will be expanded to a total of 6 subjects (if 
not already done due to observat ion of a DLT).
9.A separate, Q3W dose escalat ion will be init iated following the complet ion of dose 
escalat ion for the Q2W dose- escalat ion arm  and at the sam e time as the dose -expansio n 
phase. Dose escalat ion will begin wit h the highest dose level that has not exceeded the 
MTD or the OBD in the Q2W dose -escalat ion arm and proceed as per the rules outlined 
above.
10.Upon com pletion of the Q3W dose escalat ion, the cohort with eit her the highest dose 
level that does not exceed the MTD or the OBD will be expanded to a total of 6 subj ects 
(if not already done due to observat ion of a DLT).
4.5.7 Dose -limiting Toxicity
Dose -limit ing toxicit ies will be evaluated during the dose -escalat ion phase. The period for 
evaluat ing DLTs will be fro m the time of first administration of MEDI4736 until the planned 
administration of the third dose of MEDI4736. Subjects who do not remain on the study  up 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 71of 220 Template 14.1to this time for reasons other than DLT will be replaced with another subject at the same dose 
level. Grading of DLTs will be according to the NCI CTCAE v4.03.
A DLT will be defined as any Grade 3 or higher treatment -related toxi city that occurs during 
the DLT evaluation period, including
•Any Grade ≥ 3 colit is 
•Any Grade ≥ 3 irAE including rash, pruritus, or diarrhea that does not downgrade to 
Grade ≤2 within 3 days after onset of the event despite maximal supportive care 
including systemic corticosteroids 
The definit ion excludes the fo llowing condit ions: 
•Grade 3 decrease in lymphocy te count or increase in GGT that downgrades t o Grade ≤ 2 
within 7 days after onset of the event and resolves to Grade ≤ 1 or baseline wit hin 
14days
•Grade 3 endocrinopathy  that i s managed wit h or wit hout sy stemic corti costeroi d therapy  
and/or hormone replacement therapy  and the fo llowing criterion is met:
◦The subject is asymptomatic
•Grade 3 inflammatory  react ion attributed to a local antitumor response (eg, inflammatory 
reacti on at si tes of  metastati c disease, lymph nodes, etc) 
Immune-related AEs are defined as AEs o f immune nature (ie, inflammatory ) in the absence 
of a clear al ternat ive et iology. In the absence of clinical abnormalit y, repeat l aboratory  
testing will be conducted to confirm significant laboratory findings prior to designat ion as a 
DLT.
4.5.8 Dose Modification for Toxicity Management
Based on the m echanism o f action of  MEDI4736 leading to T -cell act ivation and 
proliferat ion, there is the possibilit y of observing irAEs during the conduct of this study . 
Potenti al irAEs m ay be similar to those seen wit h the use of ipilimumab and nivo lumab, and 
may include immune -mediated enterocolit is, dermatit is, pneumo nitis, hepat itis 
(hepatotoxi city), neurotoxi city, and endocrinopathies ( Hodi etal, 2010 ; Brahmer et al, 2012 ; 
Topalian et al, 2012 ; Wolchok et al , 2013 ). Subjects should be monitored for signs and 
symptoms of irAEs in any organ. In the absence of an alternate etio logy (eg, infect ion or 
PD), an immune -related eti ology shoul d be considered for si gns or symptom s of co litis, 
pneumo nitis, hepatit is/hepatotoxicit y, neuropathy /neurom uscular toxicit y, endocrinopathy , 
derm atitis, and nephrit is.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 72of 220 Template 14.1All toxicit ies will be graded according to NCI CTCAE v4.03. 
Treatment modifica tions will not be required for AEs that are clearly not attributed to 
MEDI4736 (such as an accident) or for laboratory  abnorm alities that are not deemed to be 
clinically significant. Dose reductions are not permitted. Dose modificat ion and management 
guidelines are provided in Appendix 15 . Dosing may  cont inue despite concurrent vit iligo of 
any AE grade.
4.5.9 Treatment Compliance
Invest igational product is administered by study  site personnel, who will mo nitor subj ect 
compliance.
4.6 Concomitant Medications
4.6.1 Permitted Concomitant Medications
Invest igators may prescribe concomitant medicat ions or treatments (eg, acetaminophen, 
diphenhydramine) deemed necessary  to provi de adequat e prophylact ic or supportive care 
except for those medicat ions ident ified as “excluded” as listed in Section 4.6.2 .
4.6.2 Excluded Concomitant Medications
Subjects m ust be instructed not to take any  medicati ons, including over- the-counter products, 
without fi rst consul ting wi th the investi gator.
The fo llowing m edicat ions are considered exclusio nary during the study . The sponsor m ust 
be notified if a subject receives any o f these during the study .
1.Any invest igational anticancer therapy
2.Any concurrent chemotherapy, radiotherapy , immunotherapy , biologic, or horm onal 
therapy  for cancer treatm ent. Concurrent use of hormones for noncancer- related 
condi tions (eg, insulin for diabetes and hormone replacement therapy ) is acceptable. 
Note: Local treatm ent of isolated lesio ns for palliative intent is acceptable (eg, by  local 
surgery  or radi otherapy )
3.Immunosuppressive medications including, but not limited to systemic corticosteroids at 
doses bey ond 10 m g/day  of predniso ne or equivalent, methotrexa te, azathi oprine, and 
tumor necrosis factor alpha (TNF -α) blockers. Use of immunosuppressive medicat ions 
for the m anagement of invest igational product -related AEs and in subjects with contrast 
allergies is acceptable. In addit ion, use of inhaled, topical, and intranasal corticosteroids 
is permitted. Temporary  courses of corti costeroi ds for treatm ent of underlying or 
concurrent illness or in the setting of palliat ive radiotherapy  may be permitted upon 
discussio n with the m edical mo nitor. 
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 73of 220 Template 14.14.Live attenuated vac cines within 30 days of MEDI4736 dosing
4.7 Subject Completion
An individual subject will be considered to have completed the study if the subject was 
followed up through the end of the study  as defined in Sect ion 4.8, regardless o f the number 
of doses of invest igational product that was received.
Subjects will be considered not to have co mpleted the study  if consent was withdrawn or the 
subject was lost to fo llow-up (see Secti on 4.2.3 ).
4.8 End of the Study
The end o f the study  (“study  com pletion”) is defined as the date of the last protocol -specified 
visit/assessment (including telephone contact) for the last subject in the study  or the date the 
study  is closed by  the sponsor, whichever occurs first. All materials or supplies provided by  
the sponsor will be returned to the sponsor or designee upon stud y completion, as di rected by  
the site monitor. The investi gator will notify the IRB/IEC when the study  has been 
completed.
5STUDY PROCEDURES
5.1 Schedule of Study Procedures
All subjects who are assigned an SID number and receive any invest igational product wil l be 
followed according to the protocol regardless o f the number of doses received, unless consent 
is wit hdrawn. The invest igator must notify the sponsor or designee of deviat ionsfrom 
protocol  visit s or evaluat ions and these evaluat ions, if applicable, mu st be rescheduled or 
perform ed at the nearest possible time to the original schedule. Protocol deviations will be 
recorded on the source document with an explanation for the deviat ion and any study -
specific case report forms (CRFs) or logs designated for c apturing protocol deviat ions, if 
applicable for the study . The invest igator must comply wit h the applicable requirements 
related to the reporting of protocol deviations to the IRB/IEC.
Subjects/legal representatives will be instructed to call study  personn el to report any  
abnorm alities during the intervals between study  visits and to com e to the study  site if 
medical evaluat ion is needed and the urgency o f the situation permits. For emergency  and 
other unscheduled visits to a medical facilit y other than the study  site, m edical  records will  
be obtained by the invest igator and made available to the sponsor or designee during 
monitoring visits.
MedImmune Protocol CD -ON-ME DI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 74of 220 Template 14.1Schedules of study  procedures for the screening and treatment period are presented in 
Table 5.1-1for Q2W or Q3W dosing schedules and Table 5.1-2for Q4W dosing sc hedule. 
Subjects in retreatment using the Q4W dosing schedule will fo llow the same schedule as 
initial treatment. A schedule o f follow-up study  procedures for subjects who have co mpleted 
MEDI4736 treatment and achieved DC (unt il confirmed PD) and subjects who have 
discontinued MEDI4736 due to toxicit y in the absence o f PD is presented in Table 5.1-3. A 
schedule of retreatment for subject in dose -escalat ion and dose -expansio n is presented in 
Appe ndix 13 . A schedule of fo llow-up study  procedures and descript ion of each visit for 
subjects who have dis continued MEDI4736 treatment due to confirmed PD is presented in 
Appendix 14 . A description o f the study  procedures i s included in Sect ion5.2. The sponsor 
may stop the collect ion of an exploratory  laboratory  evaluat ion at any  time based on 
available data.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 75of 220 Template 14.1Table 5.1-1 Schedule of Study Procedures: Screening and Treatment Period
EvaluationScreening
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 days)
Odd-
numbered 
Doses (after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 
6 Weeks 
(Day 43 
± 7 days)After 12 
Weeks and 
16 Weeks 
(Days 85 and 
113) 
Then Every  
8 Weeks 
(± 7 days)Days Days
12 
(Dose -
escala -
tion 
only)3 
(Dose -
escala -
tion 
only)5 ±1 
(Dose -
escala -
tion 
only)10 
± 115 ± 1 
(for 
Q3W)18 
± 1
Written informed 
consent/assignment
of SID numberX
Verify  eligibility  
criteriaX X
Pain questionnaire 
(dose -expansion 
phase only )X XX (Doses 3 
and 5 o nly)X X
EORTC QLQ -C30 
and cancer -specific 
modules (dose -
expansion phase 
only)X XX (Doses 3 
and5 only)X X
FACT -BL (UBC 
subjects only)X XX (Doses 3 
and 5 o nly)X X
Collect pathology 
report (if available)X
Medical history X
Smoking history X
Hepatitis B and C; 
HIVX
Serum βhCG X
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 76of 220 Template 14.1Table 5.1-1 Schedule of Study Procedures: Screening and Treatment Period
EvaluationScreening
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 days)
Odd-
numbered 
Doses (after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 
6 Weeks 
(Day 43 
± 7 days)After 12 
Weeks and 
16 Weeks 
(Days 85 and 
113) 
Then Every  
8 Weeks 
(± 7 days)Days Days
12 
(Dose -
escala -
tion 
only)3 
(Dose -
escala -
tion 
only)5 ±1 
(Dose -
escala -
tion 
only)10 
± 115 ± 1 
(for 
Q3W)18 
± 1
Urine hCG or serum 
βhCGX X X X
Kit assignment and 
MEDI4736 
administrationX X X X
Protocol/Safety Evaluations
Physical 
examinationX X X X X
Vital signs aX X X X X
Postinfusion 
observationa X X X X
Weight X X X X X
Electrocardiogram, 
Q2W dose -
escalation armbX X X (ever y 4thdose)
Electrocardiogram, 
Q3W dose -
escalation armbX X X (ever y 3rddose)
Electrocardiogram, 
Q2W dose -
expansion b,cX XX (ever y 12 weeks
starting at Dose 3)
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 77of 220 Template 14.1Table 5.1-1 Schedule of Study Procedures: Screening and Treatment Period
EvaluationScreening
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 days)
Odd-
numbered 
Doses (after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 
6 Weeks 
(Day 43 
± 7 days)After 12 
Weeks and 
16 Weeks 
(Days 85 and 
113) 
Then Every  
8 Weeks 
(± 7 days)Days Days
12 
(Dose -
escala -
tion 
only)3 
(Dose -
escala -
tion 
only)5 ±1 
(Dose -
escala -
tion 
only)10 
± 115 ± 1 
(for 
Q3W)18 
± 1
AE/SAE assessment X X X X X X X X X X
Concomitant 
medicationsX X X X X
ECOG performance 
statusX X X X X
Laboratory Evaluations
Hepatitis B and C 
viral titers (only 
HCC subjects with 
hepatitis B or C)X X
Serum chemistry X X X X X
Thyroid functio n 
tests (TSH and free 
T3 and T4)X X X X X
Hematology X XdX X X X X
Urinaly sis X X X X X
Coagulation 
parametersX X X X
Pharmacokinetic 
assessment, Q2W 
dose-escalation arm XeX X X XeX Xe
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 78of 220 Template 14.1Table 5.1-1 Schedule of Study Procedures: Screening and Treatment Period
EvaluationScreening
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 days)
Odd-
numbered 
Doses (after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 
6 Weeks 
(Day 43 
± 7 days)After 12 
Weeks and 
16 Weeks 
(Days 85 and 
113) 
Then Every  
8 Weeks 
(± 7 days)Days Days
12 
(Dose -
escala -
tion 
only)3 
(Dose -
escala -
tion 
only)5 ±1 
(Dose -
escala -
tion 
only)10 
± 115 ± 1 
(for 
Q3W)18 
± 1
Pharmacokinetic 
assessment, Q3W 
dose-escalation arm XeX X X X XeX Xe
Pharmacokinetic 
assessment, Q2W 
dose-expansion armXeXe X (ever y 12 weeks 
starting at Dose 3)
Pharmacokinetic 
assessment, Q2W 
UBC cohortXfX
(Dose 3 , 7, 
and 13 
[Day  29, 
85, and 
169])
Immunogenicity 
assessment dose -
escalation armsXX (Dose 3 
only)X (begin 
after 
Dose 4)
Immunogenicity 
assessment dose -
expansion armsXX (ever y 12 weeks 
starting at Dose 3)
Immunogenicity 
assessment UBC 
cohortXX
(Dose 3, 7, and 13 
[Day 29, 85, and 169] )
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 79of 220 Template 14.1Table 5.1-1 Schedule of Study Procedures: Screening and Treatment Period
EvaluationScreening
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 days)
Odd-
numbered 
Doses (after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 
6 Weeks 
(Day 43 
± 7 days)After 12 
Weeks and 
16 Weeks 
(Days 85 and 
113) 
Then Every  
8 Weeks 
(± 7 days)Days Days
12 
(Dose -
escala -
tion 
only)3 
(Dose -
escala -
tion 
only)5 ±1 
(Dose -
escala -
tion 
only)10 
± 115 ± 1 
(for 
Q3W)18 
± 1
sPD-L1 
concentration  dose -
escalation armsX XeX X X X X X X
sPD-L1 
concentration dose -
expansion arms cXeX X (ever y 12 weeks 
starting at Dose 3)
Flow cytometric 
analy sis -absolute 
cell counts, immune 
cell subsets, 
activatio n markers 
dose-escalation armsX XdX X X X X
Flow cytometric 
analy sis-absolute 
cell counts, immune 
cell subsets, 
activatio n markers 
dose-expansion 
arms cX X X X X h
Circulating soluble 
factors dose -
escalation armsX X gX X X X gX gX g
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 80of 220 Template 14.1Table 5.1-1 Schedule of Study Procedures: Screening and Treatment Period
EvaluationScreening
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 days)
Odd-
numbered 
Doses (after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 
6 Weeks 
(Day 43 
± 7 days)After 12 
Weeks and 
16 Weeks 
(Days 85 and 
113) 
Then Every  
8 Weeks 
(± 7 days)Days Days
12 
(Dose -
escala -
tion 
only)3 
(Dose -
escala -
tion 
only)5 ±1 
(Dose -
escala -
tion 
only)10 
± 115 ± 1 
(for 
Q3W)18 
± 1
Circulating soluble 
factors dose -
expansion arms X X XcXcXc
PBMC collection 
(immunodiversity, 
flow cytometry, or 
functional 
assessment) dose -
escalation armsX X X X X X
Anticancer/testis 
antigen antibodies 
dose-escalation armsX X
Anticancer/testis 
antigen antibodies 
dose-expansion 
arms cX X
Circulating tumor 
cells (dose 
escalation and 
TNBC for dose 
expansion)X X X
miRNA/mRNA 
analy sis dose -
escalation armsX X X X X
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 81of 220 Template 14.1Table 5.1-1 Schedule of Study Procedures: Screening and Treatment Period
EvaluationScreening
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 days)
Odd-
numbered 
Doses (after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 
6 Weeks 
(Day 43 
± 7 days)After 12 
Weeks and 
16 Weeks 
(Days 85 and 
113) 
Then Every  
8 Weeks 
(± 7 days)Days Days
12 
(Dose -
escala -
tion 
only)3 
(Dose -
escala -
tion 
only)5 ±1 
(Dose -
escala -
tion 
only)10 
± 115 ± 1 
(for 
Q3W)18 
± 1
miRNA/mRNA 
dose-expansion armsX XcXcXcXc
Archival tumor 
tissue sample i X
Confirm HPV status 
by central lab 
(HPV -positive 
cancers only)X
Disease Evaluations
Disease assessment XjX X
Submission of 
baseline imaging for 
BICR (UBC cohort 
only)X
Tumo r biopsy  
(dose -expansion 
phase only )iX Xc
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 82of 220 Template 14.1Table 5.1-1 Schedule of Study Procedures: Screening and Treatment Period
EvaluationScreening
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 days)
Odd-
numbered 
Doses (after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 
6 Weeks 
(Day 43 
± 7 days)After 12 
Weeks and 
16 Weeks 
(Days 85 and 
113) 
Then Every  
8 Weeks 
(± 7 days)Days Days
12 
(Dose -
escala -
tion 
only)3 
(Dose -
escala -
tion 
only)5 ±1 
(Dose -
escala -
tion 
only)10 
± 115 ± 1 
(for 
Q3W)18 
± 1
AE = adverse event; βhCG = beta human chorionic gonadotropin; BICR =blinded independent central review; ECG = electrocardiogram; ECOG = Eastern 
Cooperative Oncology Group; EORTC QLQ -C30 = European Organisation for Research and Treatment of Cancer quality -of-life questionnaire; FACT -BL = 
Functional Assessment of Chronic Illness Therapy -bladder; HCC = hepatoce llular carcinoma; hCG = human chorionic gonadotropin; HIV = human 
immunodeficiency virus; HPV = human papilloma virus; IHC = immunohistochemistry; miRNA =micro ribonucleic acid; mRNA = messenger ribonucleic 
acid; PBMC = peripheral blood mononuclear cell; PD-L1 = programmed death ligand 1; Q2W = every 2 weeks; Q3W = ever y 3 weeks; SAE = serious 
adverse event; SID = subject identification; sPD -L1 = soluble programmed death ligand 1; TNBC = triple negative breast cancer; TSH = thyroid -stimulating 
hormone; UBC = urothelial bladder cancer.
Note: all samples are collected predose unless otherwise indicated.
aVital signs every 15 minutes (± 5 minutes) during MEDI4736 administration, at the end of infusion (+ 5 minutes), and at 30 and 60 minutes (± 5 minutes) 
post end of infusion, followed by a 3 -hour (± 15 minutes) period of observation. For subsequent doses (at dose levels of 10 mg/kg or less), the 3 -hour 
observation period will not be required unless a subject experiences an infusion -related reaction or a higher dose level is being tested.
bECGs will be collected during screening, on Dose 1, Day 1 (within an hour prior to start of infusion, within 30 minutes post -end of infusion, and 3 hours 
[±15 minutes] post -end of infusion) and within an hour prior to start of infusion on remaining dosing days indicated.  Digital ECGs will be collected at 
selected sites. All other sites will perform ECGs per their institution’s standard.
cNot required for subjects in the UBC cohort.
dPredose (for both dose -escalatio n and dose -expa nsion subjects) and 3 hours (± 15 minutes) post end of infusion (for dose -escalation subjects only).
ePredose and post dose (+ 5 minutes) post end of infusion. For Cohort 1 subjects only, an additional sample will be taken 2 hours after start of infusi on.
fEnd of infusion (+ 5 minutes).
gPredose and 2 hours (± 15 minutes) post end of infusion.
hSample collected ever y other even dose (ie, every 8 weeks starting at Dose 4).
iFor subjects in the UBC cohort, either archival tumor tissue from within 6 months prior to study entry or a fresh biopsy isrequired for PD-L1 IHC testing. 
Additional older archival tissue regardless of age is also required, if available . 
jDisease assessments performed as part of standard of care prior to subjects signing informed consent may b e used for screening if obtained within 28 days 
before the first dose of investigational product.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 83of 220 Template 14.1Table 5.1-2 Q4W Schedule of Study Procedures: Screening and Treatment Period
Procedure ScreeningDose 1 Dose 2Odd -numbered 
Doses (after 
Dose 1; ± 3 Days)Even -numbered 
Doses (after 
Dose 2; ± 3 Days)Weeks 6, 12, 
16, Then Every 
8 Weeks (± 
7Days) Day 1 Day 2Day 15 ± 
1DaysDay 1 
± 3Days
Written informed 
consent/assignment 
of SID numberX
Verify  eligibility 
criteriaX
Collect pathology 
report (if available)X
Medical history X
Smoking history X
Hepatitis B and C; 
HIVX
Serum βhCG X
Urine hCG or serum 
βhCGX X X X
Physical 
examination 
(including weight)X X X X X X
Vital signs aX X X X X X X
Electrocardiogram bX XX (ever y other odd 
dose)
AE/SAE assessment X X X X X X X
Concomitant 
medicationsX X X X X X
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 84of 220 Template 14.1Table 5.1-2 Q4W Schedule of Study Procedures: Screening and Treatment Period
Procedure ScreeningDose 1 Dose 2Odd -numbered 
Doses (after 
Dose 1; ± 3 Days)Even -numbered 
Doses (after 
Dose 2; ± 3 Days)Weeks 6, 12, 
16, Then Every 
8 Weeks (± 
7Days) Day 1 Day 2Day 15 ± 
1DaysDay 1 
± 3Days
ECOG performance 
statusX X X X X
Hepatitis B and C 
viral titers (only 
HCC subjects with 
hepatitis B or C)X X
Serum chemistry X X X X X X
Thyroid functio n 
tests (TSH and free 
T3 and T4)X X X X X X
Hematology X X X X X X
Urinaly sis X X X X X X
Coagulation 
parametersX X X X X X
Pharmacokinetic 
assessment X cX X cX d,eX d,e
Immunogenicity X X X
sPD-L1 
concentrationX X cX X X eX e
Circulating soluble 
factorsX X X X X
Archival tumor 
tissue sampleX
Disease assessment XfX
Tumo r biopsy  XX (Week 6 ± 
7Days only )
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 85of 220 Template 14.1Table 5.1-2 Q4W Schedule of Study Procedures: Screening and Treatment Period
Procedure ScreeningDose 1 Dose 2Odd -numbered 
Doses (after 
Dose 1; ± 3 Days)Even -numbered 
Doses (after 
Dose 2; ± 3 Days)Weeks 6, 12, 
16, Then Every 
8 Weeks (± 
7Days) Day 1 Day 2Day 15 ± 
1DaysDay 1 
± 3Days
Kit assignment and 
MEDI4736 
administrationX X X X
Postinfusion 
observationX X X X
AE = adverse event; βhCG = beta human chorionic gonadotropin; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; HCC = 
hepatocellular carcinoma; hCG = human chorionic gonadotropin; HIV = human immunodeficiency virus; Q4W = every 4 weeks; SAE = serious adverse event; 
SID = subject identification; sPD -L1 = soluble programmed death ligand 1; TSH = thyroid -stimulating hormo ne.
Note: all samples are collected predose unless otherwise indicated.
aVital signs every 15 minutes (± 5 minutes) during MEDI4736 administration, at the end of infusion (+ 5 minutes), and at 30 and 60 minutes (± 5 minutes) 
post end of infusion, followed b y a 3 -hour (± 15 minutes) period of observation (for the first 4 doses only). For subsequent doses (starting at Dose 5), the 
3-hour observation period will not be required unless a subject experiences an infusion -related reaction or a higher dose level is being tested.
bECGs will be collected during screening, on Dose 1, Day 1 (within an hour prior to start of infusion, within 30 minutes post -end of infusion, and 3 hours 
[±15 minutes] post -
end of infusion) and within an hour prior to start of infusion on re maining dosing days indicated. ECGs will be performed per their 
institution’s standard.
cPredose and post dose (+ 5 minutes) post end of infusion.
dPredose and post dose (+ 5 minutes) post end of infusion for first 6 months (Doses 3 -6). 
eSampling changes to even doses (ie every 8 weeks) only starting at Dose 6. Predose sampling only after Dose 6. 
fDisease assessments performed as part of standard of care prior to subjects signing informed consent may be used for screenin g if obtained withi n 28 day s 
before the first dose of investigational product.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 86of 220 Template 14.1Table 5.1-3 Schedule of Study Procedures: Follow -up for Subjects Who Have Completed MEDI4736 
Treatment and Achieved Disease Control (Until Confir med Progressive Disease) and 
Subjects Who Have Discontinued MEDI4736 Due to Toxicity in the Absence of Confirmed 
Progressive Disease
EvaluationEnd of 
TreatmentaTime Since Last Dose of MEDI4736
Days
(± 3)Months (± 1 week)12 Months and 
Every 
3Months 
(± 2 weeks)14 30 2 3 4 6 8 10
Protocol/Safety Evaluations
Pain questionnaire (dose -expansio n phase only) X X X X X X X X b
EORTC QLQ -C30 and cancer -specific modules (dose -expansion 
phase only )X X X X X X X X b
FACT -BL (UBC subjects only) X X X X X X X X b
Physical examination X X
Vital signs X X
Weight X X
Electrocardiogram c,dX X
AE/SAE assessment X X X X X
Concomitant medications X X X
ECOG performance status X X
Subsequent anticancer therapy X X X X X X X
Survival status: phone contact with subjects who refuse to return for 
evaluations and agree to be contactedX X X X X X X
Laboratory Evaluations
Hepatitis B and C viral titers (only HCC subjects with 
hepatitis B or C)X X X X
Hematology X X
Serum chemistry X X
Thyroid functio n tests (TSH, and free T3 and T4) X X
Coagulation parameters X X
Urinaly sis X X
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 87of 220 Template 14.1Table 5.1-3 Schedule of Study Procedures: Follow -up for Subjects Who Have Completed MEDI4736 
Treatment and Achieved Disease Control (Until Confir med Progressive Disease) and 
Subjects Who Have Discontinued MEDI4736 Due to Toxicity in the Absence of Confirmed 
Progressive Disease
EvaluationEnd of 
TreatmentaTime Since Last Dose of MEDI4736
Days
(± 3)Months (± 1 week)12 Months and 
Every 
3Months 
(± 2 weeks)14 30 2 3 4 6 8 10
Pharmacokinetic assessment XdXdX
Immunogenicity assessment XdXdX Xd
sPD-L1 concentration dX X X
Flow cytometric analysis -absolute cell counts, immune cell subsets, 
activatio n markers (Q2W and Q3W subjects only) d X X X b
Circulating soluble factors dX X X X b
PBMC collection (immunodiversity, flow cytometry, or functional 
assessment; Q2W and Q3W subjects only) d X X X b
Anticancer/testis antigen antibodies (Q2W and Q3W subjects only) dX X X b
Circulating tumor cells (dose escalation and TNBC for dose 
expansion)X X X X b
miRNA/mRNA analysis (Q2W and Q3W subjects only) dX X
Disease Evaluation
Disease assessment X X X X X X X
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 88of 220 Template 14.1Table 5.1-3 Schedule of Study Procedures: Follow -up for Subjects Who Have Completed MEDI4736 
Treatment and Achieved Disease Control (Until Confir med Progressive Disease) and 
Subjects Who Have Discontinued MEDI4736 Due to Toxicity in the Absence of Confirmed 
Progressive Disease
EvaluationEnd of 
TreatmentaTime Since Last Dose of MEDI4736
Days
(± 3)Months (± 1 week)12 Months and 
Every 
3Months 
(± 2 weeks)14 30 2 3 4 6 8 10
AE = adverse event; ECOG = Eastern Cooperative Oncology Group; EORTC QLQ -C30 = European Organisation for Research and Treatment of Cancer 
quality -of-life questionnaire; ECG = electrocardiogram; FACT -BL = Functional Assessment of Chronic Illness Therapy -bladder; HCC = hepatocellular 
carcinoma; miRNA =micro ribonucleic acid; mRNA = messenger ribonucleic acid; PBMC = peripheral blood mononuclear cell; Q2W = ever y 2weeks; Q3W 
= every 3 weeks; SAE = serious adverse event; sPD -L1= soluble programmed death ligand 1; TNBC = triple negative breast cancer; TSH = thyroid -
stimulating hormone; UBC = urothelial bladder cancer. 
aEnd of treatment is defined as the last planned dosing visit within the 12 -month treatment period. For subjects who discontinue treatment prior to 
12months, end of treatment is considered the last visit where the decision is made to discontinue. All required procedures may be completed within 
± 7days of the endo of treatment visit. Note: repeat disease assessment is not required if performed wit hin 28 days prior to the end of treatment visit.
bStop evaluation at 12 months.
cDigital ECGs will be collected at select sites. All other sites will perform ECGs per their institution’s standard.
dNot required for subjects in the UBC cohort.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 89of 220 Template 14.15.1.1 Screening ……….
All screening procedures must be performed within 28 days before the first dose of 
investigat ional product (Day  -28 to Day  -1), unl ess otherwise specified. The screening 
evaluat ions m ay be carri ed out over m ore than one visit. Written informed consent and any 
locally requi red privacy act docum ent authori zation must be obtained prior to performing any 
protocol -specific procedures, including screening evaluat ions.Disease assessments 
perform ed as part of standard of care prior to subjects signing informed con sent m ay be used 
for screening if obtained within 28 days before the first dose of invest igational product.
5.1.2 Treatment Period
Includes subjects who will be receiving the first infusio n of MEDI4736 and subjects who are 
being retreated with MEDI4736 fo llowing evidence of  PD in fo llow-up. If the subject has 
completed any  safety  laboratory  tests or ECOG evaluat ion within 72 hours of Day  1, they  
will not need to be repeated.
5.1.3 End of Treatment
End of treatment is defined as the last planned dosing visit within the 12-month dosing 
period. For subj ects who di scont inue MEDI4736 prior to 12 months, end of treatment is 
considered the last visit where the decisio n is made to di scontinue treatm ent. All  required 
procedures may  be com pleted wi thin ± 7 days of the end of trea tment visi t. Repeat disease 
assessment i s not requi red if performed wit hin 28 days pri or to the end of treatment visit.
5.1.4 Post -treatment Follow -up
Post-treatm ent follow
-up assessments for subjects who have co mpleted the MEDI4736 
12-month treatment and achiev ed DC (until confirmed PD) and subjects who have 
discontinued MEDI4736 due to toxicit y in the absence o f PDare shown in Table 5.1-3. 
Assessments for subjects who have discont inued MEDI4736 treatment due to confirmed PD 
are presented in Appendix 14 .
5.2 Description of Study Procedures
5.2.1 Medical History and Physical Examination, Electrocardiogram, 
Weight, and Vital Signs
Findings fro m medical history  (obtained at screening) and physical examinat ion shall be 
given a baseline grade according to the procedure for AEs. Increases in severit y of 
pre-exist ing co nditions during the study  will be considered AEs, with resolution occurring 
when the grade returns to the prestudy  grade or below.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 90of 220 Template 14.1Physical examinat ions will be performed on study  days noted in Secti on 5.1, and will include 
assessments of the head, eyes, ears, nose, and throat, respiratory , cardi ovascular, 
gastrointestinal, urogenital, musculoskeletal, neurological, psychiatric, dermatological,
hematol ogic/lymphat ic, and endocrine systems; and height (at screening only).
Vital signs (tem perature, bl ood pressure, pul se rate, and respi ratory  rate) will  be measured on 
study  days noted i n Sect ion 5.1. On MEDI4736 treatment day s, vital signs will  be measured
within an hour pri or to start of MEDI4736 administration, every  15 minutes (5 minutes) 
during MEDI4736 administration, at the end of infusi on (+ 5 minutes), and at 30 minutes 
(±5minutes) and 60 minutes (± 5minutes) postinfusion, fo llowed by  a 3-hour 
(±15minutes) period of observat ion. For subsequent doses (at dose levels of 10 mg/kg or 
less), the 3 -hour observat ion peri od will  not be r equired unless a subject experiences an 
infusio n-related reacti on or a hi gher dose l evel is being tested. The 3 -hour observation 
period, however, will be required for the first 4 doses for any  dose l evel > 10 m g/kg (Q2W or 
Q3W) and for subjects in the 20 mg/kg Q4W dose -explorat ion cohort.
All electrocardiograms ( ECGs) recorded during the study  will be obtained in triplicate (all 3 
within a 5- minute time period at least 1 minute apart). Approximately 150 subjects at select 
sites will have ECGs collected digi tally for central  analysis. All other sites will perform 
ECGs per their institution’s standards. All ECGs will be recorded at 25 mm/second. All 
12-lead ECGs should be recorded while the subject is in the supine position. A 12 -lead ECG 
will be recorded for all subjects on study  days noted in Sect ion 5.1. The same method of 
assessment should be used throughout the study . Twelve -lead ECGs will be obtain ed after 
the subject has been rest ing in a supine position for at least 5 minutes in each case. On 
Dose 1, Day  1, ECGs will be recorded within an hour prior to start of infusio n, wi thin 
30minutes post end of infusio n, and 3 hours (± 15 minutes) post end o f infusio n. Further 
ECGs will be performed within an hour prior to start of infusio n on rem aining dosing days 
according to the schedule o f study  procedures (Secti on 5.1) and when clinically indicated, eg, 
in the event of a cardiac AE. As described in Section 5.1,ECGs are not required for subjects 
in the UBC cohort, unless clinically indicated.
Paper tracings will be used for local management, but a digital copy  of ECGs at sel ect si tes 
will be held centrally by a central ECG provider, and the data from this review will be stored 
for analysis during or at the end of the study . The independent review will not replace the 
local review by the invest igator or other medically –
qualified designee. Clinical interpretation 
and management of subjects for all ECGs will be done locally.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 91of 220 Template 14.15.2.2 Clinical Laboratory Tests
Clinical laboratory  safet y tests including serum pregnancy tests will be performed in a 
licensed clinical laboratory . Urine pregnancy  tests may be perform ed at the si te using a 
licensed test (dipst ick). Abnormal laborato ry resul ts shoul d be repeated as soon as possible 
(preferably within 24 to 48 hours).
A Laboratory  Manual will be provided to the sites that specifies the procedures for 
collect ion, processing, storage, and shipment of samples, as well as laboratory  contac t 
inform ation, specific to this clinical research study.
The fo llowing clinical laboratory  tests will  be perform ed (see Section 5.1for the schedul e of 
tests):
Serum Chemistry
•Calcium •GGT
•Chloride •Lactic dehydrogenase 
•Magnesium •Uric acid
•Potassium •Creatinine
•Sodium •Blood urea nitrogen
•Bicarbonate •Glucose
•AST •Albumin
•ALT •Total protein
•Alkaline phosphatase (ALP) •Triglycerides
•Total bilirubin •Cholesterol
Note for serum chemistries: Tests for AST, ALT, ALP, and total bilirubin must be conducted concurrently 
and assessed concurrently
Hematology
•White blood cell (WBC) count with differential •Platelet count
•Red blood cell (RBC) count •Mean corpus cular volume
•Hematocrit •Mean corpuscular hemoglobin concentration
•Hemoglobin
Urinalysis
•Color •Glucose
•Appearance •Ketones
•Specific gravity •Blood
•pH •Bilirubin
•Protein •Microscopy including WBC/high power field 
(HPF), RBC/HPF
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 92of 220 Template 14.1Pregnancy Test (females of childbearing potential only)
•Urine hCG
•Serum βhCG
Other Safety Tests
•Coagulation tests: prothrombin time, partial thromboplastin time, fibrinogen
•Hepatitis B surface antigen, hepatitis C antibody
•HIV-1 antibody
•Thyroid functio n tests: TSH, free T3 and free T4
•Hepatitis B and C viral titers  (only HCC subjects with hepatitis B or C) 
5.2.3 Pharmacokinetic Evaluation and Methods
Measurement of MEDI4736 concentrations in serum will be performed using a validated 
immunoassay.
Details for collect ion, aliquoting, storage, and shipment of serum samples for PK evaluat ions 
are presented in a separate Laboratory  Manual.
Blood sam ples f or measurement of MEDI4736 concentrations in serum will be collected in 
samples taken according to the schedules presented in S ection 5.1. 
5.2.4 Immunogenicity Evaluation and Methods
Presence of ADA will be assessed in samples taken according to the schedule presented in 
Secti on 5.1. Sam ples will  be measured for the presence of ADA by  MedImmune using a 
validated bridging immunoassay . Tiered analysis will be performed to inc lude screening, 
confirmatory  and ti ter assay  com ponents and posi tive-negat ive cut points will be emplo yed 
that were statist ically determined fro m drug naive validat ion samples. Samples will be 
collected for assessing the neutralizat ion capacit y in the futu re.
5.2.5 Biomarker Evaluation and Methods
Blood sam ples will be collected and analyzed to evaluate protein, nucleic acid, and 
cellular biomarkers that relate to MEDI4736 treatment according to the schedule presented in 
Secti on 5.1.
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 93of 220 Template 14.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other bio markers may be evaluated as determined by addit ional data. Details for sample 
collect ion, processing, storage, and shipment will be provided in the Laboratory Manual.
5.2.6 Disease Evaluation and Methods
Tumor assessments will be based on RECIST v1.1 guidelines ( Eisenhauer et al, 2009 ) with 
modificati ons f or all subjects, except those with GBM who will be evaluated based on 
RANO gui delines ( Wen et al, 2010 ), and will be performed during screening and treatment 
according to the schedule presented in Section 5.1.Modificat ion of RECIST as described 
may discourage the early discont inuat ion of MEDI4736 and provide a more complete 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 94of 220 Template 14.1evaluat ion of its ant itumor activit y than woul d be seen wi th conventi onal response cri teria. 
Nonetheless, the efficacy an alysis will be conducted primarily  based on RECIST v1.1. This 
assessment schedule also applies to th ose subjects who continue to receive MEDI4736 
beyo nd confirmed PD, and those subjects who re -enter treatment upon evidence of PD 
during follow-up. For those subjects who discont inue MEDI4736 as a result of confirmed 
PD, di sease evaluat ion will be performed at the end of treatment visit if clinically appropriate 
(ie, in the absence of rapidly deteriorating clinical status). For those subjects who enter 
follow-up after di scont inuing MEDI4736 as a result of toxicit y or having achieved DC, 
disease evaluat ion will be performed at the end of treatment visit, every  2 months f or 1 year, 
and every  3months thereafter until the end of the study  or confirmed PD. Addit ional disease 
assessments may be performed as clinically indicated.
All imaging assessments, including unscheduled visit scans, will be co llected on an ongoing 
basis and sent to the sponsor or designee for storage. The centralized storage of imaging data 
is intended for BICR of disease assessments. At t he discret ion of the sponsor, a BICR of all 
scans used in the assessment of tumors by  RECIST v1.1 and/or irRECIST will be conducted. 
Guidelines for imaging collection and storage will be provided in a separate c harter. The 
management of subjects will be based so lely upon the results of the assessment conducted by  
the invest igator based on RECIST v1.1. Note: subjects who were assessed by immune -related 
response criteria ( irRC) under ol der versio ns of this protocol will continue to be assessed by 
irRC.
The tum or assessment performed at 6 weeks after init iation of MEDI4736 will not be used to 
docum ent ant itumor efficacy or make decisio ns regarding subject participat ion in the study  
unless observed disease progression is acco mpanied by  rapidly  deteri orating clinical status. 
This is an exploratory  disease assessment only and will be used to evaluate the kinetics of 
tumor response to MEDI4736. However, the investigator and/or subject may decide at any  
time that i t is in the subject’s best interest to discont inue from the study .
Tumor assessments m ay include the following evaluat ions: physical examinat ion (wi th 
photograph and measurement of skin lesio ns as applicable); computed tomography  (CT) or 
magnet ic resonance imaging (MRI) scan o f the chest, abdomen, and pelvis; and CT or MRI 
scan of the brain. Co mputed tomography or MRI scan o f the brain will be performed only at 
screening or if the subject is neurologically symptomat ic. Subjects with GBM should use 
MRI wi th contrast for tum or assessments. The preferred method of disease assessment is CT 
with contrast except for subjects with GBM. If CT with contrast is contraindicated, CT 
without contrast i s preferred over MRI . The same method is preferred for all subsequent 
tumor as sessments.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 95of 220 Template 14.15.2.6.1 RECIST v 1.1
Physical examinat ion
•Lesio ns detected by  physical examinat ion will only be considered measurable if 
superficial, eg, skin nodules and palpable lymph nodes. Documentation by co lor 
photography  including ruler is recommended for estimat ing the size of skin lesio ns.
CT scan wit h contrast of the chest, abdomen, and pelvis 
•CT scans should be performed with cont iguous cuts in slice thickness of 5 mm or less. 
Spiral CT shoul d be perform ed using a 5 -mm cont iguous reconstruction algori thm.
MRI scans
•MRI of the abdo men and pelvis is acceptable for measurement of lesio ns provided that 
the sam e anatomical plane is used for serial assessments. If possible, the same imaging 
device should be used for serial evaluations. In case of MRI, measu rements will  be 
preferably performed in the axial (transverse) plane on contrast -enhanced T1- weighted 
images. However, there are no specific sequence recommendations.
Measurability of Tumor Lesions 
Tumor lesi ons will  be categori zed as fo llows:
•Measurable Lesions -  Must be accurately measured in at least one dimensio n 
(longest diameter in the plane of measurement is to be recorded) with a minimum size of: 
•10mm by CT scan (irrespect ive of scanner type) and MRI ( no less than double the slice 
thickness and a minimum of 10 mm). 
•10mm caliper measurement by  clinical  exam (when superficial).
•Malignant lymph nodes are considered pathologically enlarged and measurable, a lymph 
node m ust be ≥ 15 mm in short axis when assessed by  CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm).
•Nonmeasurable Lesions -Nonmeasurable lesions are defined as all other lesio ns (or 
sites of  disease), including small lesio ns (longest diameter < 10 mm or pathological 
lymph nodes with ≥ 10 to < 15 mm short axis). L esions considered truly  nonmeasurable 
include the fo llowing: l eptom eningeal disease, ascites, pleural/pericardial effusio n, 
inflammatory  breast disease, lymphangit ic involvement of skin or lung, abdo minal 
masses/abdo minal organo megaly identified by physica l exam that is not m easurable by  
reproducible imaging techniques.
•Target Lesions -All lesions up to a m aximum of 5 lesio ns total  (and a m aximum of 
2lesio ns per organ) representative of all invo lved organs should be ident ified as target 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 96of 220 Template 14.1lesions. It m ay bethe case that, on occasion, the largest lesio n does not lend itself to 
reproducible measurement in which circumstance the next largest lesion which can be 
measured reproducibly should be selected.
•Non-target Lesions -It is possible to record mult iple non target l esions invo lving the 
same organ as a single item on the case record form (eg, “mult iple enlarged pelvic lymph 
nodes” or “mult iple liver m etastases”).
Response Criteria
Evaluation of Target Lesions
•Complete Response -Disappearance of all target le sions. Any  pathol ogical lymph 
nodes (whether target or non -target) m ust have reducti on in short axis to < 10mm (the 
sum may not be “0” if there are target nodes). 
•Partial Response -At least a 30% decrease in the sum of the diameters of target 
lesions, t aking as reference the baseline sum diameters.
•Progressive Disease -At least a 20% i ncrease in the sum of diameters of target 
lesions, taking as reference the smallest sum on study  (this includes the baseline sum if 
that is the smallest on study ). In addi tion to the relative increase o f 20%, the sum  must 
also demonstrate an abso lute increase o f at least 5 mm. (Note: the appearance of one or 
more new l esions is also considered progression.)
•Stable Disease -Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum of diameters while on study .
Evaluation of Non -target Lesions
•Complete Response -Disappearance of all non -target l esions and norm alizat ion of 
tumor marker l evel. All lymph nodes must be non -pathol ogical in size (< 10 mm short 
axis). 
•Non-complete response/Non -progressive disease -Persistence of 1 or more 
non-target l esion(s) and/or m aintenance o f tumor marker l evel above the norm al limits.
•Progressive Disease -Unequivocal progr ession of exist ing non -target l esions will  be 
defined as the overall level o f substant ial worsening in non -target di sease such that, even 
in presence of SD or PR in target disease, the overall tumor burden has increased 
sufficient ly to merit discont inuat ion of therapy . In the absence of measurable disease, 
change in non -measurable disease comparable in magnitude to the increase that would be 
requi red to decl are PD for measurable disease. Examples include an increase in a pleural 
effusio n from ‘trace’ to ‘la rge,’ an increase in lymphangit ic disease fro m localized to 
widespread.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 97of 220 Template 14.1Appearance of New Lesions
The appearance of new lesio ns is considered PD according to RECIST v 1.1 guidelines. 
Considering the unique response kinetics that have been observed with im munotherapy , new 
lesions m ay not represent true disease progression. In the absence of rapid clinical 
deteri oration, subjects may continue to receive MEDI4736 if invest igators consider that 
subjects continue to benefit fro m treatm ent (see Secti on 3.4for a di scussio n of 
immunotherapy  response kinetics). 
Evaluation of Overall Response with Modifications
Confirmation o f CRand PR is requi red by a repeat assessment no less than 4 weeks from the 
date of first documentation. Progressive disease shoul d be confirmed, preferably  at the next 
scheduled disease assessment, and no less than 4 weeks fro m the first documentation of PD, 
in the absence of clinical deterioration. Treatment with MEDI4736 will cont inue between the 
initial assessment of PD and confirmat ion for PD. In addit ion, subjects may  cont inue to 
receive MEDI4736 beyo nd confirmed PD in the absence of clinical deterioration and if 
investigators consider that subjects continue to receive benefit from treatment. In the absence 
of clinical deteri oration, such m odificat ions to the RECIST or RANO criteria may discourage 
the early discontinuat ion of MEDI4736 and provide a more comple te evaluat ion of its 
antitumor activit y than woul d be seen wi th conventi onal response cri teria.Table 5.2.6.1 -1
provi des overall responses for all poss ible co mbinations o f tumor responses in target and 
non-target l esions wi th or wi thout the appearance of new lesio ns.
Table 5.2.6.1 -1 Evaluation of Overall Response
Target Lesions Non-target Lesions New Lesions Overall Response
Complete responseComplete response (or no non -
target lesion)No Complete response
No target lesion aComplete response No Complete response
Complete response Not evaluable bNo Partial response
Complete responseNon-complete response /
non-progressive diseaseNo Partial response
Partial responseNon-progressive disease and
not evaluable (or no non -target 
lesion) bNo Partial response
Stable diseaseNon-progressive disease and
not evaluable (or no non -target 
lesion) bNo Stable disease
Not all evaluated Non-progressive disease No Not evaluable
No target lesion aNot all evaluated No Not evaluable
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 98of 220 Template 14.1Table 5.2.6.1 -1 Evaluation of Overall Response
Target Lesions Non-target Lesions New Lesions Overall Response
No target lesion a Non-complete response /
non-progressive diseaseNoNon-complete response /
non-progressive disease
Progressive disease Any Yes/No Progressive disease
Any Progressive disease Yes/No Progressive disease
Any Any Yes Progressive disease
No target lesion aUnequivocal progressive disease Yes/No Progressive disease
No target lesion aAny Yes Progressive disease
aDefined as no target lesion at baseline.
bNot evaluable is defined as either when no or only a subset of lesion measurements are made at an 
assessment.
5.2.6.2 Revised RANO Criteria
All measurable and nonmeasurable lesions should be assessed using the same techniques as 
at baseline. Ideally, subjects should be imaged on the same MRI scanner, or at least with the 
same m agnet strength, for the duration of the study to reduce difficult ies in int erpreting 
changes.
MRI Scans
Specific lesio ns must be evaluated ser ially, and comparat ive analysis o f changes in the area 
of contrast enhancement, as well as the nonenhancing component, should be performed. The 
product of the maximal cross -sectional enhancing diameters will be used to determine the 
size of the contrast -enhancing lesio ns.
Minimum sequences required:
•Pre-contrast T1, T2/ fluid attenuated inversio n recovery  (FLAIR)
•Post-contrast T1, with two orth ogonal  planes (or a vol ume acquisit ion) recommended
•Reco mmended slice thickness ≤ 5 mm wit h no gap
Measurability of Tumor Lesions 
Tumor lesi ons are categori zed as fo llows:
•Measurable disease is defined as bidimensio nally contrast enhancing lesio ns wit h clearly 
defined margins by CT or MRI scan, with two perpendicular diameters of at least 10 mm, 
visibl e on two or m ore axi al slices that are preferably , at m ost, 5 mm  apart wi th 0-mm 
skip. 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 99of 220 Template 14.1•Nonm easurable disease is defined as either unidimensio nally measurable lesio ns, m asses 
with margins not clearly defined, or lesio ns wi th maximal perpendicular diameters less 
than 10 mm. Subjects without measurable disease, such as those who undergo a gross 
total resect ion, cannot respond and can only achieve SD as their best radiographic 
outcom e.
◦There are two ty pes of  non-target l esions 
▪Enhancing (T1 with contrast) 
▪Non-enhancing (T2/FLAIR) 
◦These are assessed subject ively. So me rules are recommended for object ive 
assessment of progression eg, if a nonmeasurable enhancing lesio n beco mes 
measurable, AND either has absolute increase of > 5 mm OR > 25% in sum o f 
products o f diameter
Response Criteria
Evaluation of Target Lesions
•Com plete response -Requi res all  of the fo llowing: com plete disappearance of all 
enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new 
lesions; stable or im proved no n-enhancing (T2/FLAIR) lesio ns; patients must be off 
corticosteroi ds (or on physio logic replacement doses only); and stable or improved 
clinically. Note: Subjects with nonmeasurable disease only, cannot have a CR; the best 
response possible is SD.
•Parti al response -Requi res all  of the f ollowing: 50% decrease compared with baseline in 
the sum  of products of perpendicular diameters of all measurable enhancing lesio ns 
sustained for at least 4 weeks; no progression of nonmeasurable disease; no new lesio ns; 
stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of 
corticosteroi ds co mpared with baseline scan; the corticosteroid dose at the time of the 
scan evaluat ion should be no greater than the dose at time o f baseline scan; and stable or 
impr oved clinically. Note: Subjects with nonmeasurable disease only, cannot have a PR; 
the best response possible is SD.
•Stabl e disease -Requi res all  of the fo llowing: does not qualify for CR, PR, or 
progression; stable nonenhancing (T2/FLAIR) lesions on same or lower dose of 
corticosteroi ds co mpared with baseline scan. In the event that the corticosteroid dose was 
increased for new symptoms and signs wit hout confirmat ion of disease progression on 
neuro imaging, and subsequent fo llow-up imaging shows that this increase in 
corticosteroi ds was requi red because of disease progression, the last scan considered to 
show SD will be the scan obtained when the corticosteroid dose was equivalent to the 
baseline dose.
•Progression -Defined by any o f the following: 25% incr ease in sum of the products of 
perpendicular diameters of enhancing lesio ns co mpared with the smallest tumor 
measurement obtained eit her at baseline (if no decrease) or best response, on stable or 
increasing doses of corticosteroids; significant increase i n T2/FLAIR nonenhancing 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 100of 220 Template 14.1lesion on stable or increasing doses of corticosteroids compared with baseline scan or 
best response after init iation of therapy  not caused by  com orbid events (eg, radiation 
therapy , demyelinat ion, ischemic injury , infect ion, seizur es, postoperative changes, or 
other treatment effects); any new lesio n; clear clinical deterioration not attributable to 
other causes apart from the tumor (eg, seizures, medicat ion adverse events, complications 
of therapy , cerebrovascular events, infection ) or changes in corticosteroid dose; failure to 
return for evaluat ion as a result of death or deteriorating condit ion; or cl ear progressi on of  
nonmeasurable disease.
Evaluation of Enhancing Non- target Lesions
•Com plete response -All enhancing non -target l esions have disappeared completely
•Incomplete response/SD -Enhancing lesions present; stable or decreased in size
•Progressive disease -Unequivocal progression
•Unable to assess -Unable to evaluate enhancing lesions because o f technical factors
Evaluatio n of T2/FLAIR Lesion Response
•Improved -Signal abnorm ality decreased
•Unchanged -Unchanged co mpared to prior imaging
•Worse -Unequivocal worsening/progression o f signal abnorm ality
•Unable to assess -Unable to evaluate non -enhancing lesio ns because of technical factors
5.2.7 Archival Tumor Samples and Tumor Biopsies
5.2.7.1 Archival Tumor Samples
Archival tumor samples are required for all subjects and adequate tissue for bio marker 
analysis must be deemed available during the screening period. This will be waived fo r 
subjects who have no archived sample because no previous biopsy has been performed 
(eg,recent ly diagnosed or diagnosed with fine needle aspirat ion); however a biopsy must be 
perform ed for all  subjects for whi ch sui table archived tum or sam ple is not avai lable. Subjects 
in the UBC cohort must provi de ei ther a fresh tumor biopsy during screening or an ar chived 
tumor specimen from wit hin 6 mo nths prior to study  entry  (ie, from subject si gning consent 
to parti cipate in the study ) for PD -L1 IHC analysis . In a ddition, UBC subjects must provide
additional archival tum or tissue regardl ess of age if available. Form alin fixed paraffin 
embedded (FFPE) tumor samples will be collected for IHC and additional correlat ive 
markers (eg, tumor mutation analysis, RNA analysi s, and immunodiversit y). If a tum or block 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 101of 220 Template 14.1cannot be provided for this study , then only  freshly prepared unstained sect ions should be 
provi ded as described in the Laboratory  Manual .
5.2.7.2 Tumor Biopsies
Image-guided core needl e tum or biopsy  will be perform ed acco rding to inst itutional pract ice 
during screening and again 6 weeks after init iation of MEDI4736 (if clinically  appropriate, 
ie, repeat biopsy  after 6 weeks does not pose unacceptable medical risk to a subject as 
determined by the invest igator) for subjects in the dose -exploration cohort and 
dose-expansio n phase of the study . For subj ects in dose -expansio n, tum or biopsies resul ting 
in adequate tissue for analysis will be required during screening for 10 subjects each enrolled 
in the pancreat ic adenocarcino maand nasopharyngeal carcino ma cohorts; 20 subjects 
enrolled in the advanced cutaneous melano ma, uveal melano ma, HCC, gastroesophageal 
cancer, SCCHN, TNBC, UBC, ovarian cancer, soft tissue sarco ma, SCLC, MSI -high 
cancers, and HPV -positive cancers cohorts; a nd for all subjects enro lled in the NSCLC 
squamous histo logy and NSCLC non -squam ous histol ogy cohorts. If m ore than 10 subjects 
are enrolled in the pancreat ic adenocarcino ma or nasopharyngeal carcino ma cohorts; more 
than 20 subjects are enrolled in the HCC , gastroesophageal cancer, SCCHN, TNBC, UBC, 
ovari an cancer, soft tissue sarco ma, SCLC, MSI -high cancers, or HPV -posit ive cancers 
cohorts, either a fresh biopsy during screening or archival t issue fro m less than 6 m onths 
prior to enrollment will be require d. For all subjects in the UBC cohort enrolled under 
Amendment 8 and beyo nd, either a f resh biopsy  during screening or archival tissue from less 
than 6 months prior to enrollment will be required for PD -L1 IHC analysis . Tum or biopsies 
at 6weeks after init iation of MEDI4736 are strongly encouraged for all subjects with the 
exception of subjects in the UBC cohort . For subjects entering retreatment, tumor biopsies 
during rebaseline and at 6 weeks after init iation of retreatm ent are encouraged, if clinically 
feasible with the except ion ofsubjects in the UBC cohort. Tum or lesions used for biopsy  
shoul d not be l esions used as RECIST target l esions. Addi tional tum or biopsies are permitted 
as clinically indicated and if feasible (eg, for mixed responses or upon PD ).If clinically 
practi cal, at each time point, subjects will undergo 4core biopsies . The fi rst and thi rd core 
biopsies will be pl aced in form alinand processed for FFPE , while the second and fourth core 
biopsies ( fourthbiopsy, if available) will be imme diately frozen in liquid nitrogen or 
equivalent m ethod and then stored at -60°C or below.  In except ional cases, excisio nal or 
punch biopsies are permitted and may be subst ituted for the required core biopsies if 
sufficient ly large (4 mm or greater in diam eter).
Tumor biopsies will  be stored at MedImmune or an appropriate vendor selected by  
MedImmune. Core biopsies may be used for correlative studies such as IHC, tumor mutation 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 102of 220 Template 14.1analysis, RNA analysis, proteomic analysis, and immunodiversit y. Additional deta ils for 
sample collect ion, processing, storage, and shipment will be provided in the Laboratory  
Manual.
5.2.8 Patient -reported Outcomes Assessments
The pain quest ionnaire, European Organisation for Research and Treatment of Cancer 
qualit y-of-life questionnaire ( EORTC QLQ -C30), and cancer -specific m odules are 
self-administered questionnaires and are to be completed by  the subject wi thout the 
assistance of the investigational site personnel. All questionnaires should be completed 
before any other study  procedures a re conducted at the visit. Patient -reported outcome 
questionnaires need to be administered at screening visit, Day  1 of Dose 1, 3, and 5, and at 
the sam e visi t as the di sease assessment by  physical  examinat ion and CT scans, before 
other clinical procedures . If subjects get scans at an outside facilit y or missed a scheduled 
data collect ion, PRO questionnaires need to be administered at the next visit. It takes about 
15-20 minutes for subjects to complete all 3 quest ionnaires and the subjects are asked to onl y 
fill out questionnaires that have been validated to be relevant to their specific ty pe of  cancer; 
hence the burden to the subject is moderate. When the subject completes the questionnaires, 
study  coordinators need to review the quest ionnaires for missing responses and then ask 
subject to date and sign at places specified in the questionnaires. Note: subjects who began 
treatm ent under ol der versio ns of this protocol  prior to im plementati on of  PRO assessments 
will not be required to complete the questionnai res. Subj ects will not be required to complete 
questionnaires if unavailable in their nat ive language. Subj ects in the dose -exploration cohort 
are not required to complete PRO assessments.
5.2.8.1 Pain Questionnaire
A pain quest ionnaire ( Appendix 2 ) containing one question is used: “On a scale ranging from 
0 (absent) to 10 (worst imaginable), please rate the severit y of your pain in the l ast 24 hours.” 
5.2.8.2 EORTC QLQ -C30 and Cancer -specific Modules
The EORTC QLQ -C30 i s a 30 -item self-administered questi onnai re (Appendix 3 ). There are 
9 multiple-item scales: 5 scales that assess aspects of funct ioning (physical, role, cognit ive, 
emotional, and soci al); 3 symptom  scales (fatigue, pain, and nausea and vomit ing); and a 
global heal th status/qualit y of life scale. There are 5 single -item measures assessing 
additional symptom s commo nly reported by  cancer pati ents (dy spnea, l oss of  appeti te, 
insomnia, const ipation, and diarrhea) and a single item concerning perceived f inancial impact 
of the di sease. All but 2 questions have 4- point scales: “Not at all,” “A litt le,” “Quite a bit,” 
and “Very  much.” The 2 quest ions concerning global healt h status and qualit y of life have 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 103of 220 Template 14.17-point scales wit h ratings ranging fro m “Very poor” to “Excellent.” For each of the 
15domains (9 mult iple-item scales, 6 single -item scales), final scores are transformed such 
that they  range from  0-100 whereas higher scores indicate greater funct ioning, greater qualit y 
of life, or greater level of sympto m (Aaronson et al, 1993 ). 
Triple Negative Breast Cancer
For TNBC subjects, a disease -specific 23- item self-administered quest ionnaire for breast 
cancer was developed (EORTC QLQ -BR23; Appendix 4 ) to be used in conjunct ion with the 
EORTC QLQ -C30. It incorporates 4 funct ional scales (body  image, sexual funct ioning, 
sexual enjo yment, and future perspective) and 4 sym ptom  scales (arm symptoms, breast 
symptoms, sy stemic therapy  side -effects, and upset by  hair loss). Both questi onnai res are 
widely used wit h cancer patients ( Montazeri, 2008 ; Nagel  et al , 2001
; Svensson et al, 2010 ; 
Park et al , 2010 ).
The EORTC QLQ -BR23 contains 3 items that ask about sexual functioning. Alt hough so me 
subjects may  view this as a highly personal issue area, for wom en wi th breast cancer 
sexualit y can be greatly impacted. The developers of this standardized questionnaire included 
these items when the quest ionnaire was developed and require that they be retained. Subjects 
can skip these questions if they d o not f eel comf ortable to answer. 
Lung Cancer
For NSCLC and SCLC subjects, a disease -specific 13 -item self-administered questionnaire 
for lung cancer was developed (EORTC QLQ -LC13; Appendix 5 ) to be used in conjunct ion 
with the EORTC QLQ -C30 ( Bergman et al, 1994 ). It com prises both m ulti-item and single -
item measures of lung cancer- associ ated symptom s (ie, coughin g, hem optysis, dyspnea, and 
pain) and side effects fro m conventional chemotherapy  and radi otherapy  (ie, hair l oss, 
neuropathy , sore m outh, and dysphagia). 
Gastroesophageal Cancer
For gastroesophageal cancer subjects, a disease -specific 22- item self-
administered questionnaire for gastroesophageal cancer was developed 
(EORTC QLQ -STO22; Appendix 6 ) to be used in conjunct ion with the EORTC QLQ -C30 
(Blazeby, et al  2004 ). It com prises both m ulti-item and single -item measures of 
gastroesophageal cancer -assoc iated symptom s (ie, dy sphagia, pain, reflux, eating, anxiet y) 
and side -effects from  conventi onal chem otherapy and radi otherapy  (ie, dry  mouth, taste, 
body  image, and hair loss). 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 104of 220 Template 14.1Pancreatic Adenocarcinoma
For pancreatic adenocarcino ma subjects, a disease -specific 26- item self-
administered questionnaire for pancreatic adenocarcino ma was developed (EORTC 
QLQ -PAN26; Appendix 7 ) to be used in conjunct ion with the EORTC QLQ -C30 
(Fitzsimm ons and Johnson, 1998 ; Fitzsimm ons et al , 2005 ). The m odule com prises 
26 questions assessing pain, dietary changes, jaundice, altered bowel habi t, em otional 
probl ems rel ated to pancreat ic adenocarcino ma, and other symptoms such as cachexia, 
indigest ion, flatul ence, dry  mouth, and taste changes. 
Head and Neck Cancer
For head and neck cancer, a disease -specific 35- item self-administered questionnai re for 
head and neck cancer was developed (EORTC QLQ -H&N35; Appendix 9 ) to be 
used inconjunct ion with the EORTC QLQ -C30 ( Bjordal et al , 1994 ; Bjordal  et al , 1999 ; 
Bjordal  et al , 2000 ). It com prises both m ulti-item and single -item measures of head and neck 
cancer -associ ated symptoms (i e, pain, swallowing, senses, speech, social eat ing, social 
contact, sexualit y) and side -effects from  conventi onal chem otherapy  and radi otherapy .
The EORTC QLQ -H&N35 contain items that ask about sexual functioning. Alt hough so me 
subjects may  view this as a highly personal issue area, for those with head and neck cancer 
sexualit y can be greatly impacted. The developers of this standardized questionnaire included 
these items when the quest ionnaire was developed and require that they be retained. Subjects 
can skip these questions i f they do not feel co mfortable to answer.
Hepatocellular Cancer
For HCC, a disease -specific 18- item self-administered questionnaire for HCC was developed 
(EORTC QLQ -HCC18; Appendix 8 ) to be used in conjunct ion with the EORTC QLQ -C30 
(Blazeby et al , 2004 ). It comprises mult i-item scales assessing fatigue, body  image, j aundice, 
nutrition, pain, and fever, with 2 single -items addressing sexual interest and abdo minal 
swelling.
The EORTC QLQ -HCC18 contains items that ask about sexual functioning. Alt hough so me 
subjects may  view this as a highly personal issue area, for those with head and neck cancer or 
HCC sexualit y can be g reatly impacted. The developers of this standardized quest ionnaire 
included these items when the questionnaire was developed and require that they  be retained. 
Subjects can skip these quest ions if they do not feel comfortable to answer.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 105of 220 Template 14.1Melanoma
With the e xcepti on for uveal  melano ma, subjects are only required to complete the EORTC 
QLQ -C30 quest ionnaire. For uveal melano ma subjects, since most of the metastasis are in 
liver, the liver cancer module EORTC QLQ -HCC18 ( Appendix 8 ), will be used to collect 
subject reported liver metastasis related symptoms in conjunction wit h the EORTC 
QLQ C30.
Glioblastoma Multiforme
For subjects with GBM, a disease -specif ic, 20 -item self-administered questionnaire for brain 
cancer was developed (EORTC QLQ -BN20 [ Osoba et al, 1996 ; Taphoorn et al, 2010; 
Maringwa et al, 2011 ]; Appendix 10 ) to be used in conj unction with the EORTC QLQ -C30. 
It includes 4 symptom scales (future uncertainty , visual  disorder, m otor dy sfunct ion, an d 
communicat ion deficit) and 7 symptom items (headaches, seizures, drowsiness, hair loss, 
itching skin, weakness of both legs, and bladder control). The EORTC QLQ -C30 
andtheEORTC QLQ -BN20 have been used in a number of brain cancer 
clinical trials(Taphoorn et al, 2005; Keime -Giubert et al , 2007 ; Grabenbauer et al, 2009 ; 
Chinot et al, 2011 ; Flechl  et al , 2012 ).
Ovarian Cancer
For subjects with ovarian cancer, a disease -specific, 28 -item self-administered questionnaire 
for wom en wi th ovarian cancer was developed (EORTC QLQ -OV28; Appendix 11 ) to be 
used in conjunct ion with the EORTC QLQ -C30.  It includes 7 items on 
abdo minal/gastrointestinal symptoms, 3 items on peripheral neuropathy, 7 items on other 
chemotherapy side effects, 2 ite ms on hormonal/menopausal symptoms, 2 items 
onbody image, and 3 items on attitude toward disease and treatment ( Cull et al, 2001; 
Greimel aet al, 2003 ).
The EORTC QLQ -OV28 contains 4 items that ask about sexual funct ioning. Alt hough some 
subjects may  view this as a highly personal issue area, for women with ovarian cancer 
sexualit y can be greatly impacted. The developers of this standardized questionnaire included 
these items when the quest ionnaire was developed and require that they  be retained. Subjects 
can skip these questions if they do not feel co mfortable answering them.
5.2.8.3 FACT-BL
For subjects with bladder cancer, a disease -specific, 39 -item self-administered questionnaire 
for bladder cancer was developed (Funct ional Assessment of Chronic Illness Therapy-
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 106of 220 Template 14.1bladder [FACT -BL]; Appendix 12 ). Of the 39 questions, 27 come fro m the Funct ional 
Assessment of Chronic Illness Therapy -General (FACT -G) and 12 questions are specific to 
bladder cancer. All quest ions inquire about the subject’s healt h-related quali ty of life during 
the past week. The FACT -BL (versio n 4) covers the domains of physical well -being, 
social/family  well -being, emotional well -being, funct ional well -being as well as urinary, 
bowel , and sexual  function (Cella et al, 1993 ).
The FACT -BL contains 3 i tems that ask about sexual funct ioning; one of these ite ms is for 
men only. Although so me subjects may view this as a highly personal issue area, for people 
with bladder cancer sexualit y can be greatly impacted. The developers of this standardized 
questionnaire included these items when the questionnaire was de veloped and require that 
they be retained. Subjects can skip these questions if they do not feel co mfortable answering 
them.
5.2.9 Estimate of Volume of Blood to be Collected
Q2W or Q3W Dosing Schedule
A total o f 45 mL will be required for all screening tests, w hich may be conducted over 1 or 
more days during screening. No more than 51 mL of blood will be drawn on any  visit day  
after screening. Approximately 179 mL of blood will be collected at all visits related to the 
first dose. The total  volume to be collecte d will depend on the number of doses administered 
and the length of fo llow-up. Subjects in the first cohort in the dose -escalat ion phase will have 
an addit ional 3.5 -mL blood sample drawn for PK at 2 hours after the start of the first 
infusio n. 
Q4W Dosing Schedule
Approximately  28 mL will be requi red for all screening tests. No more than 33 mL of blood 
will be drawn on any visit day  after screening. Approximately  56 mL of bl ood will  be 
collected at all visit s related to the first dose. The total vo lume to b e collected will depend on 
the number of doses administered and the length of fo llow-up.
6ASSESSMENT OF SAFETY
6.1 Safety Parameters
6.1.1 Adverse Events
The Internat ional Conference on Harmonisat ion (ICH) Guideline for Good Clinical Pract ice 
(GCP) E6(R1) defines an AE as:
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 107of 220 Template 14.1Any untoward medical occurrence in a patient or clinical invest igation subject 
administered a pharmaceutical product and which does not necessarily  have a causal  
relationship with this treatment. An AE can therefore be any unfavorable and unintended
sign (incl uding an abnorm al laboratory  finding), symptom, or disease temporally 
associ ated wi th the use of a m edicinal product, whether or not considered related to the 
medicinal product.
An AE includes but is not limited to any  clinically  significant wor sening of a subject’s 
pre-exist ing condit ion. An abnormal laboratory  finding (including ECG finding) that requires 
an act ion or intervent ion by the invest igator, or a finding judged by the investigator to 
represent a change bey ond the range of normal physi ologic fluctuati on, shoul d be reported as 
an AE.
Adverse events may be treatment emergent (ie, occurring after init ial receipt of 
investigat ional product) or nontreatment emergent. A nontreatment -emergent AE i s any new 
sign or symptom , disease, or other un toward medical event that begins after written informed 
consent has been obtained but before the subject has received invest igational product.
Elect ive treatment or surgery or preplanned treatment or surgery  (that was scheduled prior to 
the subject being e nrolled into the study ) for a docum ented pre -existing condit ion that di d not 
worsen from baseline is not considered an AE (serious or nonserious). An untoward medical 
event occurring during the prescheduled elect ive procedure or routinely scheduled treatme nt 
shoul d be recorded as an AE or SAE.
6.1.2 Serious Adverse Events
An SAE is any  AE that:
•Results in death
•Is immediately life -threatening
•This term refers to an event in which the subject was at risk of death at the time of the 
event; it does not refer to an e vent that may have led to death.
•Requi res inpat ient hospi talizat ion or prolongat ion of exist ing hospi talizati on 
•In general, hospitalizat ion signifies that the subject has been detained (usually invo lving 
at least an overnight stay ) at the hospi tal or em ergency ward for observat ion and/or 
treatm ent that woul d not have been appropriate in an outpatient setting. 
•Results in persistent or significant disabilit y/incapacit y 
•The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct norm al 
life funct ions.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 108of 220 Template 14.1•Is a congenital ano maly/birth defect in o ffspring of the subject
•Is an important medical event that may jeopardize the subject or may require medical 
intervent ion to prevent one of the outcomes listed above.
•Medical or scient ific judgmen t shoul d be exercised in deciding whether expedited 
reporting is appropriate in this situat ion. Examples of medically important events are 
intensive treatm ent in an emergency  room  or at home for allergic bronchospasm, blood 
dyscrasias, or convulsio ns that do not result in hospitalizat ions; or development of drug 
dependency  or drug abuse.
6.1.3 Other Events of Special Interest
Adverse events of special interest are events of scient ific and medical interest specific to the 
further understanding of the MEDI4736 safet y profile and require close monitoring and rapid 
communicat ion by the invest igator to the sponsor. MEDI4736 AESIs may be serious or non -
serious. The rapi d reporti ng of these AESIs allows ongoing analysis o f these events in order 
to characterize and un derstand them in associat ion with the use of thi s invest igational 
product.
Adverse events of special interest for MEDI4736 include but are not limited to events with a 
potenti al inflammatory  or immune -mediated mechanism and which may require more 
frequent monitoring and/or intervent ions such as steroids, immunosuppressants and/or 
horm one repl acement therapy . Thes e AESIs are being closely  monitored in clinical  studi es 
with MEDI4736 m onotherapy  and combinati on therapy . An i rAE is defined as an AEthat is 
associ ated wi th drug exposure and is consistent with an immune -mediated mechanism of 
action and where there is no clear al ternate eti ology. Serol ogic, immuno logic, and histol ogic 
(biopsy) data, as appropriate, should be used to support an irAE diagnosis. Appropriate 
efforts should be made to rule out neoplast ic, infectious, metabo lic, toxin, or other etiologic 
causes of the i rAE. 
If the invest igator has any quest ions in regards to an AE being an irAE, the invest igator 
shoul d prom ptly contact the study physician.
Adverse events of special interest observed with MEDI4736 include:
•Colit is
•Pneumo nitis
•ALT/AST increases / hepat itis / hepatotoxicit y 
•Neuropathy /neurom uscular toxicit y (ie, events of encephalit is, peri pheral m otor and 
sensory  neuropathi es, Guillain -Barré, and myasthenia gravis)
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 109of 220 Template 14.1•Endocrinopathy  (ie,events of hypophysit is, adrenal insufficiency, and hyper -and 
hypothy roidism )
•Derm atitis
•Nephrit is
•Pancreat itis  (or labs suggest ive of pancreat itis -increased serum lipase , increased serum 
amylase)
Further informat ion on these risks (eg ,present ing symptoms) can be found in Appendix 15 .
6.1.3.1 Pneumonitis
Pneumo nitis has been reported in associat ion with use of  anti-PD-L1/ant i-PD-1 antibodies 
(Brahmer et al 2012 ). Ini tial work -up should include a hi gh-resolution CT scan, ruling out 
infect ion, and pulse oximetry . Pulm onary  consul tation is recommended.
Further informat ion on these risks (eg, present ing symptoms) can be found in the current 
versio n of the MEDI4736 Invest igator’s Brochure. Guidelines for the management of 
subjects wi th immune -mediated events including pneumo nitis are outlined in Appendix 15 .
6.1.3.2 Hypersensitivity Reactions
Hypersensi tivity react ions as well as infusio n-related reacti ons have been reported with 
anti-PD-L1 and ant i-PD-1 therapy  (Brahmer et al  2012 ). As wi th the administration o f any 
foreign protein and/or other biologic agents, reactions following the infus ion of MAbs can be 
caused by  various mechanisms, including acute anaphylact ic (IgE -mediated) and 
anaphylactoi d reacti ons against the MAb, and serum sickness. Acute allergic reactions may 
occur, m ay be severe, and may  resul t in death. Acute allergic react ions may include 
hypotension, dyspnea, cyanosis, respiratory  failure, urti caria, pruri tus, angioedema, 
hypotoni a, urticari a, arthral gia, bronchospasm, wheeze, cough, dizziness, fat igue, headache, 
hypertensio n, myalgia, vo miting and unresponsiveness.
Guidelines f or management of subjects with hypersensit ivity (including anaphylactic 
reacti on) and infusio n
-related reacti ons are outlined in Appendix 15 .
6.1.3.3 Hepatic Function Abnormalities (Hepatotoxicity)
Increased transaminases have been reported during treatment with ant i-PD-L1 
(Brahmer et al 2012). Inflammatory hepati tis has been reported in 3% to 9% of subjects 
treated with ant i-CTLA -4 MAbs (eg, ipilimumab). The clinical manifestations of 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 110of 220 Template 14.1ipilimumab -treated pati ents included general weakness, fat igue, nausea and/or mild fever and 
increased liver funct ion tests such as AST, ALT, alkaline phosphatase, and/or total bilirubin.
Hepati c funct ion abnormalit y is defined as any  increase in ALT or AST to greater than 
3 ×ULN and concurrent increase in bilirubin to greater than 2 × ULN (ie, Hy’s law cases). 
Concurrent find ings are those that derive from a single blood draw or from separate blood 
draws taken within 8 days of each other. Follow -up invest igations and inquiries will be 
initiated prompt ly by the investigational site to determine whether the findings are 
reproduc ible and/or whether there is object ive evidence that clearly supports causation by a 
disease (eg, chol elithiasis and bile duct obstruction with distended gallbladder) or an agent 
other than the invest igational product.
If the underlying diagnosis for the h epatic funct ion abnormalit y is known (including 
progression of pre -exist ing disease such as primary or metastatic malignancy), the diagnosis 
shoul d be recorded as an AE/SAE.
If the underlying diagnosis for the hepatic funct ion abnormalit y rem ains unknown, the term  
“hepatic funct ion abnormal” should be used to report the AE/SAE.
Hepati c funct ion abnormalit y of unknown et iology, or which is considered attributable to 
investigat ional product, i s requi red to be reported as “hepatic funct ion abnormal” within 
24hours of knowledge of the event to MedImmune Patient Safet y using the SAE Report 
Form , even if the event is considered to be non -serious (see Sect ion 6.4.2.2 for contact 
inform ation). The invest igator will review the data with the medical mo nitor. The 
investigator should then use clinical judgment to establish the cause based on local standard 
of care and fo llow the subject by  conduct ing testing as c linically indicated.
6.2 Assessment of Safety Parameters
6.2.1 Assessment of Severity
Assessment of severit y is one of the responsibilit ies of the invest igator in the evaluation o f 
AEs and SAEs. Severit y will be graded according to the NCI CTCAE v4.03. 
The determinat ion of severit y for all other events not listed in the CTCAE should be made by  
the invest igator based upon medical judgment and the severit y categori es of  Grade 1 to 5 as 
defined below.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 111of 220 Template 14.1Grade 1 (mild) An event that is usually transient and may require on ly minimal 
treatm ent or therapeutic intervent ion. The event does not 
generally interfere with usual act ivities of daily living.
Grade 2 (m oderate) An event that is usually alleviated with addit ional specific 
therapeuti c intervent ion. The event interferes w ith usual 
activit ies o f daily living, causing disco mfort but poses no 
significant or permanent risk of harm to the subject.
Grade 3 (severe) An event that requires intensive therapeutic intervent ion. The 
event interrupts usual act ivities of daily living, o r significantly 
affects the clinical status of the subject.
Grade 4 (life threatening) An event, and/or its immediate sequelae, that is associated with 
an imminent risk of death or with physical or mental 
disabili ties that affect or limit the abilit y of th e subject to 
perform  activities of daily living (eating, ambulat ion, toilet ing, 
etc).
Grade 5 (fatal) Death (loss of life) as a result of an event.
It is important to dist inguish between serious criteria and severit y of an AE. Severit y is a 
measure of inte nsity whereas seri ousness is defined by  the cri teria in Sect ion 6.1.2 . A 
Grade 3 AE need not necessarily be considered an SAE. For example, a Grade 3 headache 
that persi sts for several  hours m ay not m eet the regul atory  defini tion of  an SAE and would be 
considered a nonserious event, whereas a Grade 2 seizure result ing in a hospital admissio n 
woul d be considered an SAE.
6.2.2 Assessment of Relationship
6.2.2.1 Rela tionship to Investigational Product
The invest igator is required to provide an assessment of relat ionship of AEs and SAEs to the 
investigat ional product.
An event will be considered “not related” to use of the investigational product if any of the 
following tests are m et:
•An unreasonable temporal relat ionship between administration of the invest igational 
product and the onset of the event (eg, the event occurred either before, or too long after, 
administration of the investigat ional product for it to be con sidered product -related)
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 112of 220 Template 14.1•A causal relat ionship between the investigational product and the event is bio logically  
implausible (eg, death as a passenger in an automobile accident)
•A clearly  more likely al ternative explanati on for the event is present (eg, ty pical adverse 
reacti on to a concomitant drug and/or ty pical disease -related event)
Individual AE/SAE reports will be considered “related” to use of the investigational product 
if the “not related” criteria are not met.
“Related” implies that the event is consi dered to be “associated with the use of the drug” 
meaning that there is “a reasonable possibilit y” that the event may  have been caused by  the 
product under invest igation (ie, there are facts, evidence, or arguments to suggest possible 
causat ion).
6.2.2.2 Rela tionship to Protocol Procedures
The invest igator is also required to provide an assessment of relat ionship of SAEs to protocol 
procedures on the SAE Report Form. This includes nontreatment -emergent SAEs (ie, SAEs 
that occur prior to the administration o f investigational product) as well as treatment -
emergent SAEs. A protocol -related SAE m ay occur as a resul t of a procedure or intervention 
requi red during the study  (eg, bl ood collect ion, washout of an exist ing medicat ion). The 
following guidelines should be used by  investi gators to assess the relat ionship of SAEs to the 
protocol :
Protocol  related: The event occurred due to a procedure/intervention that was described 
in the protocol for which there is no alternat ive et iology  present in the 
subject’s medical record.
Not protocol related: The event is related to an etio logy other than the procedure/ 
intervent ion that was described in the protocol (the alternative et iology 
must be documented in the study  subject’s m edical record).
6.3 Recording of Safety Parameters
6.3.1 Recording of Adverse Events and Serious Adverse Events
Adverse events will be recorded on the CRF using a recognized medical term or diagnosis 
that accurately reflects the event. Adverse events will be assessed by the invest igator for 
severit y, relationship to the invest igational product, possible etio logies, and whether the 
event m eets cri teria of an SAE and therefore requires immediate notificat ion to MedImmune 
Patient Safet y. See Secti on 6.1.2 for the definit ion of SAEs, and Sect ion 6.2.1 and 
Secti on6.2.2for guidelines for assessment of severity  and relati onship, respectively. If an 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 113of 220 Template 14.1AE evo lves into a condit ion that m eets the regulatory  defini tion of “seri ous,” i t will be 
reported on the SAE Report Form.
6.3.2 Recording of Other Events of Special Interest 
Hepat ic Function Abnormality
Events of hepat ic function abnormalit y (as defined in Sect ion 6.1.3.3 ) should be recorded 
according to the definit ions of AE and SAE (Section 6.1.1 and Section 6.1.2 , respectively):
•If an event of hepat ic function abnormalit y is considered to be related to a pre -exist ing 
condi tion and does not represent a worsening of this condit ion and/or is considered to be 
within the range of normal physio logical  fluctuati on for the subject, the event does not 
meet the definit ion of an AE and does not need to be recorded as such.
•If a definit ive diagnosis for an underlying condit ion unrelated to the invest igational 
product is established for an event of hepat ic functio n abnormalit y, the diagnosi s shoul d 
be recorded as an AE/SAE per Section 6.3.1 .
•If no definit ive diagnosis is determined for an event of hepat ic function abnorm ality, the 
term “hepatic funct ion abnormal” should be used to report the AE/SAE per Section 6.3.1 .
6.4 Reporting Requirements for Safety Parameters
6.4.1 Study Reporting Period and Follow -up for Adverse Events
The reporti ng period for AEs is the period immediately fo llowing the time that written 
inform ed consent i s obtained through 90 days after the last dose of MEDI4736 or until the 
initiation of alternat iveanticancer therapy.
New (nonserious) AEs that start after the reporting period has ended will not be collected. All 
AEs that start during the reporting period will be followed to resolut ion through the end of 
subject participat ion in the study .
6.4.2 Reporting of Serious Adverse Events 
6.4.2.1 Study Reporting Period and Follow -up for Serious A dverse Events
The reporti ng period for SAEs is the period immediately fo llowing the time that written 
inform ed consent i s obtained through 90 days after the last dose of MEDI4736. After 
submitt ing an init ial SAE report for a subject (to MedImmune Pat ient Safet y), the 
investigator is required to follow the subject proactively and provide further informat ion on 
the subject’s condit ion to MedImmune Patient Safety .
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 114of 220 Template 14.1At any time after co mpletion of the study , if an investi gator or qualified designee becomes 
aware of an SAE that is suspected by  the invest igator or qualified designee to be related to 
investigat ional product, the event must be reported to MedImmune Patient Safet y.
The invest igator is responsible for fo llowing all SAEs until resolut ion, until the subject 
returns to baseline status, or until the condit ion has stabilized with the expectation that it will 
remain chronic, even if this extends bey ond study  parti cipat ion.
6.4.2.2 Notifying the Sponsor of Serious A dverse Events
Within 24 hours of identifying an SAE, regardless of the presumed relationship to the 
investigational product, the investigator or qualified designee must complete the SAE 
Report Form and fax it to MedImmune Patient Sa fety.
MedImmune contact informat ion: 
Patient Safet y 
MedImmune
One MedImmune Way
Gaithersburg, MD 20878
USA
Fax: +1 301-398-4205
The sponsor is responsible for reporting certain SAEs as expedited safet y reports to 
applicable regulatory  authori ties, ethi cs co mmittees, and participat ing invest igators, in 
accordance with ICH Guidelines and/or local regulatory  requi rements (see Secti on 6.4.2.3 ). 
The sponsor may be required to report certain SAEs to regulatory  authori ties wi thin 
7calendar days of being notified about the event; th erefore, i t is important that invest igators 
submit addit ional information requested by  the sponsor as soon as it becomes available.
Invest igators should provide all available informat ion at the time o f SAE Report Form 
completion. Invest igators should not w ait to collect addit ional informat ion to fully document 
the event before notifying MedImmune Patient Safety  of an SAE. When addit ional 
inform ation beco mes available, invest igators should submit a fo llow-up SAE Report Form 
(separate from the init ial report form) with the new informat ion. Any fo llow-up inform ation 
to an SAE also needs to be provided to MedImmune Patient Safet y within 24 hours of 
learning of the new informat ion.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 115of 220 Template 14.16.4.2.3 Safety Reporting to Investigators, Institutional Review Boards or 
Independent Ethi cs Committees, and Regulatory A uthorities
The sponsor is responsible for reporting all applicable SAEs to regulatory  authori ties, 
investigators, and IRBs/IECs, as applicable, in accordance with nat ional regulations in the 
countri es where the study  is conducted. The sponsor will also prepare an expedited report for 
other safet y issues where these might materially  alter the current benefit -risk assessment of 
an invest igational product or that would be sufficient to consider changes in the 
administration of th e investigat ional product or in the overall conduct of the study .
For all invest igators located in the European Economic Area, the sponsor will be responsible 
for reporting suspected unexpected serious adverse reactions (SUSARs) and any  other 
applicable SA Es to regulatory  authori ties including the European Medicines Agency, 
investigators, and IRBs/IECs, as applicable, in accordance with nat ional regulations in the 
countri es where the study  is conducted. Suspected unexpected serious adverse reactions will 
besubmi tted wi thin 7 days for fatal  and life -threatening events and within 15 days for other 
serious events, unless otherwise required by nat ional regul ations.
For all other invest igators, the sponsor will prepare an expedited report for all SAEs that are 
unexpected and potentially  related to the invest igatio nal product, and copies will be 
distributed to all concerned regulatory  authori ties, investigator(s), and IRBs/IECs according 
to applicable laws and regulat ions. The invest igational site also will forwar d a copy  of all 
expedited reports to the site’s applicable IRB/IEC. Invest igators must also submit safety 
inform ation provi ded by  the sponsor to the IRB/IEC as detailed in Sect ion 10.1 and 
Secti on10.2.
6.4.3 Other Events Requiring Immediate Reporting
6.4.3.1 Overdose
An overdose is defined as a subject receiving a dose of invest igational product in excess of 
that specified in the Investigator’s Brochure , unless otherwi se specified in this protocol.
Any overdose of a study  subject wi th the invest igational product, with or without associated 
AEs/SAEs, is required to be reported within 24 hours of knowledge of the event to 
MedImmune Pat ient Safet y using the Safety  Fax Notification Form (see Sect ion 6.4.2.2 for 
contact informat ion). If the overdose results in an AE, the AE must also be recorded on the 
AE CRF (see Secti on 6.3.1 ). Overdose does not automat ically make an AE serious, but if the 
consequences of the overdose are serious, for example deat h or hospitalizat ion, the event is 
serious and must be reported as an SAE (see Section 6.3.1 and Section 6.4.2 ).
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 116of 220 Template 14.16.4.3.2 Hepatic Function Abnormality
Hepati c funct ion abnormalit y (as defined in Sect ion 6.1.3 ) in a study  subject, wi th or wi thout 
associ ated clinical manifestations, is required to be reported as “hepat ic function abnorm al” 
within 24 hours of knowledge of the event to MedImmune Patient Safet y using the Safet y 
Fax Notificat ion Form  (see Secti on 6.4.2.2 for contact informat ion), unless a definit ive 
underlying diagnosis for the abnormalit y (eg, cho lelithiasis and bile duct obstruct ion) that is 
unrelated to invest igational product has been confirmed.
•If the definit ive underlying diagnosis for the abnormalit y has been established and is 
unrelated to invest igational product, the decisio n to conti nue dosing o f the study  subject 
will be based on the clinical judgment of the investigator.
•If no definit ive underlying diagnosis for the abnormalit y is established, dosing of the 
study  subject m ust be interrupted immediately. Follow- up investi gations and inqui ries 
must be init iated by  the inves tigational site without delay. 
Each reported event of hepat ic function abnormalit y will be fo llowed by  the invest igator and 
evaluated by the sponsor. If the etio logy of the event remains unconfirmed and/or is 
considered related to invest igational product (see Section 6.2.2.1 ), a prompt cumulat ive 
review of safet y data and the ci rcumstances of the event in quest ion will be conducted and 
assessed by  the internal  safety  governance bodi es(see Section 6.5) to determine whether 
continued dosing of current study  subjects and/or study  entry  shoul d be interrupted, whether 
the protocol will be modified, or whether the study will be discont inued per manently. 
Review and approval by the internal safet y governance bodies is required for resumpt ion of 
subject dosing or study  entry  in the event that the study  is interrupted. Where applicable, 
regul atory  authori ties and IRBs/IECs will be notified of any ac tions taken with the study .
6.4.3.3 Pregnancy
Pregnancy in a female subject who has received investigational product is required to be 
reported within 24 hours of knowledge of the event to MedImmune Patient Safet yusing the 
Safety Fax Notificat ion Form  (see Sect ion 6.4.2.2 for contact inform ation).
Subjects who beco me pregnant during the study period must not receive addit ional doses o f 
investigat ional product but will not be withdrawn from the study. After obtaining the 
subject’s consent, the pregnancy  will be followed for outcome of the mother and child 
(including any premature terminat ions) and should be re ported to MedImmune Patient Safety
after outcom e. 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 117of 220 Template 14.1Shoul d the invest igator beco me aware of a pregnancy in the partner of a male study subject 
who has received invest igational product(s) this should be reported within 24 hours of 
knowledge of the event to M edImmune Patient Safety or designee using the Safet y Fax 
Notificat ion Form. The sponsor will endeavor to collect fo llow-up inform ation on such 
pregnancies provided the partner of the study  subject provi des consent.
6.4.3.4 Events Meeting Study -stopping Criteria
Events that m eet any  of the study -stopping criteria (Section 3.3), with or without associated 
AEs or SAEs, are required to be reported within 24 hours of knowledge of the event to 
MedImmune Pat ient Safet y using the Safety  Fax Notification Form (see Sect ion 6.4.2.2 for 
contact informat ion). The occ urrence of these events does not automatically make an AE 
serious, but if the consequences of the event are serious, for example death or h ospitalizat ion, 
the event is serious and must be reported as an SAE (see Section 6.3.1 and Section 6.4.2 ).
6.5 Safety Management During the Study
The MedImmune medical mo nitor has primary  responsibili ty for the ongoing m edical review 
of safet y data throughout the study . Thi s includes review of SAEs and timely  review of AEs 
and “other events” reported during the study . MedImmune Patient Safet yis res ponsible for 
the recei pt, immediate review, investigation, and follow- up of  SAEs and other immediately 
reportable events (eg, overdose and pregnancies) reported fro m the clinical study  sites.
A study -specific Dose Escalat ion Co mmit tee will  provi de ongoing safet y surveillance of the 
study , with regularly scheduled reviews of safet y and other relevant data. This co mmittee 
will be responsible for dose -escalat ion decisio ns and making reco mmendat ions regarding 
further conduct of the study . The Dose Escal ation Co mmittee includes the MedImmune 
medical mo nitor for the study , the MedImmune Pati ent Safet y physician for the study , and 
the principal invest igator from each actively enrolling study site. This committee will review 
data, including all AEs, laboratory  param eters, PK and pharmacodynamic data, following the 
full enro llment of any dose -escalat ion cohort and complet ion of the DLT evaluat ion peri od. 
This committee will also review data at other time points in response to AEs assessed as 
medically relevant by  the medical mo nitor. Dose -escalat ion decisio ns and outcomes of 
reviews o f safety  and other rel evant data will be communicated to the internal safet y 
governance bodies . The sponsor will notify sites when enrollment into each dose cohort has 
been co mpleted and w hen enro llment into the next dose cohort is permitted.
The MedImmune Safet y Review Team (SRT) provides safety  surveillance, gui dance, and 
oversi ght for all clinical development studies of MEDI4736 in which MedImmune has 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 118of 220 Template 14.1sponsor accoun tabilit ies. The SRT re views protocol -specific safet y data at regularly 
scheduled meetings and ad hoc meetings, and provides oversight for individual study  
protocol  safety  commi ttees, such as those specified for early -phase dose -escalation studies. 
Based on review of safet y data, the SRT m ay recommend suspensio n of enrollment or 
subject dosing in clinical studies, request modificatio n of study  documents, or take other 
actions as deemed necessary .
7STATISTICAL CONSIDER ATIONS
7.1 General Considerations
Data will be provided in data list ings sorted by  treatm ent group and subject number. Tabular 
summaries will be presented by  treatm ent group. Categori cal data will be summarized by the 
number and percentage of subjects in each category. Cont inuous variables will be 
summarized by  descriptive statistics, including mean, standard deviat ion, median, minimum, 
and maximum. Confidence intervals (CIs) will be two -sided, unless otherwise stated. Details 
of endpo int analyses will be described in the Statistical Analysis Plan.
7.2 Analysis Populations
The DLT Evaluable Populat ion includes all subjects enrolled in the dose- escalat ion phase 
who receive at least 2 doses of MEDI4736 and complete the safety fo llow-up through the 
DLT evaluat ion peri od (defined as the time period fro m the first administrati on of  
MEDI4736 until the planned administration of the third dose of MEDI4736) or experience 
any DLT. The DLT Evaluable Populat ion will be used for the MTD evaluation.
The As -treated Popul ation includes all subjects who receive any treatment with MEDI4736. 
The As -treated Popul ation will be used to evaluate baseline characterist ics as well as all 
endpo ints for the safet y and efficacy  profiles , unless otherwise specified.
The full analysis set (FAS) includes all subjects from the As- treated Population who have 
basel ine disease assessment with measurable disease per BICR and at least 24 weeks 
follow-up at the time of the data cutoff (i e,dosed at least 24 weeks pri or to the time of the 
data cutoff). This is the primary  analysis popul ation for the analysis o f efficacy endpo ints 
using the BICR data.
The PD -L1-positive FAS includes those PD -L1-posit ivesubjects in the FAS as defined by an 
IHC assay  devel oped by Ventana. The PD -L1-negative FAS includes those PD -L1-negat ive
subjects in the FAS as defined by an IHC assay dev eloped by  Ventana. The definit ion for a 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 119of 220 Template 14.1subject whose PD -L1 status is PD -L1 posit ive or negative may be specific for each tumor 
type, as described below.
•For NSCLC and SCCHN cohorts, posit ive for PD -L1 as defined by  ≥ 25% tum or cell 
membrane for PD -L1 at a ny intensity. A subject’s PD -L1 status will be determined from 
a fresh tumor biopsy  obtained during screening and/or avai lable archival tumor samples. 
•For the UBC cohort, posit ive for PD-L1 is defined as ≥ 25% tum or cell membrane or 
≥25% immune cell staining . A subject’s PD -L1 status will be derived fro m a fresh tumor 
biopsy taken during screening and/or available tumor samples taken fro m ≤
6months 
prior to study  entry . In cases where mult iple samples are available, a subject’s PD -L1 
status will be d erived fro m the most recent tum or sam ple (pri or to first dose of study  
treatm ent) wi th a quant ifiable result. If all samples taken ≤6 months pri or to the study  
entry  are non -evaluable by IHC, PD -L1 status may be derived form an o lder archival 
sample.
7.3 Endpoints
7.3.1 Primary Endpoints
For the dose -escalat ion phase, the primary objective is to determine the MTD or OBD, and 
safet y profile of MEDI4736 in subjects with advanced melanoma, RCC, NSCLC, and CRC 
refractory  to standard therapy  or for whi ch no standard the rapy exists.
Endpoints related to this object ive include an evaluation of DLTs, overall safet y, and 
param eters rel ated to the MTD or OBD. The MTD evaluat ion will be based on the DLT 
Evaluable Populat ion. The OBD will be determined based upon analysis o f all available 
subject data, including safet y, PK, pharmacodynamic, bio marker, and response data.
For the dose -expansio n phase, the primary object ives are: 
•To determine the safet y profile of MEDI4736 in subjects with advanced cutaneous 
melano ma, uveal mela noma, HCC, SCCHN, NSCLC squamous histology, NSCLC 
non-squamous histology , gastroesophageal cancer, TNBC, pancreatic adenocarcinoma, 
UBC, GBM, ovarian cancer, soft tissue sarco ma, SCLC, MSI -high cancers, HPV -positive 
cancers, or nasopharyngeal carcino ma.
•Toevaluate the ant itumor activit y of MEDI4736 in subjects with non -squamous NSCLC 
who have received 2 or more prior lines of therapy and subjects with squamous NSCLC 
who have received 1 prior lines of therapy  and 2 or m ore pri or lines of therapy .
•To evaluat e the ant itumor activit y of MEDI4736 in subjects with PD- L1-positive UBC .
Endpoints for safety  profile include assessments of AEs, SAEs, laboratory  evaluat ions, vital 
signs, and physical examinat ions. The occurrence of AEs, abnormal laboratory  values, and
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 120of 220 Template 14.1SAEs reported fro m the signing of an ICF through 90 day s after the l ast dose of MEDI4736 
will be summarized and/or listed for all subjects who received at least one dose of 
MEDI4736 (As- treated Populat ion). Any  SAEs occurring after 90 day s after the l ast dose of 
MEDI4736 that, in the opinio n of the investigator, are related to study  drug will also be 
reported and summarized and/or listed . Adverse events and SAEs will be graded according to 
the NCI CTCAE v4.03 and described by system organ class using the M edical Dict ionary for 
Regulatory  Activities (MedDRA) preferred term, severit y, and rel ationship to MEDI4736.
The primary  endpoint of antitumor activit y for the NSCLC and UBC cohorts is object ive 
response (OR), which is defined as a best overall response (BoR)of CR or PR accordi ng to 
RECIST v1.1 as determined by BICR. BoR is defined as the best response (in the order of 
CR, PR, SD, PD, and not evaluable) among all overall responses recorded fro m the start of 
treatm ent until objective documentation of PD (pe r RECIST v1.1 as assessed by BICR ), or 
the last evaluable disease assessment in the absence of PD prior to init iation of subsequent 
anticancer therapy  or discont inuat ion from the study, whichever occurs first. The best overall 
response of CR or PR must be confirmed, which means a response of CR/PR is recorded at a
visit and confirmed by repeat imaging noless than 4 weeks after the visit when the response 
was first observed with no evidence of progression between the init ial and CR/PR 
confirmat ion visits. The ORR is defined as the proportio n of subjects with OR. The 95% CI 
of ORR will be est imated using the exact probability method. 
For NSCLC, t he ORR (based on RECIST v1.1 by  BICR) along wi th its 95% CI will  be 
provi ded for all NSCLC subjects in each line by  histol ogy and f or the subpopulat ion in the 
≥second -line squamous NSCLC subjects who have tumoral PD -L1 expressio n as determined 
by prospect ive testing prior to enrollment.
For UBC, the primary  analysis of ORR based on RECIST v1.1 by BICR will be performed 
for all UBC subjects (second -orgreater line oftherapy ) in the PD -L1-positive FAS enro lled 
in the ent ire study . The primary endpo int for UBC cohort in PD -L1-positive subgroup i s 
considered to be met if the lower -limit of the exact 2 -sided 95% CI for ORR excludes a 
histori cal response r ate of 10% or l ess (Bellmunt et al, 2009 ). An analysis o f ORR for all 
UBC subjects in the PD -L1-positive FAS enrolled under Amendment 8 and beyo ndwill be 
conducted as a supportive analysis. 
If the primary  endpoint fo r the PD -L1-positive subgroup of the UBC cohort is met, the ORR 
based on RECIST v1.1 by BICR along wit h its 95% CI will be also provided for all UBC 
subjects (second -or greater line of therapy ) in the FAS (regardless of PD -L1 status) enrolled 
in the ent ire study . The primary endpo int for UBC cohort in all -comers is consi dered to be 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 121of 220 Template 14.1met if the lower -limit of the exact 2 -sided 95% CI for ORR excludes a historical response 
rate of 10% or less (Bellmunt et al, 2009 ). In addit ion, the ORR based on RECIST v1.1 by 
BICR along wit h its 95% CI will be provided for all UBC subjects (second -or greater line of 
therapy ) in the PD -L1-negat ive FAS enrolled in the ent ire study and in the PD -L1-negative 
FAS enro lled under Amendment 8 and beyo nd. The primary  analysis for UBC cohort will 
occur at least 24 weeks after the last PD -L1-positive UBC subject’s first dose of study  
treatm ent.The analyse s of ORR per BICR described abov e for the UBC cohort will be 
repeated for the UBC subjects (second -or greater lineoftherapy ) in the PD -L1-positive
FAS, the PD- L1-negative FAS and the FAS (regardl ess of PD -L1 status )enrolled in the 
entire study . 
In order to validate the potential o f PD-L1 expression to predict response to MEDI4736 
treatm ent, the ORR per BICR for UBC subjects in the PD -L1-positive FAS and the PD -L1-
negat ive FAS enro lled under Amendment 8 and beyo nd will be co mpared using one -sided 
Fisher’s exact test with a significance level o f 5%. The difference in the ORR alo ng with the 
exact 2 -sided 90% CI will be est imated based on Chan and Zhang’s method based on score 
statist ics (Chan and Zhang, 1999). A m ultivariate logi stic regressio n analysis may be 
conducted to assess the difference after adjust ing for important baseline characterist ics. An 
odds rati o with its associated profile likelihood 90% CI will be provided. 
Addit ional analysis o f ORR as determined by the investigator according to RECIST v1.1 will 
be conducted in the same manner as those described for the BICR -assessed ORR. The 
investigator’s recorded measurements and assessments for target, non -target, and new lesio ns 
according to RECIST v1.1 will be used to derive the overall response and progression 
programmat ically.
For the dose -exploration cohort, the primary objective is to determine the safet y profile of 
MEDI4736 in subjects with advanced cutaneous melano ma, uveal melano ma, HCC, SCCHN, 
NSCLC s quam ous histol ogy, NSCLC non -squamo us histology , gastroesophageal cancer, 
TNBC and pancreat ic adenocarcino ma using a Q4W dosing schedule. Endpo ints for safet y 
profile including assessments of AEs, SAEs, laboratory  eval uations, vi tal signs, and physical 
examinat ions will be summarized in the same manner as those described above for 
dose-expansio n phase.
7.3.2 Secondary Endpoints
7.3.2.1 Pharmacokinetics
Individual MEDI4736 concentrations will be tabulated by  dose cohort al ong wi th descript ive 
statist ics. Noncompartmental PK data analysis will be performed for data obtained from each 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 122of 220 Template 14.1dose cohort with scheduled PK sample co llection. If data allow, descript ive statist ics of 
nonco mpart mental PK parameters (area under the curve, C max, systemic clearance, half -life) 
will be prov ided.
A population PK model will be developed using a non -linear mixed -effects m odeling 
approach in subjects treated with MEDI4736. The impact of physio logically -relevant subject 
characterist ics (covari ates) and disease characteristics on PK will be evalua ted. The 
relationship between MEDI4736 blood exposure and response or safety will be evaluated. 
Any such analysis will be described in a separate populat ion PK/pharmacodynamic analysis 
plan and the resul ts for this expl oratory  analysis will be reported sep arately fro m the main 
study  report.
7.3.2.2 Immunogenicity
The immunogenic potential o f MEDI4736 will be assessed by summarizing the number and 
percentage of subjects who develop detectable ADAs. The impact of ADAs on PK will be 
assessed if data allow. Samples wil l be co llected for evaluating neutralizing capacit y of 
ADAs in the future.
7.3.2.3 Antitumor A ctivity
Assessments of ant itumor activit y will be based on the ORR (except for subgroups of 
NSCLC and UBC cohorts where OR is considered the primary  endpoint) , DCR, 
durat ionofresponse (DR), progression -free survival (PFS), and OS. RECIST v1.1
(Eisenhauer et al, 2009 ) will be used to determine tumor response (see Section 5.2.6 ).
The ORR is defined in Sect ion 7.3.1 . The DCR is defined as the proportion of subjects with 
CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for 
≥12 weeks). Disease control rate will be analy zed in a m anner similar to ORR. The 95% CI 
of DCR will be est imated using the exact probability method. Duration of response will be 
defined as the duration from the first documentation of object ive response to the first 
docum ented di sease progressi on or d eath due to any cause, whichever occurs first. For 
subjects who are alive and progression -free at the time of data cutoff for analysis, DR will be 
censored at the last tumor assessment date. The DR will only be evaluated 
forthesubgroup of subjects wi th an object ive response using the Kaplan -Meier method 
(Kaplan and Meier, 1958).
Progression -free survival will be measured fro m the start of treatment with MEDI4736 until 
the docum entati on of  disease progression or death d ue to any  cause, whichever occurs first. 
For subjects who are alive and progression -free at the time o f data cutoff for analysis, PFS 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 123of 220 Template 14.1will be censored at the last tumor assessment date. Progression- free survival will be 
evaluated using the Kaplan -Meier m ethod. Overall survival will be determined as the time 
from the start of treatment with MEDI4736 unt il death. For subjects who are alive at the time 
of data cutoff for analysis or lost to foll ow-up, OS will be censored on the last date when 
subjects areknown tobe alive. The OS will be evaluated using the Kaplan -Meier method 
(Kaplan and Meier, 1958 ).
Separate analyses of efficacy  endpoints will  be perform ed based on BICR assessment (if 
BICR data are available) and invest igator assessment.
7.3.3 Exploratory Endpoints
Descript ive statistics will be the primary methods used for the exploratory  analyses. 
Depending on the nature of the data, geometric mean and other appropriate statist ical 
summaries might be used as well. It i s hypothesized that MEDI4736 will induce measurable 
changes in the immune status of subjects. Among the variables to be examined in the 
exploratory  analyses to assess these changes are:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL 8.Archived tumor samples may be evaluated by  IHC f or PD -L1 expressio n on tum or cells 
to evaluate any  predict ive or prognostic relat ionship with subject re sponse to treatment. 
The expressio n level and localizat ion of other immune -related or response -related 
markers by  IHC may  also include, but not be limit ed to, CTLA- 4, CD3, CD4, CD8, 
CD45RO, FoxP3, granzyme B, OX40, PD -1, cleaved caspase 3 and Ki67 
9.Fresh ( de novo) tum or biopsy  samples (dose -expansio n phase) m ay be examined for 
PD-L1 target expressio n and localizat ion by IHC and possibly addit ional markers as 
above. These studies serve the purpose of evaluating target expressio n and modulat ion, 
and lymphocy te infil tration in response to treatment with MEDI4736. Correl ation 
between target expressio n and m odulation in tum or tissue and clinical act ivity will also 
be evaluated
10.Archived material (or biopsies if available), will be analyzed for the presence of key 
mutati ons which m ay include but are not limited to: K -ras, N -ras, B -raf, APC, B -catenin, 
ALK and C -met to eval uate thei r potenti al relevance and correlat ions wi th response to 
MEDI4736 treatment
 
 
7.4 Subgroup Analysis
In the dose -expansio n phase, the ant itumor activit y by baseline PD -L1 expressio n (positive 
vsnegat ive), line of therapy , ECOG performance status, and metastatic site at baseline, when 
practi cal and appropri ate,will be assessed in each as well as across all disease cohorts.
In assessment of ant itumor activit y in the UBC populat ion, subjects will be also be analyzed 
by baseline hemoglo bin levels ( ≤ 10 g/dL vs > 10 g/dL), baseline creatinine clearance levels 
(<60 m L/min vs ≥ 60 m L/min), PD -L1 subgroups defined based on tumor cell staining only, 
and PD-L1 subgroups defined based on immune cell staining only.
7.5 Interim Analysis
For the UBC cohort, the first interim analysis wi ll be conducted after approximately 30 PD -
L1-positive UBC subjects are enrolled and fo llowed for at l east 12 weeks. The efficacy 
analysis will be based on invest igator RECIST data.
The second interim analysis for the UBC cohort will be conducted after approximately a 
minimum o f 60PD-L1-positive second -or greater line UBC subjects are enrolled in the 
entire study  and fo llowed f or at l east 16 weeks. The primary efficacy analysis populat ion for 
this analysis wil l be based on the treated PD -L1-posit ive UB C subjects (second -or greater 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 125of 220 Template 14.1line) with measurable disease at baseline per BICR who have had an opportunit y of being 
followed up for at least 16 weeks by  the interim  analysis. The analysis will be primarily  
based on RECIST v1.1 by  BICR, and addit ional an alysis based on investigator RECIST data 
will be conducted as supportive. 
The purpose of those interim analyses for the UBC cohort will be for early evaluat ion of 
efficacy  and safety  data for internal program decision and/or potential interact ions wit h 
regulatory  agencies on future development . Addit ional data cut -offs for the UBC cohort may 
also take place before the primary  analysis of ORR to support interactions with the regulatory  
authori ties.The enro llment will not be interrupted or terminated for ef ficacy based on the 
interim analysis .
7.6 Sample Size and Power Calculations
 
Dose -escalation Phase
The number of subjects requi red will depend upon the toxicit ies observed as the study  
progresses. Up to approximately  50evaluable subjects (3+3 subjects per dose cohort) could 
be required during the dose -escalation phase if the separate Q3W escalat ion is implemented 
upon com pletion of  dose escal ation for the MEDI4736 Q2W dose -escalation arm. More 
subjects may  be enrolled to invest igate intermediate doses for M TD evaluat ion if DLTs are 
observed in either the 3.0 or 10 mg/kg dose cohort. In addition, more subjects may be 
enrolled if doses higher than 10 mg/kg Q2W are evaluated during dose escalat ion. 
Non-evaluable subjects will be replaced in the same dose cohort . Table 7.6-1provides the 
probabilit y of dose escalat ion to the next higher level for each underlying true DLT rate. For 
example, for a commo n toxi city that occurs in 10% of subjects, there is a greater than 90% 
probabilit y of escalat ing to the next higher dose level. Conversely, for a toxicit y that occurs 
with a rate of 60%, the probabilit y of escalat ing to the next higher dose level is less than 
10%.

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 126of 220 Template 14.1Table 7.6-1 Probability of Escalation for Different True Underlying 
Dose -limiting Toxicity Rate at a Given Dose Level
True underlying DLT rate 10% 20% 30% 40% 50% 60% 70% 80% 90%
Probability of escalating dose 0.91 0.71 0.49 0.31 0.17 0.08 0.03 0.009 0.001
DLT = dose -limiting toxicity.
Dose -exploration Phase
Approximately  20 subjects will be enrolled in the dose -exploration cohort of the study  to 
determine the safet y of 20 m g/kg Q4W dose schedule.  
 
 
Dose -expansion Phase
A minimum of approximately 692subjects will be enro lled in the dose -expansio n phase as 
follows. Addit ional subjects, described in each cohort below, may be enrolled if promising 
clinical act ivity is observed in any o f these cohorts.
•Advanced cutaneous melano ma, uveal melano ma, HCC, SCCHN, gastroesophageal 
cancer, TNBC, UBC (initial cohort enrolled prior to Amendment 8) , GBM, ovarian 
cancer, soft tissue sarco ma, SCLC, MSI -high cancers, and HPV -positive cancers cohorts: 
A minimum of 20 subjects will be enrolled in each of these 13 disease cohorts. The 
sample size is chosen to obtain a preliminary assessment of ant itumor activit y in terms of 
DCR for each disease cohort. The DCR will be estimated by  the proporti on of  subjects 
with CR, PR, or SD ≥ 12 weeks in each d isease cohort and its 80% CI will be estimated 
by the exact probabilit y method  
 
Addit ional subjects, up to a total of 60 subjects 
in any of these dose -expansion cohorts may be enrolled if pro mising clinical act ivity is 
observed in that cohort. If the HPV- positive canc ers, MSI -high cancers, GBM, ovarian, 
or soft ti ssue sarcoma cohorts are expanded beyo nd 20 subjects, enrollment may be 
priori tized to tum or sub -type(s) that showed promising clinical act ivity, at the sponsor’s 
discreti on.
Table 7.6-2
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 127of 220 Template 14.1Table 7.6-2
 
 
•Pancreat ic adenocarcino ma and nasopharyngeal carcino ma cohorts: A minimum o f 
10subjects will be enro lled in each of these cohorts. The DCR will be estimated by the 
proporti on of  subjects wi th CR, PR, or SD ≥ 12 weeks in each cohort and its 80% CI will 
be est imated by the exact probabi lity method ( Table 7.6-3). Addit ional subjects, up to a 
total of 60 subjects in eit her of these 2 cohorts may be enro lled if promising clinical 
activi ty is observed in that cohort. 
Table 7.6-3
 
 
•NSCLC: Preliminary  data from  the dose -escalat ion phase of this study  as well  as data 
from other antibodies targeting the PD- 1/PD -L1 pathway suggest that subjects with 
NSCLC may  benefi t from treatm ent wi th an agent such as MEDI4736. As a result, a 
minimum o f approximately  110 subjects in the non -squamous histology  NSCLC cohort 
and 170 subjects in the squamous histology  NSCLC cohort will be enrolled from amo ng 
specific subpopulat ions of NSCLC as outlined below. 
◦For the non -squamous NSCLC cohort, the enrollme nt will include approximately 
10subjects who are treatment naïve, approximately 20 subjects who have received 
1prior line of therapy , and approximately 80 subjects who have received at least 
2prior lines of therapy . Addi tional subjects, up to a total  of30 each for the first -line 
and second -line therapy groups, may be enrolled.
◦For the squamous NSCLC cohort, the enro llment will include approximately 
10subjects who are treatment naïve, approximately 80 subjects who have received 
1prior line of therapy , and approximately 80 subjects who have received at least 2 
prior lines of therapy . Additional subjects, up to a total of 30 for the first -line therapy 
group, m ay be enrolled.
◦The minimum sample sizes o f 10 and 20 subjects were chosen to provide a 
prelimina ry assessment of ORR for MEDI4736 as first -line therapy for both 
squamous and non -squamous NSCLC and second -line therapy  for non -squamous 
NSCLC, respect ively, similar to the aforementioned other cohorts in other tumor 
types. 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 128of 220 Template 14.1◦The sample size of 80 subjects for MEDI4736 as third or greater -line therapy in 
non-squamous NSCLC and as second -line therapy  as well as thi rd or greater -line 
therapy  for squam ous NSCLC, respectively, was chosen to provide a formal 
statist ical test ing of the fo llowing hypothesis
H0: OR R ≤10% vs H 1: ORR > 10%
 
 
In order to have the estimat ion with reasonable precision for ORR in the NSCLC 
subpopulation with subjects who have tumoral PD -L1 expression, all remaining subjects in 
the non -squamous NSCLC dose -expansio n cohort will be required to have tumoral PD- L1 
expression as determined by  prospective testing prior to enrollment. In the squamous NSCLC 
dose-expansio n cohort, a minimum of 80 subjects in the squamous NSCLC dose -expansio n 
cohorts (a minimum o f 10 subjects in the first -line therapy , a minimum of 35 subject s in each 
of the second- line therapy and third- line or greater therapy  cohorts) will be required to have 
tumoral PD-L1 expression as determined by prospective testing prior to enrollment. 
Table 7.6-4provides the est imated ORR and its 95% confidence interval (CI) in squamous 
NSCLC subjects based on the exact bino mial distribut ion.
Table 7.6-4 Estimated ORR an d 95%  CI in Squamous NSCLC 
Subjects with Tumoral PD -L1 Expression
Category N = 35 aN = 70 bN = 80 b
Number of 
CR/PR 
observed7 9 11 18 21 25 20 24 28
Estimated 
ORR20% 25.7% 31.4% 25.7% 30% 35.7% 25% 30% 35%
Lower 
limit of 
95% CI8.4% 12.5% 16.9% 16.0% 19.6% 24.6% 16.0% 20.3% 24.7%
Upper 
limit of 
95% CI36.9% 43.3% 49.3% 37.6% 42.1% 48.1% 35.9% 41.3% 46.5%
CI = confidence interval; CR = complete response; NSCLC = non -small cell lung cancer; ORR = objective 
response rate; PD -L1 = programmed death ligand 1; PR = partial response.
aSubjects from either second -line therapy or third- line o r greater therapy squamous NSCLC
bSubjects from the second -line therapy and third -line or greater therapy squamous NSCLC cohorts pooled 
together

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 129of 220 Template 14.1•UBC: Under Amendment 7, approximately 60 UBC subjects were enrolled. Under 
Amendment 8 and beyo nd, approximately  132additional UBC subjects wi th inoperable 
or metastati c disease (second- or greater line) will be enrolled, which includes 
approximately  70PD-L1-positive and 50 PD -L1-negative subjects, assuming a PD -L1-
positive prevalence of 60% and approximately 10% of subjec ts wi th tumor sam ples non -
evaluable for PD -L1(based on preliminary data from the init ial UBC cohort of this study; 
seeSecti on 1.2.3 ). 
Of 192UBC subjects enrolled in the study , it is expected that there will be approximately  
100 PD -L1-positive subjects in the second -or grea terlineof treatm ent (approximately 30 
enrolled under Am endment 7 and approximately 70 enrolled under Amendment 8 and 
beyo nd). when the ORR is expected to be in the 17% to 33% range 
(Plimack et al, 2015 ; Rosenberg et al, 2015 ), a total o f 100 subjects woul d provi de a wi dth of 
< 9% between the observed ORR and its lower limit of the exact 95% CI  
 
Table 7.6-5
 
 
 
 
 
  

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 130of 220 Template 14.1The prevalence of PD -L1 status for UBC subjects will b e monitored t hrough the study. After 
a total  of approximately  132subjects are enrolled under Amendment 8and beyo nd, the 
enrollment of only PD -L1-positive subjects maycontinue to ensure a minimum total of 70 
PD-L1-positive subjects are enrolled .
With 70 PD-L1-positive and 50 PD -L1-negat iveUBC subjects enrolled under Amendment 8
and bey ondto validate the potential o f PD-L1 expressio n to predi ct response to MEDI4736 
treatm ent, 
The response 
rate for the PD -L1-negat ive group is assumed to be similar to that observed wit h 
chemotherapy in a second -line UBC populat ion (Bellm unt et al , 2009 ).
8DIRECT ACCESS TO SOURCE DOCUMENTS
The study  will be m onitored by  the sponsor or designee on a regular basis throughout the 
study  period. During m onitoring visi ts, the invest igator will provide direct access to all 
source documentation relevant to the subject’s participat ion in the study . Source 
docum entati on includes, but is not limited to, the subject’s clinic and/or office chart, hospital 
chart, ICFs, treatment notes, laboratory  reports, pharm acy records, radiographs, recorded data 
from autom ated instrum ents, and any  other records maintained to conduct and evaluate the 
clinical study . The investigator m ust also ensure that direct access to study  documents be 
made available for study -related audi ts, IRB/IEC review, or regulatory  inspect ion.
9QUALITY CONTROL AND QUALITY ASSURANCE
9.1 Data Collection
As part of the responsibilit ies assumed by  parti cipating in the study , the investigator agrees to 
maintain adequate and accurate case histories for the subjects treated under this protocol. 
Case hi stories include CRFs and supporting data including, but not limited to, signed and 
dated ICFs, progress notes, hospital charts, nurse’s notes, diary cards or other worksheets 
provi ded to subj ects, l aboratory  reports, ECG stri ps, etc.
Subject dem ographi cs and key /essent ial disease baseline characteristics thought to affect 
outcom e, ie, stratificat ion vari ables and other prognostic factors, may  be collected, as 
available, for all subjects who provide written info rmed consent. For subjects who provided 
inform ed consent and were not entered into the study , the reason the subject was not entered, 
ie, di d not m eet one or m ore incl usion criteria, met one or m ore exclusio n criteria, or other 
(eg, l ost to follow -up, consent wi thdrawn), m ay also be collected.

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 131of 220 Template 14.19.2 Study Monitoring
The primary  source docum ent for this study  will be the subject’s medical record. If separate 
research records are maintained by  the invest igator(s), both the medical record and the 
research records will be monitored/audited for the purposes of the study .
The invest igator and inst itutions invo lved in the study  will permit study -related m onitoring 
and provide direct access to all study  records and facilit ies. Adequate time and space for 
monitoring visits should be made by the investigator or other in vestigator site staff.
The m onitor will  visit study  facilit ies at peri odic interval s, in addit ion to m aintaining 
necessary  contact through tel ephone, e -mail, and letter, to ensure that the study  is conducted 
and docum ented in accordance with the protocol, GCP, and applicable regulat ions. The 
monitor will  assess subject enrollment and informed consent procedures; invest igational 
product storage, dispensing, administration and accountabilit y; co mpliance wi th protocol  
procedures; completeness and accuracy o f data entered on to validated data collection 
instrum ents (paper CRF or electronic data screen) against original source documents; the 
continued acceptabilit y of the facilit ies and qualifications of the site staff; and the occurrence 
of AEs/SAEs. All aspects of the study  will be carefully mo nitored for com pliance wi th the 
protocol , applicable regulatory  requi rements, GCP, and the site’s standard operating 
procedures.
The m onitor will  discuss the conduct and progress of the study  with the invest igator and 
other site staff. The investigator must cooperate with the monitor to ensure that corrective 
action is taken to resolve any  problems noted in the course of the monitoring, and that the 
preventative measures are put into place to prevent recurrence of issues. In cases where 
compliance is not achieved, shipment(s) of invest igational product to the invest igator will be 
discontinued and study  parti cipat ion by that invest igator will be terminated.
9.3 Audit and Inspection of the Study
During and after the study , the spon sor or i ts representati ve m ay conduct audi ts of any  data 
and any  facility parti cipat ing in the study . The investigator and inst itutions invo lved in the 
study  will permi t such study -related audi ts and provide direct access to all study  records and 
facilit ies. The invest igator must maintain a co mprehensive and centralized filing system of 
all study -related docum entati on that i s suitable f or inspecti on by  the sponsor or i ts desi gnated 
monitors, audi tors, or regul atory  agency representatives. The invest igator a grees to 
participate in audits conducted at a convenient time in a reasonable manner.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 132of 220 Template 14.1Government regulatory  authori ties may  also perform inspect ions eit her during or after the 
study . In the event of an inspect ion by any regulatory  authori ty, the invest igator should 
prom ptly notify the sponsor. The investigator agrees to cooperate fully  with inspect ions 
conducted by  regul atory  authori ties and to allow representatives of the regulatory  authori ty 
access to all study  records. The investigator will fo rward to th e sponsor a copy  of any 
inspection records received.
10ETHICS
10.1 Regulatory Considerations
The study  will be conducted in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with the ICH guidelines on GCP, any applicable 
laws and requirements, and any  condi tions requi red by  a regulatory  authori ty and/or IRB/IEC 
that approves this study  to be conducted in its territory . Good clinical pract ice is defined as a 
standard for the design, conduct, performance, mon itoring, audi ting, recording, analysis, and 
reporting of clinical studies in a way that provides assurance that the data and reported results 
are credible and accurate, and that the rights, safety, and well -being o f study  subjects are 
protected.
Per GCP, t he protocol will be reviewed and approved by the IRB or IEC of each part icipating 
center prior to study  initiation. Seri ous adverse events regardless o f causalit y will be reported 
to MedImmune Patient Safet y or desi gnee, and the invest igator will keep the IRB/IEC 
inform ed as to the progress of the study .
The invest igator will explain the nature of the study and will inform the subject/legal 
representative that participat ion is vo luntary and that the subject can withdraw or be 
withdrawn from  the study  at any time. Wri tten inform ed consent will be obtained from each 
subject/legal representative prior to the screening procedures to determine if study  eligibilit y 
criteria are met. A copy  of the signed ICF(s) will be given to every  subject/l egal 
representative, a nd the original(s) will be maintained with the subject’s records.
10.2 Institutional Review Board or Independent Ethics Committee
A list of IRB/IEC members or a Statement of GCP Compliance should be obtained by the 
investigator and provided to the sponsor.
Any docum ents that the IRB/IEC may need to fulfill it s responsibilit ies, such as protocol 
amendments, and information concerning subject recruit ment, payment, or compensat ion 
procedures, or information fro m the sponsor will be submitted to the IRB/IEC. The 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 133of 220 Template 14.1IRB/IEC’s wri tten uncondi tional approval  of the study  protocol , the ICF(s), and any other 
written m aterials to be provided to subjects will be in the possessio n of the invest igator and 
the sponsor before the study  is init iated. The IRB/IEC’s uncondit ional approval  statem ent 
will be transmitted by  the invest igator to the sponsor prior to shipment of investigational 
product supplies to the site. This approval must refer to the study  by exact protocol tit le and 
number, and should ident ify the documents reviewed a nd the date of review.
Protocol  modificati ons or changes may not be init iated wi thout pri or wri tten IRB/IEC 
approval  except when necessary  to eliminate immedi ate hazards to the subjects or when the 
change(s) invo lves only logist ical or administrative aspec ts of the study . Such m odificat ions 
will be submitted to the IRB/IEC and written verification that the modificat ion was submitted 
shoul d be obtained.
The IRB/IEC must be informed by  the invest igator of ICF changes or revisio ns of other 
docum ents ori ginally submi tted f or revi ew; seri ous and/or unexpected adverse experiences 
occurring during the study  (as applicable according to local regulat ions); new informat ion 
that may  affect adversely  the safet y of the subjects or the conduct of the study ; an annual 
upda te and/or request for re -approval; and when the study  has been co mpleted.
10.3 Informed Consent
Freely  given informed consent will be obtained and documented for all subjects under this 
protocol  (or a subj ect’s legal representative, if the subject is unable to provide informed 
consent) in accordance with ethical principles that have their origin in the Declarat ion of 
Helsinki and are consistent with the ICH guidelines on GCP, any  applicable l aws and 
requi rements, and any  condi tions requi red by a regul atory  autho rity and/or IRB/IEC.
Inform ation shoul d be given in both oral and written form, and subjects or their legal 
representatives must be given ample opportunit y to inquire about details o f the study . Wri tten 
inform ed consent will addit ionally be obtained for th e conduct of certain protocol -specified 
procedures including consent for biopsy  of tumor tissue in the dose -expansion phase of the 
study  using separate ICFs. If the study  will enroll subjects who are unable to give written 
inform ed consent, such as incapac itated subjects, informed consent will be obtained 
according to the site’s standard operating procedures.
The ICF(s) generated by  the investi gator m ust be approved by  the IRB/IEC and be acceptable 
to the sponsor. Informed consent forms must be written so a s to be understood by  the 
prospective subject/legal representative. Informed consent will be documented by the use of 
a wri tten ICF(s) approved by  the IRB/IEC and signed and dated by  the subject or the 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 134of 220 Template 14.1subject’s legal representative, and by the person who conducted the informed consent 
discussio n. The signature confirms the consent is based on informat ion that has been 
understood. Each subject’s signed ICF(s) must be kept on file by the invest igator for possible 
inspection by the sponsor or its designated m onitors, audi tors, or regulatory  agency 
representatives. The subject or the subject’s legal representative should receive a copy  of the 
signed and dated wri tten ICF(s) and any other written informat ion provi ded to the subject, 
and should receive copies of any signed and dated consent form updates and any  
amendments to the wri tten inform ation provi ded to subjects.
10.4 Withdrawal of Consent for Continued Study Participation
Data and Samples Obtained for the Main Study
Study  data are protected by  the use of a subject ident ification number, which is a number 
specific to the subject. The invest igator is in control o f the inform ation that i s needed to 
connect a study  sample to a subj ect. A subject’s consent to the use of data does not have a 
specific expirat ion date, but the subject may  withdraw consent at any  time by notifying the 
investigator. If consent is wit hdrawn, any data collected prior to that time may st ill be given 
to and used by the sponsor but no new data or samples will be co llected unless specificall y 
requi red to m onitor saf ety of the subject.
Samples Obtained for Genetic Research or Future Research
Samples obtained for genetic research or future research will be labeled with a sample 
ident ificat ion number but will not be labeled wit h personal ident ifiers such as the subject’s 
name. A file linking this sample identification number with the SID number will be kept in a 
secure place at the sponsor with restricted access. If the subject withdraws consent for 
participat ing in the genet ic research or future research, this link will allow the sponsor to 
locate the subject’s sample and destroy  it. The coding of samples and results is to ensure that 
these research results are kept confident ial by keeping the subject’s ident ity and these results 
separate.
If the subject consents to have his/her samples used for genetic research or future research, 
this addi tional research m ay not start immediately  and may  start at any  time during the 
storage peri od. The subject’s sample(s) including any specimens of extracted DNA will be 
stored by  the sponsor wi th similar samples from other subjects at a secure central laboratory . 
The subject’s samples will not be kept for more than 25 y ears after the end of the study  in 
which they  were collected. If the subject chooses not to all ow his/her study  samples to be 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 135of 220 Template 14.1used for genetic research or future research, the samples will be destroyed by the sponsor 
once they  are no longer requi red for the m ain study .
If consent is wit hdrawn after a sample has been taken but before the subject’s sa mple is sent 
to the sponsor for genetic research or future research, the invest igator will arrange to have it 
destroy ed. If  consent is withdrawn after the subject’s sample(s) have been sent to the sponsor 
for genet ic research or future research, the sponso r and the invest igator will ensure that these 
sample(s) are destroy ed unless the sample identification number has been removed and the 
subject can no longer be linked to any  sample(s). However, if the subject’s sample(s) have 
already been used for research , the sponsor is not required to destroy  resul ts of this research. 
In thi s case only the remaining sample(s) will be destroy ed.
11DATA HANDLING AND RE CORD KEEPING
To m aintain confident iality, all laboratory  specimens, evaluat ion forms, reports, and other 
records transmitted outside the clinical site will be ident ified by a subject’s identificat ion 
number or coded number and age. All study  records, source medical records, and code sheets 
or logs linking a subject’s name to an SID number will be kept in a secur e locati on. Study  
records such as CRFs may be maintained electronically and require the same securit y and 
confident iality as paper. Clinical informat ion will not be released without written permissio n 
of the subject/legal representative, except as specifie d in the ICF(s) (eg, necessary  for 
monitoring by  regulatory  authori ties or the sponsor of the clinical study ). The investi gator 
must al so com ply with all applicable privacy  regulati ons (eg, HIPAA 1996, EU Data 
Protecti on Di rective 95/46/EC).
Study  docum ents (including subject records, copies of data submitted to the sponsor, study  
notebook, and pharmacy  records) m ust be kept secured in accordance wit h the specific data 
retenti on peri ods that are described in the clinical study  site agreement and based upon local 
requi rements. Study  docum ents m ust not be destroyed wit hout pri or wri tten approval  of the 
sponsor.
12FINANCING AND INSURA NCE
Financing and insurance are addressed in the individual site contracts.
13PUBLICATION POLICY
Publicat ion by the site of any  data from this study  must be carried out in accordance wit h the 
clinical study  site agreement.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 136of 220 Template 14.114REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European 
Organizat ion for Research and Treatment of Cancer QLQ -C30: a qualit y-of-life instrument 
for use in internat ional clinical tri als in onco logy. J Natl  Cancer Inst. 1993 Mar 3;85(5):365-
76.
Aglietta M, Barone C, Sawy er MB, Moore MJ, Miller WH, Bagal C, et al. A phase I dose -
escalat ion trial of trem elimumab (CP -675206) in combi nation with gemci tabine in 
chemotherapy -nave pat ients with metastati c pancreatic adenocarcino ma. 2012. 14th National 
Congress of the Italian Society  for Medi cal Oncol ogy (AIOM). Rome, Italy; Abstract A9.
Alexandrov LB, Nik -Zainal S, Wedge DC, Aparicio SA, Behjat i S, Biankin AV, et al. 
Signatures of m utational processes in human cancer. Nature. 2013 Aug 22;500(7463):415 -
21.
American Cancer Societ y. Global Cancer Facts and Figures. 2nd edit ion. At lanta: American 
Cancer Societ y; 2011.
Atkins MB, Lotzeb MT, Dut cher JP, Fisher RI, Weiss G. High -dose recombinant interleukin 
2 therapy  for pati ents wi th metastati c melano ma: analysis o f 270 pati ents treated between 
1985 and 1993. J Clin Onco l. 1999;17:2105 -16. 
Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L , Daugaard G, et al . Phase III 
trial of vinflunine pl us best supportive care compared with best supportive care alone after 
platinum -containing regimen in pat ients with advanced transit ional cell carcino ma of the 
urothelial tract. J Clin Onco l. 2009;27:4454-61.
Berger R, Rotem -Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safet y 
and pharmacokinet ic study  of CT-011, a humanized antibody  interact ing with PD -1, in 
patients wi th advanced hematol ogic malignancies. Clin Cancer Res. 
2008 May 15;14(10):3044 -51.
Bergm an B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ- LC13: a 
modular supplement to the EORTC Core Qualit y of Life Questionnaire (QLQ -C30) for use 
in lung cancer clinical trials. EORTC Study  Group on Qualit y of Life. Eur J Cancer. 1994; 
30A(5):635 -42.
Besse B, Johnson M, Janne PA, Garassino M, Eberhardt WEE, Peters S, et al. Phase II, 
single- arm trial (BIRCH) of atezolizumab as first -line or subsequent therapy for locally 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 137of 220 Template 14.1advanced or metastatic PD -L1 selected non -small  cell lung cancer (NSCLC). Ann Onco l. 
2015;suppl:abstract 16LBA. 
Bjordal  K, Ahlner -Elmqvist M, Tollesson E, Jensen AB, Razavi D, Maher EJ, Kaasa S. 
Development of a European Organizat ion for Research and Treatment of Cancer (EORTC) 
questionnaire module to be us ed in qualit y of life assessments in head and neck cancer 
patients. EORTC Qualit y of Life Study  Group. Acta Onco l. 1994;33(8):879 -85. 
Bjordal  K, Hammerlid E, Ahlner -Elmqvist M, et al. for the EORTC Qualit y of Life Group. 
Qualit y of life in head and neck c ancer patients: Validat ion of the European organizat ion for 
research and treatment of cancer qualit y of life questi onnaire -H&N35. J. Clin. Oncol. 
1999;17:1008 -19. 
Bjordal  K, De Graeff A, Fayers PM, et al. on behalf o f the EORTC Qualit y of Life Group. A 
12country  field study  of the EORTC QLQ -C30 (versi on 3.0) and the head and neck cancer 
specific module (EORTC QLQ -H&N35) in head & neck patients. Eur. J. Cancer 
2000;36:1796 -1807.
Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, et al. Blockade of PD-L1 
(B7-H1) augments human tumor -specific T cell responses in vitro. Int J Cancer. 
2006;119(2):317 -27.
Blazeby  JM, Curri e E, Zee BCY, Chu Chie W, Poon RT, Garden OJ. Development of a 
questionaire module to supplement the EORTC QLQ -C30 to assess qualit y of life in pat ients 
with hepatocellular cancer EORTC QLQ -HCC18. Eur J Cancer. 2004; 40:2439 -
44.
Borghaei H, Paz -Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivo lumab versus 
docetaxel in advanced nonsquamous non -small -cell lung cancer. N Engl  J Me d. 
2015;373(17):1627 -39.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study  
of single -agent anti -programmed death -1 (MDX -1106) in refractory  solid tum ors: safety , 
clinical act ivity, pharm acodynamics, and immunologic co rrelates. J Clin Oncol . 
2010 Jul1;28(19):3167 -75.
Brahmer JR, Ty kodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safet y and 
activit y of anti-PD-L1 ant ibody  in pat ients with advanced cancer. N Engl J Med. 2012 Jun 
28;366(26):2455 -65.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 138of 220 Template 14.1Cella DF, Tulsky  DS, Gray  G, Sarafian B, Linn E, Bonomi A, et al. The funct ional 
assessment of cancer therapy  scale: development and validation o f the general measure. J 
Clin Onco l 1993;11:570 -9.
Chan ISF, Zhang Z. Text -based exact confidence intervals for the difference o f two bino mial 
proporti ons. Bi ometrics. 1999;55:1202 -9.
Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial o f bevacizumab 
plus tem ozolomide and radiotherapy  in newly diagnosed glio blastoma mult iforme. Advances 
in Therapy. 2011 Apr; 28(4 ): 334 -40.
Cockcroft DW, Gault MH. Prediction of creat inine clearance fro m serum  creat inine. 
Nephron. 1976;16:31 -
41.
Cull A, Howat S, Greimel E, Waldenstrom AC,Arraras J, Kudelka A, Chauvenet L, et al, on 
behalf o f the EORTC Qualit y of Life Group and the S cottish Gynaeco logical Cancer Tri als 
Group. Development of a European Organization for Research and Treatment of Cancer 
questionnaire module to assess the qualit y of life of ovarian cancer patients in clinical trials: 
a progress report. European Journal of Cancer. 2001; 37(1):47 -53.
Dong H, Zhu G, Tamada K, Flies DB, van Deurson JM, Chen L. B7- H1 determines 
accumulat ion and delet ion of intrahepat ic CD8(+) T lymphocytes. Immunit y. 
2004;20:327 -36.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluat ion criteria in so lid tumors: Revised RECIST guideline (versio n 1.1). Eur J 
Cancer. 2009;45:228 -47.
Fife BT, Bluestone JA. Control of peripheral T -cell tolerance and autoimmunit y via the 
CTLA -4 and PD- 1 pathways. Immunol Rev. 2008 Aug;224:166-82.
Fitzsimm ons D, Johnson CD. Qualit y of life after treatment of pancreat ic cancer. 
Langenbeck’s Arch Surg.1998;383: 145 –51.
Fitzsimm ons D, Kahl S, Butturini G, van Wyk M, Bornman P, Bassi C, Malfertheiner P, 
George SL, Johnson CD. Symptoms and qualit y of life in chronic pancreat itis assessed by 
structured interview and the EORTC QLQ- C30 and QLQ -PAN26. Am J Gastroenterol. 2005 
Apr;100(4):918 -
26.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 139of 220 Template 14.1Flechl B, Ackerl M, Sax C, Dieckmann K,Crevenna R, Gaiger A, et al. Neurocognit ive and 
sociodem ographi c funct ioning o f glioblastoma lo ng-term survivors. Journal  of Neurooncol . 
2012 Sept;109(2):331-
9.
Galsky  MD, Hahn N M, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of 
patients wi th metastati c urothelial cancer “ unfit” for Cisplat in-based chem otherapy. J Clin 
Onco l.2011;29 (17):2432 -8.
Garon EB, Ri zvi NA, Hui  R, Leighl  N, Balmanouki an AS, Eder JP, et al. Pembrolizumab for 
the treatment of non -small -cell lung cancer. N Engl J Med. 2015;372(21):2018 -28.
Grabenbauer G G, Gerber KD, Ganslandt O, et al. Effects of concurrent topotecan and 
radiation on 6- month progression -free survival in the primary treatment of glio blastoma 
multiforme. Int. J. Radiation Onco logy Biol. Phys. 2009;75(1):164–9.
Greimela E, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauvenet L, et al, on behalf 
of the EORT Qualit y of Life Group and the Qualit y of Life Unit. An international field study  
of the reliabilit y and validit y of a disease -specific questionnaire module (the QLQ -OV28) in 
assessing the qualit y of life of pat ients with ovari an cancer. European Journal of Cancer. 
2003;39(10):1402 –8.
Ham anishi  J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed 
cell death 1 ligand 1 and tumor -infiltrating CD8+ T lymphocy tes are prognosti c factors of 
human ovarian cancer. Proc Nat Acad Sci U S A. 2007;104(9):3360-
5.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety  and tum or 
responses wit h lambro lizumab (ant i-PD-1) in melano ma. N Engl J Med. 2013 Jul 
11;369(2):134-44.
Herbst RX, Gordon MS, Fine GD, Sosman J, Soria JC, Hamid O, et al. A study  of 
MPDL3280A, an engineered PD -L1 ant ibody  in pati ents wi th locally advanced or metastatic 
tumors. 2013.49th Annual ASCO Annual Meet ing. Chicago, IL; Abstract X.
Hirano F, Ka neko K, Tam ura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7 -H1 
and PD- 1 by monoclonal ant ibodies potentiates cancer therapeutic immunit y. Cancer Res. 
2005;65(3):1089 -96.
Hodi  FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanan JB, et al. Improv ed 
survival with ipilimumab in patients with metastatic melano ma. N Engl J Med. 2010; 
363:711-23.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 140of 220 Template 14.1Iwai Y, Ishi da M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD- L1 on 
tumor cells in the escape fro m host immune system and tumor immunotherapy  byPD-L1 
blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293 -7.
Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression o f metastases fro m 
melano ma: review of the literature. Melano ma Res. 2009;19:275 -82.
Kaplan EL, Meier P. Non -parametric est imation from incomplete observat ions. J Am Stat 
Assoc. 1958;53:457-81.
Keime -Guibert F, Chinot O, Taillandier L, Cartalat -Carel  S, Frenay M, Kantor G, et. al. 
Radiotherapy  for Glioblastom a in the El derly . N Engl  J Med. 2007 Apr; 356:1527 -
35.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD -1 and i ts ligands in tol erance and 
immunit y. Annu Rev Immuno l. 2008;26:677-704.
Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibo vich BC, et al. 
Survivin and B7- H1 are collaborative predictors of survival and represent p otenti al 
therapeuti c targets for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1749 -
56.
Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, et al. PD -L1-deficient 
mice show that PD -L1 on T cells, ant igen-present ing cells, and host tissues negat ively 
regul ates T cells. Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10691 -6.
Leffers N, Gooden MJM, deJong RA, Hoogeboom BN, ten Hoor KA, Hollema H, et al. 
Prognosti c significanc eof tumor -infiltrating T -lymphocy tes in primary  and metastat ic lesions 
of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58:449 -59.
Lipson EJ, Drake CG. Ipilimumab: an ant i-CTLA -4 antibody  for m etastati c melanom a. Clin 
Cancer Res 2011 [cited 2011 Oct 10]. Available from: clincancerres.aarcjournals.o rg
Loi S, Si rtaine N, Pi ette F, Sal gado R, Vi ale G, Van Eenoo F, et al. Prognostic and predict ive 
value of tumor -infiltrat ing lymphocy tes in a phase III randomized adjuvant breast cancer trial 
in node- positive breast cancer comparing the additio n of doceta xel to doxorubicin wit h 
doxorubi cin-based chemotherapy: BIG 02 -98. J Clin Onco l. 2013;31(7):860 -7.
Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, et al. Clinical significance 
and regulation of the costimulatory  molecule B7- H1 in pancreat ic aden ocarcino ma. Cancer 
Lett. 2008;268(1):98 -109.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 141of 220 Template 14.1Madan RA, Gulley  JL. Si puleucel -T: harbinger of a new age of therapeutics for prostate 
cancer. Expert Rev Vaccines. 2011 Feb;10(2):141-50.
Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, et al; on be half of the 
EORTC PROBE Project and Brain Cancer Group. Minimal clinically meaningful differences 
for the EORTC QLQ -C30 and EORTC QLQ -BN20 scales in brain cancer patients. Ann 
Onco l. 2011 Sep;22(9):2107-12.
McCarthy  EF. The toxins of William B. Coley  and t he treatment of bone and so ft-tissue 
sarcomas. Iowa Orthop J. 2006;26:154-8.
McDermott DF, Regan MM, Clark JI, Flahert y LE, Weiss GR, Logan TF, et al. Randomized 
phase III trial of high -dose interl eukin- 2 versus subcutaneous interleukin -2 and interferon in
patients wi th metastati c renal  cell carcino ma. J Clin Onco l. 2005;23:133-41.
Montazeri A. Health -related qualit y of life in breast cancer patients: A bibliographic review 
of the li terature from  1974 to 2007. J Exp Clin Cancer Res. 2008 Aug 29;27:32.
Motze r RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall 
survival and updated results for sunit inib co mpared with interferon alfa in pat ients with 
metastati c renal cell carcino ma. J Clin Onco l. 2009;27:3584 -90.
Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expressio n of PD -L1 in lung cancer 
may contribute to poor prognosis and tumor cells immune escape through suppressing tumor 
infiltrat ing dendrit ic cells maturation. Med Oncol. 2011 Sep;28(3):682 -8.
Nagel  GC, Schmidt S, Strauss BM , Katenkamp D. Qualit y of life in breast cancer patients: a 
cluster analy tic approach. Em pirically  derived subgroups of the EORTC -QLQ BR 23 -a 
clinically oriented assessment. Breast Cancer Res Treat. 2001 Jul;68(1):75 -87.
Nishimura H, Minato N, Nakano T, Ho njo T. Immuno logical studi es on PD -1 deficient mice: 
implicat ion of PD -1 as a negative regulator for B cell responses. Int Immuno l. 
1998;10(10):1563 -72.
Nishimura H, Honj o T. PD -1: an inhibitory immunoreceptor invo lved in peripheral tolerance. 
Trends Immun ol. 2001;22:265-8.
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 142of 220 Template 14.1Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and 
therapeutic potential  of the programmed death -1 ligand/programmed death -1 pathway  in 
human pancreat ic adenocarcino ma. Clin Cancer Res. 2007 Apr 1;13(7):2151 -7.
Oganesy an V, Gao C, Shi rinian L, Wu H, Dall’Acqua WF. Structural characterization o f a 
human Fc fragment engineered for lack of effector funct ions. Acta Crystallogr D Bio l 
Crystallogr. 2008;64(6):700 -4.
Okudai ra K, Hokari  R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, et al . Blockade of 
B7-H1 or B7 -DC induces an ant i-tumor effect in a mouse pancreat ic adenocarcino ma model. 
Int J Oncol. 2009;35(4):741 -9.
Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. 
The development and psy chometric validati on of  a brain cancer qualit y-of-life quest ionnaire 
for use in combinat ion with general cancer -specific questionnaires. Qual Life Res. 1996 
Feb;5(1):139 -50.
Pages F, Galon J, Dieu- Nosjean MC, Tartour E, Sautès -Fridman C, Fridman WH. Immune 
infiltrat ion in human tumors: a prognosti c factor that shoul d not be i gnored. Oncogene. 
2010;29(8):1093 -102.
Park IH, Ro J, Lee KS, Kim SN, Yun YH, Nam BH. Phase II study  of gemci tabine in 
combinat ion with vinorelbine versus gemcitabine followed by  vinorelbine for m etastati c 
breast cancer. Invest New Drugs. 2010 Oct;28(5):659-69.
Park J, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, August ine MM, et al. B7- H1/CD80 
interact ion is required for the induction and maintenance of peripheral T -cell tolerance. 
Blood. 2010;116( 8):1291 -8.
Plimack ER, Bellmunt J, Gupta S, Berger R, Montgomery RB, Health K, et al. 
Pembrolizumab (MK -3475) for advanced urothelial cancer: updated results and bio marker 
analysis fro m KEYNOTE -012. J Clin Onco l. 2015;33(suppl):abstract 4502.
Quei rolo P, S pagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, et al. Efficacy 
and safet y of ipilimumab in pat ients with advanced melanom a and brain metastases. J 
Neurooncol. 2014 Feb 16. [Epub ahead of print].
Ralph C, El kord E, Burt DJ, O’Dwy er JF, Aust in EB, Stern PL, et al. Modulat ion of 
lymphocy te regul ation for cancer therapy : A phase II trail o f tremelimumab in advanced 
gastri c and esophageal adenocarcinoma. Clin Cancer Res. 2010;16:1662 -72.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 143of 220 Template 14.1 
 
 
 
 
 
Robert C, Thomas L, Bondarenko I, O’Day  S, We ber J, Garbe C, et al. Ipilimumab plus 
dacarbazine for previously untreated metastatic melano ma. N Engl J Med. 2011;364:2517-
26.
Rosenberg JE, et al. Atezolizumab in pat ients (pts) with locally -advanced or m etastati c 
urothelial carcino ma (m UC): resul ts from a pivotal mult icenter phase II study  (IMvigor 210). 
Ann Onco l. 2015. Abstract 21LBA.
Rosenblatt J, McDermott DF. Immunotherapy  for renal  cell carcino ma. Hematol Onco l Clin 
N Am. 2011;25:793-812.
Sagiv -Barfi I, Raj apaksa A, Czerwinski D, Chang S, Hebb J, Chester C, et al. Local tumor 
irradi ation combined with α -PDL -1 immune checkpoint inhibit ion results in local and 
systemic anti -tumor responses: successful translat ion of a mouse model to a human case 
series. Annual  Meeting of the American Associat ion for Cancer Research (AACR). 
05-09Apr2014; San Diego, CA. Abstract 2941.
Sangro B, Gom ez-Mart in C, DeLa Mata M, Iarrairaegui M, Garralda E, Barrera P, et al. A 
phase 2 clinical trial o f the CTLA -4-blocking agent tremelimumab in pat ients with 
hepatocellular carc inoma and chronic hepat itis C virus infect ion. 2012; 6th Anual Conference 
of the International Liver Cancer Association (ILCA). Berlin, Germany; abstract O -031.
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ 
tumor-infilt rating lymphocy tes and a high CD8+/regulatory  T cell  ratio are associ ated wi th 
favorable prognosis in ovarian cancer. Pro Natl Acad Sci USA. 2005 Dec 20;102(51):18538 -
43. 
Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, et al. Immun e 
response against frameshift -induced neopeptides in HNPCC pat ients and healt hy HNPCC 
mutati on carri ers. Gastroenterol. 2008;134:988 -97.

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 144of 220 Template 14.1 
 
 
Sheley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus 
Calmette -Guerin in Ta and T1 bladder cancer. Cochrane Database Sy st Rev. 
2000;(4):CD0019986.
Song X, Pak M, Chavez C, Liang M, Lu H, Schwickart M , et al . Popul ation 
Pharmacokinet icsand pharm acodynamics of MEDI4736, a fully  human ant i-programmed 
death ligand 1 (PD -L1) monoclonal an tibody , in pati ents wi th advanced so lid tumors. J Clin 
Onco l.J Clin Onco l (Meet ing Abstracts) May 2015 vol. 33 no. 15_suppl e14009 .
Soria JC, Cruz C, Bahleda R, Delord JP, Horn L Herbst RS, et al. Clinical activit y, safet y, 
and bio markers of PD -L1 blockade in non -small cell lung cancer (NSCLC): additional 
analyses fro m a clinical study  of the engineered antibody  MPDL3280A (anti -PDL1). 2013. 
38th ESMO Congress. Amsterdam, Netherlands; Abstract 3408.
Svensson H, Einbeigi Z, Johansson H, Hatschek T, Br andberg Y. Qualit y of life in wo men 
with metastati c breast cancer during 9 months after randomizat ion in the TEX trial 
(epirubicin and paclitaxel w/o capecitabine). Breast Cancer Res Treat. 2010 Oct;123(3):785 -
93.
Swann JB, Smyt h MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137 -46.
Taphoorn MJB, Stupp R, Coens C, Osoba D, Kartmann R, van den Bent MJ, et al, for the 
EORTC Brain Tumour Group, EORTC Radiotherapy  Group, and the NCIC CTG. Health -
related quali ty of life in patients with glio blastom a: a randomised controlled trial. Lancet 
Onco l. 2005; 6(12): 937 –44.
Taphoorn MJB, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al, on behalf o f 
the EORTC Qualit y of Life Group, and Brain Cancer, NCIC, and Radiotherapy  Groups. An 
internat ional validat ion study  of the EORTC brain cancer module (EORTC QLQ -BN20) for 
assessing healt h-related quali ty of life and symptoms in brain cancer patients. Eur J Cancer. 
2010 Apr;46(6):1033 -
40.
Thom pson RH, Gillett MD, Chevillem JC, Lohsem CM, Dong H, Webster WS , et al . 
Costimulatory  molecule B7- H1 in primary  and metastati c clear cell  renal cell  carcinoma. 
Cancer. 2005;104(10):2084-91.

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 145of 220 Template 14.1Thom pson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor 
B7-H1 is associ ated wi th poor prognosi s in renal cell carcinoma pati ents wi th long-term 
follow-up. Cancer Res. 2006;66(7):3381 -
5.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
activit y, and immune correl ates of ant i-PD-1 antibody  in cancer. N Engl J Med. 2012 Jun 
28;366(26):2443 -54.
US Department of Health and Human Services, National Inst itutes of Healt h, Nati onal 
Cancer Inst itute. Commo n Termino logy Criteria f or Adverse Events Version 4.03. 
http://evs.nci.nih.gov/ftp1/CTCAE/About.html
US Department of Health and Human Services, Food and Drug Administration. Estimat ing 
the Maximum Safe Starting Dose in Init ial Clinical Trials for Therapeutics in Adult Healthy 
Volunteers. 2005.
Vansteenkiste J, Craps J, De Brucker N, Wauters I. Immunotherapy  for non -small -cell lung 
cancer: the past 10 y ears. Future Oncol . 2015 May  20:1 -15. [Epub ahead of print]
Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical significance of B7 -H1 and B7 -1 
expressio ns in pancreatic carcino ma. World J Surg. 2010;34(5):1059- 65.
Wen PY, Macdonald DR , Reardon DA, Cloughesy TF, Sorensen G, Galanis E, et al. Updated 
response assessment criteria for high- grade glio mas: response assessment in neuro -oncol ogy 
working group. J Clin Oncol. 2010;28:1963 -72.
Wolchok JD, Hoos A, O’Day  S, Weber JS, Hamid O, Lebbé , et al . Gui delines for the 
evaluat ion of immune therapy  activity in solid tumors: immune -related response cri teria. Clin 
Cancer Res. 2009;15:7412 -20.
Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, et al. Ipilimumab 
efficacy  and safety  in patients with advanced melano ma: a retrospective analysis o f HLA 
subtype from four tri als. Cancer Immun. 2010 Oct 20;10:9.
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. 
Nivo lumab plus ipilimumab in advanced melano ma. N Engl J M ed. 2013;369:122-33.
Yervo y™ [prescribing information]. Princeton, NJ, IN: Bristol -Myers Squibb Com pany; 
2011 [cited 2011 Dec 3]. Available fro m: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 146of 220 Template 14.1Zeng J, See AP, Phallen J, Jackson CM, Bel caid Z, Ruzevick J, et al . Ant i-PD-1 blockade 
and stereotactic radiation produce long -term survival  in mice with intracranial glio mas. Int J 
Radiat Oncol Bio l Phys. 2013 June 1;86(2):343-9.
Zhang C, Wu S, Xue X, Li M, Qin X, Li W, et al. Ant i-tumorimmunotherapy  by bl ockade of  
the PD -1/PD -L1 pathway with reco mbinant human PD -1-IgV. Cy totherapy . 
2008;10(7):711 -9.
Zou W, Chen L. Inhibitory  B7-family molecules in the tumour microenvironment. Nat Rev 
Immunol. 2008;8(6):467
-77.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 147of 220 Template 14.115SUMMARY OF PROTOCOL AMENDM ENTS AND 
ADMINISTRATIVE CHANG ES TO THE PROTOCOL
Protocol Amendment 1, 11Jul2012
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 1. Major changes to the protocol are summarized below.
Secti on 3.1 (Overview of Study  Design): The section was updated to reflect that the first 
cohort will enroll a minimum o f 3 subjects and that all subjects in this cohort will receive the 
initial dose as a 4 -hour infusio n. If 2 or more DLTs are observed in this cohort, the starting
dose will be de -escalated as previously described. The est imated number of subjects was 
changed to 110.
Secti on 4.5.1.1 (Invest igational Product Preparation): The sect ion was updated to reflect that 
the first cohort will enro ll a minimum of 3 subjects and that all subjects in this cohort will 
receive the init ial dose as a 4 -hour infusio n.
Secti on 4.5.5 (Moni toring of Dose Administration): The frequency of monitoring of vital 
signs during all infusio ns was changed to every  15minutes (± 5 minutes). After th e infusio n, 
subject vital signs will be assessed at the end of infusion (± 5 minutes) and at 30 minutes 
(±5minutes) and 60 minutes (± 5minutes) postinfusion, fo llowed by  a 3-hour peri od of  
observat ion.
The study  site must have immediate access to emerge ncy resuscitat ion team s and equipment 
in addition to the abilit y to admit subjects to an intensive care unit if necessary .
Secti on 4.5.6 (Dose Escalat ion): The rules for dose escalation were modified so that the 
definit ion of the DLT evaluation period is t he time fro m the first dose of MEDI4736 until the 
administration of the third dose. Subjects are evaluable for assessment of DLTs if they 
receive 2 full assigned doses of MEDI4736. The section was also modified to reflect that all 
dose cohorts will include more than 1 subject.
Secti on 4.5.7 (Dose -limit ing Toxicit y): The period for evaluat ing DLTs is fro m the time of 
first administrati on of  MEDI4736 until the administration of the third dose of MEDI4736.
The DLT definit ion was m odified so that any  Grade ≥ 3 colitis is a DLT, as is any  Grade ≥ 3 
irAE of rash, pruritus, or diarrhea that does not downgrade to Grade ≤2 within 3 days after 
onset despi te maximal supporti ve care including systemic corticosteroids. Previously stated 
exclusio ns remain valid. 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 148of 220 Template 14.1Secti on5.1 (Schedule of Study  Procedures): Tables 5.1- 1 and 5.1 -2 were m odified to add the 
post-infusio n observat ion to protocol/safet y evaluati ons. 
Secti on 5.1.2 (Treatm ent Period), Secti on 5.1.3 (Maintenance Period for Subjects in the 
Expansio n Phase Who Achi eve Disease Control), and Sect ion 5.2.1 (Medical History  and 
Physical Examinat ion, El ectrocardi ogram , Weight, and Vi tal Signs): The interval of vital 
signs m onitoring during all  infusi ons was changed to every  15minutes (± 5 minutes). 
Postinfusio n monitoring includes vital signs assessment at the end of infusion (± 5minutes), 
at 30 minutes (± 5minutes) and 60 minutes (± 5minutes) postinfusio n, followed by  a 3-hour 
period of  observat ion.
Secti on 7.2 (Analysis Populat ions): The definit ion of the DLT Eval uable Population was 
modified so that the DLT evaluat ion peri od is defined as the time period unt il the 
administration of the third dose of MEDI4736. 
Secti on 7.5 (Sam ple Si ze and Power Calculations): The sample size was modified to reflect a 
total of up to approximately 110 evaluable subjects and up to approximately 50 subjects in 
the dose -escalat ion phase.
Protocol Amendment 2, 24Jul2012
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 2. Major changes to the p rotocol are summarized below.
1.Secti on 5.1 (Schedul e of Study  Procedures): Table 5.1 -1 was modified to schedule the 
first IM assessment during treatment on the day  of the Dose 3 infusio n. The IM 
assessment was added per FDA request in order to capture poten tial early  onset of ADA.
2.Secti on 5.1.2.9 (Odd -numbered Doses [After Dose 1]): Per FDA request, an IM 
assessment was added before Dose 3 only. Remaining IM sample times are unchanged.
3.Secti on 5.2.3 (Pharm acokinetic Evaluat ion and Methods): The list of sampl es taken at the 
time of the second dose was corrected by  adding Day  8.
4.Secti on 15 (Summary  of Protocol  Amendments and Administrative Changes to the 
Protocol ), Am endment 1, was revi sed to cl early state that the postinfusio n observat ion 
period of  3 hours fo llows the 60- minute vital sign assessment.
Protocol Amendment 3, 12Jun2013
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 3. The protocol was amended to reflect the fo llowing:
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 149of 220 Template 14.1•The dose -expansio n phase was broadened to include MEDI4736 treatment for the 
following tum or types: advanced cutaneous melanoma, uveal melanoma, HCC, SCCHN, 
NSCLC squamous and non -squamous histology , gastroesophageal cancer, TNBC, and 
pancreat ic adenocarcino ma. Co lorectal  cancer was r emoved fro m the dose -expansio n 
phase. These addit ional tumor ty pes are included in the dose -expansio n phase based on 
high unmet need and preclinical data suggesting that an anti -PD-L1 antibody  may be 
beneficial in these populat ions.
•Changed the duration o ftreatm ent from 6 months past the observat ion of DC plus an 
additional 6 months of maintenance (every  2 months) treatm ent to a treatm ent peri od of  
up to 12 months. The maintenance treatment period has been removed fro m this study  
and will be evaluated in f uture studi es. The Q2W and Q3W treatment periods were 
extended to allow for continued treatment up to 12 months in the absence o f maintenance 
treatm ent and to allow for consistent dosing across all subjects enrolled. In addit ion, 
language was added to perm it continuati on of  treatment in subjects with confirmed PD 
but no signs of clinical deterioration if invest igators consider that subjects continue to 
receive benefit from treatment .In the absence o f rapid clinical  deteri oration, these 
changes may  discoura ge the early discontinuation of MEDI4736 and provide a more 
complete evaluat ion of its ant itumor activit y.
•Clarified that subj ects in fo llow-up m ay be retreated with MEDI4736 at the highest dose 
previously received if evidence of PD is during fo llow-up, an d that only  one round of 
retreatm ent will be allowed.
•Added assessments to evaluate PRO.
•Revised object ives to support the dose -expansio n phase and addit ion of PROs.
•Antitumor activit y will be assessed by RECIST guidelines (v1.1; Eisenhauer et al, 2009) 
with modificat ions instead of irRC. RECIST guidelines are the standard basis for disease 
assessments in so lid tumors and will be familiar to investigators invo lved in the broader, 
revised dose -expansio n phase of this study . In additi on, clinical data to date with PD-1 
and PD- L1 targeting antibodies suggests that the majority  of response patterns will be 
amenable to assessment with RECIST -based measurement.
•B7-H1 was changed to PD -L1 throughout the protocol for consistency.
•In addit ion, clarificati ons were add ed to certain sections to aid in operational 
implementation and minor copy edits were made.
Major changes to the protocol are summarized below: 
Title page: Updated to reflect the change in medical monitor.
List of Abbreviat ions: Updated to match the conte nts of this protocol  amendment.
Study  Abstract: Updated to be consistent with changes made to the body  of the protocol  
amendment.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 150of 220 Template 14.1Secti on 1.1 (Disease Background): Addit ional tumor ty pes were m entioned for the 
dose-expansio n phase, the life expectancy  for each, and the treatment options.
Secti on 1.2.2 (Summary  of Nonclinical Experience): New nonclinical data were added.
Secti on 1.2.3 (Summary  of Clinical  Experience): Available clinical safet y, PK, 
pharmacodynamic, and ADA data fro m this study  were added. Cl inical experience fro m 
competitor data was added to discuss recent advancements and rat ionale for addit ional tumor 
types being added to the dose -expansion phase.
Secti on 1.3 (Research Hypothesis): Updated for consistency with change in exploratory  
objectives.
Secti on 1.4 (Rati onale for Study  Conduct): Included tumor ty pes that were added to the 
dose-expansio n phase.
Secti on 1.5 (Benefit -risk and Ethical Assessment): Updated to include co mpet itor efficacy 
and safet y data to support addit ional tumor ty pes in the dose -expansio n phase.
Secti on 2.1 (Primary  Object ive): A primary objective for the dose -expansio n phase was 
added.
Secti on 2.3 (Expl oratory  Objectives): An exploratory  objective for PROs was added for 
consistency wit h exploratory  endpo int analysis.
Section 3.1 (Overview of Study  Design): Updated to incorporate changes to dose -expansion 
phase and clarify presentation of study  design; Figure 3.1 -1 was revised for consistency with 
inform ation in text and clarit y of study  design. The enrollment status for t he MEDI4736 
Q2W dose -escalat ion arm  was added.
Secti on 3.2 (Estimated Duration of Subject Participation): Changed the duration of treatment 
from 6 months past the observat ion of DC plus an addit ional 6 mo nths of maintenance (every 
2 months) treatm ent to a period of up to 12 months. The maintenance treatment period has 
been remo ved from this study  and will  be eval uated in future studi es. The Q2W and Q3W 
treatm ent peri ods were extended to allow for continued treatment up to 12 months in the 
absence of mainten ance treatm ent and to allow for consistent dosing across all subjects 
enrolled. In addit ion, language was added to permit con tinuati on of  treatm ent in subjects with 
confirmed PD but no signs of clinical deterioration if invest igators consider that subjects
continue to receive benefit from treatment .In the absence of rapid clinical deterioration, 
these changes may discourage the early discont inuation of MEDI4736 and provide a more 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 151of 220 Template 14.1complete evaluat ion of its ant itumor activit y. Also, cl arified that only  one round of 
retreatm ent wi th MEDI4736 will be allowed.
Secti on 3.3 (Study -stopping Cri teria): Changes were made to the criteria to align wit h new 
procedures and other protocols.
Secti on 3.4 (Rati onale for Study  Design and Doses): Included rationale to support the 
additional tumor types in the dose -expansio n phase and the use of RECIST v1.1 guidelines 
with modificat ion for disease assessment. 
Secti on 4.2 (Subj ect Select ion and Wit hdrawal): Text was added to include all tumor ty pes 
and therapeut ic response crit eria for the dose -expansio n phase.
Secti on 4.2.1 (Incl usion Criteria): Incorporated addit ional inclusio n criteria and revised 
exist ing criteria to support tumor ty pes in the dose -expansio n phase.
Secti on 4.2.2 (Excl usion Criteria): Incorporated addit ional exclusion criteria and revised 
exist ing criteria to support tumor ty pes in the dose -expansio n phase.
Secti on 4.2.3 (Wi thdrawal  Criteria): Item  5 was added to align with study  procedures and 
other protocols. Item 11 was expanded to require, in addit ion to c onfirmation o f PD, an 
investigator determinat ion that the subject is no longer benefit ing fro m treatm ent wi th 
MEDI4736.
Secti on 4.5.1.1 (Invest igational Product Preparation): Added statement that WFI will be 
supplied by  each si te, and clarified invest igational product preparati on to align wi th study  
procedures.  
Secti on 4.5.3 (Treatm ent Regimen): Section was expanded to provide more detailed 
descript ion of the treatment regimens in the dose -escalat ion and dose -expansio n phases, and 
include figures for clar ity.
Secti on 4.5.4 (Treatm ent Administration): Revised text to align wit h study  procedures.
Secti on 4.5.5 (Moni toring of Dose Administration): Window of ± 15 minutes was added to 
the postinfusio n 3-hour peri od of  observat ion for clarification of study  proc edure. Dose rate 
modificati on was cl arified for subjects experiencing Grade ≤ 2 infusi on-related reacti ons.
Secti on 4.5.6 (Dose Escalat ion): Cl arified that the Q3W dose -escalat ion arm  will be init iated 
in parallel wit h the dose -expansio n phase. Criteria fo r expl oring higher doses were also 
clarified.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 152of 220 Template 14.1Secti on 4.5.7 (Dose -limit ing Toxicit y): Deleted hormone levels to be within normal limit s as 
a criterion for managed Grade 3 endocrinopathy . 
Secti on 4.5.8 (Dose Modificat ion for Toxi city Management): Added tha t dose m odificat ion 
will not be required for laboratory  abnorm alities that are not deemed to be clinically 
significant; Table 4.5.8 -1 modified to include addit ional irAE term s and toxi city assessments. 
Secti on 4.6.1 (Permitted Concomitant Medicat ions): Ad ditional details were added for 
clarificati on.
Secti on 4.6.2 (Excl uded Conco mitant Medi cations): Addi tional details were added for 
clarificati on.
Secti on 5.1 (Schedul e of Study  Procedures), Section 5.1.1 (Screening), Section 5.1.2 
(Treatm ent Period), Secti on 5.1.3 (End of Treatment), Section 5.1.4 (Post Treatment 
Follow-up): 
•Schedule of study  procedures table for the maintenance period and sect ion describing 
assessments during the maintenance period were removed for consistency wit h changes 
in treatment sc hedule;
•Treatment periods were clarified;
•PRO assessments were added for the dose -expansion phase;
•Hepati tis B and C viral t iters were added for HCC subjects with hepat itis B or C;
•Every  8-week ECG assessments were deleted and scheduled to coincide with ME DI4736 
administration;
•Assessment schedules were modified for alignment with changes to the dose -expansio n 
cohorts and to accommodate subjects in retreatment. 
•Table 5.1 -2 was revised to only present a schedule of study procedures in fo llow-up for 
subjects who have completed the MEDI4736 12 -month treatment and achieved DC and 
subjects who have discontinued MEDI4736 due to toxicit y in the absence o f PD. 
•A new appendix was created (Appendix 9) to present a separate schedule o f study  
procedures in fo llow-up for subjects who have discontinued MEDI4736 treatment due to 
confirmed PD.
Secti on 5.2.2 (Clinical Laboratory  Tests): Added hepatit is B and C viral t iters as an 
additional safety  test for HCC subjects with hepatitis B or C.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 153of 220 Template 14.1Secti on 5.2.3 (Pharm acokinetic E valuat ion and Methods): Assessment schedule modified for 
alignment with changes to treatment schedule; assessment schedule for subjects being 
retreated with MEDI4736 after evidence of PD in follow -up was clarified.
Secti on 5.2.5 (Bi omarker Eval uation and Methods): Added collection of CTC fro m TNBC 
subjects in the dose- expansion phase. Clarified that whole blood for RNA and/or 
miRNA/mRNA sample preparation will be collected fro m all subjects and tumor samples 
will be co llected from dose -expansio n subjects.
Secti on 5.2.6 (Di sease Evaluat ion and Methods): Revised tumor assessments to be based on 
RECIST gui delines (v1.1; Eisenhauer et al, 2009) with modificat ions. The modificat ion 
included is to require a repeat confirmatory  scan upon docum entati on of  disease p rogression, 
and is similar to the irRC.
Secti on 5.2.7.1 (Archival Tumor Samples): Clarified that archival tumor samples must be 
deem ed available during the screening period, to permit assessment of tumoral PD -L1 
expressio n at screening if necessary  to m eetminimum requirement that 10 subjects with 
NSCLC and 10 subjects with TNBC have tumoral PD -L1 expression.
Secti on 5.2.7.2 (Tum or Bi opsies): Cl arificat ion was added for the number of subjects 
requi red to have tumor biopsies in the dose -expansio n phase. Biopsies using fine -needle 
aspirations were removed. Core biopsies are considered to be more valuable than fine -needle 
aspirations for the analyses included in this study .
Secti on 5.2.8 (Patient -reported Outcomes Assessments): New section was added to support 
addition of  PRO endpo int.
Secti on 5.2.9 (Estimate of Volume of Blood to be Collected): Updated volume of blood to be 
collected to be consistent with study  procedures.
Secti on 6.4.3.2 (Hepatic Funct ion Abnormalit y): Included “(or equivalent)” after SMC sinc e 
it may change in name.
Secti on 6.5 (Safet y Management During the Study): The MedImmune safet y management 
descript ion was updated to reflect current practices.
Secti on 7.2 (Analysis Populat ions): Rem oved Efficacy  Evaluable Popul ation and changed 
title of Safety Popul ation to As- treated Popul ation. Wi th the except ion of MTD evaluation, 
all analyses, including safet y and efficacy , will be conducted wi th the As -treated Popul ation.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 154of 220 Template 14.1Secti on 7.3.1 (Primary  Endpoints): Identified the tumor ty pes to be assessed un der the 
primary  object ive for the dose -escalat ion phase and added a primary  object ive for the 
dose-expansio n phase.
Secti on 7.3.2.3 (Ant itumor Activit y): Revised to align with change to RECIST guidelines 
with modificat ion for tum or assessment instead of ir RC. Modified the definit ion of duration 
of response to extend to death due to any  cause, so that duration of response is now defined 
as the duration fro m the first docum entati on of  objective response to the first documented 
disease progressi on or death due to any  cause, whichever occurs first.
Secti on 7.3.3 (Expl oratory  Endpo ints): Items 8 and 9, revised the assessments to be 
conducted on archived and fresh tumor samples. A PRO endpoint was added to support the 
exploratory  object ive.
Secti on 7.4 (Subgroup A nalysis): New sect ion added to describe the subgroup analysis for 
the dose -expansio n cohorts.
Secti on 7.6 (Sam ple Si ze and Power Calculations): The sample size descript ion for the 
dose-expansio n was updated to reflect the changes in the number and size of cohorts.
Appendix 1: Updated to reflect changes in signatories.
Appendices 2 through 8: New appendices providing sample PRO quest ionnaires.
Appendix 9: New appendix present ing a schedule of study procedures in fo llow-up and a 
descript ion of each visit for subjects who have discontinued MEDI4736 treatment due to 
confirmed PD. Assessments separated from fo llow-up assessments for subjects who 
completed MEDI4736 treatment and achieved DC and subjects who have discont inued 
MEDI4736 due to toxicit y in the absence of PD for greater clarit y.
Protocol Amendment 4, 04Nov2013
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 4. The protocol was amended to reflect the fo llowing:
•The number of subjects to be enrolled in the N SCLC cohorts was increased.
•The dose -expansio n procedures were clarified and a number of sample timepo ints were 
reduced.
•A schedule o f procedures for retreatment was added as an appendix for clarit y.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 155of 220 Template 14.1Major changes to the protocol are summarized below: 
List of Abbreviat ions: Updated to be consistent with the body  of the protocol .
Study  Abstract: Updated to reflect changes in the body  of the protocol  amendment.
Secti on 1.2.3 (Summary  of Clinical  Experience): Safet y, efficacy , and PK data were updated.
Secti on 1.5 (Benefit -risk and Ethical Assessment): Section was updated to reflect current 
safet y and efficacy data for the study .
Secti on 3 (Study  Desi gn): The study  flow diagram  was updated to reflect the revised number 
of subjects in each dose -expansio n cohort.
Secti on 3.1.2 (Dose Expansio n): A descript ion of the NSCLC squamous and non -squamous 
cohorts was added to give details on the number of subjects with each line o f therapy . A 
revisio n of the description o f PD-L1 posit ive sample requirements for each cohort was also 
added.
Secti on 3.4 (Rati onale for Study  Design and Doses): A rationale for use of MEDI4736 in 
NSCLC was added.
Secti on 4.2.1 (Incl usion Criteria): Inclusio n criterion #3c was added to define NSCLC 
requi rements. Incl usion criterion #4 was m odified to discuss the number of subjects and ty pe 
of cancer that will be required to have PD- L1 tum or posi tivity in the study . Inclusio n 
criterion #5 was added to define the number of subjects in each NSCLC cohort that is 
requi red to be tum oral PD-L1 posi tive for this study. Inclusio n criterion #6 was added to 
define disease progression and what is required for the NSCLC previous lines of therapy . 
Inclusio n criterion #13 was revised to give more details around archived tumor sample 
requi rements. Incl usion criterion #15 was added and inclusio n criterion #16 was revised to 
give more detail around biopsy requirements.
Secti on 4.5.5 (Moni toring of Dose Administration): Section was revised to remove the 
requi rement for 3 hour observat ion peri od for subjects in d ose-expansio n since only one 
infusio n-related reacti ons has been reported in the Q2W dose -escalat ion cohorts.
Secti on 5.1 (Schedul e of Study  Procedures): Tables 5.1- 1 and 5.1 -2 were m odified to 
describe sampling during the dose- expansion phase and to reduc e the number of laborartory  
evaluat ion required for subjects.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 156of 220 Template 14.1Secti on 5.1.1 (Screening), Section 5.1.2 (Treatment Period), Section 5.1.3 (End of 
Treatment), and Section 5.1.4 (Post -treatm ent Follow -up): Sections were updated to reflect 
the changes to the s chedule of study  procedures.
Secti on 5.2.6 (Di sease Evaluat ion and Methods): A sentence was added to clarify that scans 
woul d be stored for possible future central evaluat ion.
Secti on 5.2.7.1 (Archival Tumor Samples): The descript ion of the archival tumor sample 
requi rements was cl arified.
Secti on 5.2.7.2 (Tum or Bi opsies): The sect ion was modified to clarify requirements for 
tumor biopsies and PD -L1 tum or posi tivity.
Secti on 5.2.8.2 (EORTC QLQ -C30 and Cancer -specific Modul es): Several  typographical 
errors w ere corrected.
Secti on 7.3.2.1 (Pharm acokinet ics): A descript ion of popul ation analysis was added.
Secti on 7.6 (Sam ple Si ze and Power Calculations): The section was updated to reflect the 
changes in samples size for the NSCLC cohorts and the requirements f or number of subjects 
per cohort that need to have tumoral PD- L1 posit ivity.
Appendix 2 (Pain Quest ionnaire): An example o f the pain quest ionnaire was added for 
clarity.
Appendix 10 (Schedule of Study  Procedures for Subjects in Retreatment of MEDI4736): A 
schedule of study  procedures was added to clarify what procedures are required in 
retreatm ent.
Protocol Administrative Change 1, 10Jan2014
The purpose of this administration change is to correct inadvertent errors created during the 
last protocol amendment .
The fo llowing changes were made:
Cover Page –EudraCT number was added.
Secti on 3.1.2 (Dose Expansio n) –Correct a ty pographical error.
Secti on 4.5.3.1 (Treatm ent Regimen) –Correct a typographical error.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 157of 220 Template 14.1Secti on 4.5.3.2 (Dose Expansio n) -Correct a ty pographical error.
Secti on 5.1 (Schedul e of Study  Procedures) –Align anticancer/testis ant igen ant ibodies 
collect ion time po ints for dose -escalat ion and dose -expansio n phases. Clarify  that Vi sits for 
Dose 1 Day s 3 and 5 are for dose -escalat ion subjects only.
Secti on 5.1.2.1 (Dose 1, Day  1) –Added note that PBMC co llection is for dose -expansio n 
phase only to match Table 5.1 -1.
Secti on 5.1.2.3 (Dose 1, Day  3) –Clarify that miRNA/mRNA co llection and AE/SAE 
assessments are only  for subjects in the dose -escalat ion phase.
Secti on 5.1.2.4 (Dose 1, Day  5) –Added a note that Circulating so luble factor, hematology , 
and AE/SAE collect ions are only  for subjects in the dose -escalat ion phase.
Secti on 5.1.2.9 (Odd -numbered Doses) –Immunogenicit y assessment was clarified and add 
miRNA co llection for dose -expansio n subjects was added.
Secti on 5.1.2.10 (Even -numbered Doses) –Immunogenicit y, PK, and sPD- L1 co llections 
were cl arified for dose -escalat ion and dose -expansio n subjects to match Table 5.1-1.
Protocol Amendment 4.1 ,Germany, 08May2014
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 4. The protocol was amended to reflect the fo llowing:
•Add EudraCT number to protocol
•Add the dose -expansio n rati onale to the protocol .
Major changes to the protocol are summarized below: 
Cover page: The EudraCT number was added to the protocol.
Abstract and Section 3.1.2 (Dose Expansion): A statement was added that the 10 mg/kg Q2W 
is being taken into expansio n.
Secti on 3.4 (Rati onale for S tudy Design and Doses): A rationale for dose -expansio n was 
added.
Table 4.5.8 -1 (MEDI4736 Dose Modificat ion Due to Toxicit y): The col umn header was 
corrected.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 158of 220 Template 14.1Protocol Amendment 5, 21May2014
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 5. The protocol was amended to reflect the fo llowing:
•The ti tle of the study  was changed to a Phase 1/2 to support the NSCLC and SCCHN 
expansio n cohorts. The dose -escalat ion phase was considered the Phase 1 part of the 
study  and the dose -expansio n phase is considered the Phase 2 portion of the study .
•The number of subjects to be enrolled in the SCCHN expansion cohort is being increased 
based on preliminary efficacy and safet y data in the first 60 subjects. The additional 
SCCHN subjects will be enrolled according to tumoral PD -L1 expressio n to allow for a 
correl ation to clinical response. Addit ional clinical characterist ics (prior therapies, HPV 
status, smoking history , etc.) and potenti al biomarkers will  also be expl ored in rel ation to 
clinical benefit derived from MEDI4736 treatment in subjects with SCCHN.
•The pancreatic adenocarcino ma and uveal melanoma expansio n cohorts are being 
increased based on preliminary efficacy  and safet y in the first 20 -30 subjects to allow for 
additional signal searching to ident ify a subset of patients that may benefit from 
MEDI4736 treatment (including any  correl ation between PD -L1 expressio n and clinical 
response). 
•Eight new expansio n cohorts were added based on the potential for efficacy  of 
MEDI 4736 in a broad range of tumor ty pes. These addi tional cohorts were chosen based 
on 1) unm et medical need, 2) PD -L1 tumoral expressio n, 3) evidence of responsiveness 
to other immunotherapy  treatments, 4) vi ral etiology and expressio n of virally -induced 
tumor associ ated ant igens, 5) associat ion of the cancer with TILs, 6) high levels of tumor 
antigens due to a high mutation burden or translocations, or 7) preclinical efficacy 
modeling.
•Digital ECGs at select si tes were added to provide robust ECG data for ME DI4736 and to 
support future pivotal studies.
•Updated MEDI4736 clinical experience was added fro m mo notherapy  studi es to provi de 
clinical rationale (safet y and preliminary  efficacy ) to support continuat ion of the study  
and addit ion of newly defined expansi on cohorts.
•Some study  procedures were clarified and a number of sample timepo ints were reduced 
to eliminate subject burden.
Major changes to the protocol are summarized below: 
Title Page: Replaced  
as back -up m edical  monitor. In addi tion, the EudraCT number was added to the 
protocol  cover page.
List of Abbreviat ions: Updated to be consistent with the body  of the protocol .

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 159of 220 Template 14.1Study  Abstract: Updated to reflect changes in the body  of the protocol amendment.
Secti on 1.1 (Disease Background): Out -dated data was removed.
Secti on 1.2.2 (Summary  on Nonclinical Experience): Final interim audited data for a 
3-month GLP toxicit y study  were added.
Secti on 1.2.3 (Summary  of Clinical  Experience): Safety, efficacy , and PK data were updated 
for Study  CD-ON-MEDI4736
-1108 and safet y data for Study  D4190C00002 were added. In 
addition, data on other PD -1 and PD -L1 studies were updated.
Secti on 1.3 (Research Hypothesis): The co -primary objectives were add ed for com pleteness.
Secti on 1.4 (Rati onale for Study  Conduct):  The rationale of the study  was updated to reflect 
the addi tional expansi on cohorts and increased SCCHN expansion cohort.
Secti on 1.5 (Benefit -risk and Ethical Assessment): Section was updated to reflect current 
safet y and efficacy data for the study .
Secti on 2.1 (Primary  Object ive): An addit ional primary  object ive for the dose -expansio n 
phase was added for SCCHN.
Secti on 2.3 (Expl oratory  Object ives): A new explo ratory  object ive of ant itumor ac tivity 
assessed by  irRECIST was added.
Secti on 3 (Study  Desi gn): The study  flow diagram  was updated to reflect the revised number 
of subjects in each dose -expansio n cohort. The descript ion of dose expansio n was revised to 
include the new tumor cohorts.
Section 3.4 (Rati onale for Study  Design and Doses): Rationale for use of MEDI4736 in 
bladder cancer, GBM, ovarian cancer, soft tissue sarcoma, SCLC, MSI -high cancers, 
HPV -positive cancers, and nasopharyngeal carcinoma were added. A rationale for dose -
expansio n dose was added.
Secti on 4.2.1 (Incl usion Criteria): Inclusio n criterion #3 was m odified to add the new tumor 
types. Incl usion criterion #6 was added to further define the SCCHN populat ion. Inclusio n 
criterion #7 was added to define the MSI -high populat ion. Inclusio n criterion #8 was added 
to define the HPV -positive cancer populat ion. Inclusion criterion #9 was added to limit the 
GBM subject population. Inclusion criterion #10 was added to define the ovarian populat ion. 
Inclusio n criterion #13 was m odified to describe the requirement for each tumor ty pe. 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 160of 220 Template 14.1Inclusio n criterion #19 was revised to add the RANO guidelines for GBM. The biopsy  
language in inclusio n criteria #22 and #23 were modified to exclude GBM.
Secti on 4.2.2 (Excl usion Criteria): Excl usion criterion #6 was modified to describe the 
steroi d dose and durati on for GBM. Excl usion criterion #25 was added to describe edema in 
subjects wi th GBM.
Secti on 4.5.1.1 (Invest igational Product Preparation): The language was modified to allow 
dose preparation up to 30 m g/kg and to allow dosing day  weight to be used for dose 
calculat ion.
Secti on 4.5.3.2 (Dose Expansio n): The new expansio n cohorts were added.
Secti on 4.5.8 (Dose Modificat ion for Toxi city Management):  Pneum onitis was added as 
potenti al irAE.
Table 4.5.8 -1 (MEDI4736 Dose Modificat ion Due to Toxicit y): The col umn header was 
corrected.
Secti on 4.6.2 (Excl uded Conco mitant Medi cations): Tem porary  use of corti costeroi ds was 
added and may  be permitted upon discussio n with the medical mo nitor for underlying or 
concurrent illness.
Secti on 5.1 (Schedul e of Study  Procedures): Table 5.1 -1 was modified to reduce procedures 
and visits during expansion and to add questionnaires and procedures for the new tumor 
types. Table 5.1 -2 was m odified to reduce procedures in follow-up. Footnotes were added to 
both tables to describe procedures and time requirements for clarificat ion.
Secti on 5.1.1 (Screening): The detailed descript ions of procedures were removed to reduce 
redundancy and errors.
Secti on 5.1.2 (Treatm ent Peri od): The detailed descript ions of procedures were removed to 
reduce redundancy and errors.
Secti on 5.1.3 (End of Treatment): Section number revised. A definit ion of end of treatment 
was added for clarification. The detailed descriptions o f procedures were re moved to reduce 
redundancy and errors.
Secti on 5.1.4 (Post -treatm ent Follow -up): The detailed descript ions of procedures were 
removed to reduce redundancy  and errors.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 161of 220 Template 14.1Secti on 5.2.1 (Medi cal History  and Physical Examinat ion, Electrocardi ogram , Weight, and 
Vital Signs): A description of ECG procedures was added and a description of digital ECG 
procedures was added.
Secti on 5.2.6 (Di sease Evaluat ion and Methods): The RANO guidelines for GBM were 
added. 
Secti on 5.2.7.2 (Tum or Bi opsies): The number of tumor bio psies by tum or type was revised 
and the new expansio n cohort information was added.
Secti on 5.2.8.2 (EORTC QLQ -C30 and Cancer -specific Modul es): Descript ion of the GBM 
and ovarian cancer -specific modules were added.
Secti on 5.2.8.3 (FACT -BL): Section was a dded to describe the bladder cancer -specific 
module.
Secti on 6.1.3 (Other Events of Special Interest): Definit ion of AESI was added and 
descript ions of pneumo nitis and hypersensit ivity reacti ons were added.
Secti on 7.3.1 (Primary  Endpoints): The description of the endpo int for SCCHN was added 
for com pleteness.
Secti on 7.6 (Sam ple Si ze and Power Calculations): Section was revised to reflect the 
increased sample sizes and the new expansio n cohorts.
Secti on 14 (References): New references were added to support the text in the body  of the 
protocol .
Appendix 10 (Patient -reported Outcome Quest ionnaire EORTC QLQ -BN20): Sam ple 
questionnaire added.
Appendix 11 (Patient -reported Outcome Quest ionnaire EORTC QLQ -OV28): Sample 
questionnaire added.
Appendix 12 ( Patient-reported Outcome Quest ionnaire FACT -BL): Sam ple quest ionnaire 
added.
Appendix 13 (Schedule of Study  Procedures for Subjects in Retreatment of MEDI4736): 
Table 13- 1 was m odified to reduce procedures in retreatment. Footnotes were added for 
clarifica tion of  timing and to add descript ions. 
Secti on 15.1 (Rebaseline) and Section 15.1.1 (Retreatment Period): The detailed descriptions 
of procedures were removed to reduce redundancy and errors.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 162of 220 Template 14.1Appendix 14 (Schedule of Study  Procedures in Follow -up for Sub jects Who Have 
Discontinued MEDI4736 Treatment Due to Confirmed Progressive Disease): Flow 
cytometry at 2 m onths was rem oved from  Table 15 -2. The collect ion of the FACT -BL was 
added to Table 15 -2. A descript ion of digital ECGs was added to Table 15-2 as a footnote. 
The detailed descript ions of procedures were removed to reduce redundancy and errors.
Protocol Amendment 6, 18Jun2014
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 6. The protocol was amended to r emove the expanded 2L SCCHN cohort after 
consultation with the US FDA.
Protocol Administrative Change 2, 21Jul2014
The purpose of this administrative change is to correct inadvertent errors created during the 
last protocol amendment.
The fo llowing changes were m ade: 
•Secti on 5.1 (Schedul e of Study  Procedures), Table 5.1-1 – Removed footnote “c” for 
flow cy tometry samples in dose -expansio n cohorts and corrected footnote “c” to clarify  
that the 3 -hour post end of infusio n sample is for subjects in dose -escala tion cohorts only .
•Appendix 13 (Schedule of Study  Procedures for Subjects in Retreatment of MEDI4736), 
Table 15-1 – Row added for ECGs for Q2W dose -expansio n. Fixed footnote lettering to 
start at “a”; changed immunogenicit y collection to every 12 weeks sta rting at Dose 3 to 
match PK sample; removed post- dose sample co llections for sPD -L1from Dose 1 and 
every 12 weeks starting at Dose 3 for Q2W and every  third dose for Q3W; remo ved post -
dose sam ple collection for PK from every  12 weeks starting at Dose 3 for Q2W and every 
third dose for Q3W; removed post -Dose 1 collect ion for flow cytometry; changed flow 
cytometry collecti on from odd doses to even doses after Dose 2; and fixed footnote 
lettering to match list throughout the table. Post -dose samples were remov ed from 
circulat ing so luble factors and the footn ote del eted.
Protocol Amendment 6 ,France, 30Jul2014
The protocol was amended to state that French sites will not enroll subjects in the expanded 
NSCLC cohorts.
Protocol Amendment 6, United States, 11Sep201 4
The purpose of this amendment was to add a 20 -subject dose -exploration cohort to examine 
the safet y of 20 m g/kg dosed Q4W.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 163of 220 Template 14.1Major changes to the protocol are summarized below: 
Title Page: Added the 2 primary  medical m onitors from  the CRO and rem oved the back -up 
medical mo nitor. Naimish Pandya was replaced with Dominic Lai as the sponsor’s medical 
monitor.
Study  Abstract: Updated to reflect changes in the body  of the protocol  amendment.
Secti on 2.1 (Primary  Object ive): A primary objective for the dose-exploration cohort was 
added.
Secti on 3.1 (Overview of Study  Design): The dose -exploration cohort was added and the 
sample size was revised to reflect the additional 20 subjects. Figure 3.1 -1 was revised to add 
the dose -exploration cohort. 
Secti on 3. 1.2 (Dose Exploration): Section was added to describe the dose -exploration cohort.
Secti on 3.4 (Rati onale for Study  Design and Doses): The rational for the Q4W dosing 
schedule for dose -exploration was added.
Secti on 4.2 (Subj ect Select ion and Wit hdrawal): The dose -explorat ion cohort was added.
Secti on 4.2.1 (Incl usion Criteria): Inclusio n criterion 5f was added to define the NSCLC 
subjects to be enrolled in the dose -explorat ion cohort. Inclusio n criterion #24 was added to 
define the dose -exploration subject s.
Secti on 4.2.4 (Repl acement of Subjects): Dose -explorat ion subjects will not be replaced.
Secti on 4.5.3.2 (Dose Exploration): Section added to describe the Q4W treatment for the 
dose-exploration subjects.
Secti on 4.5.5 (Moni toring of Dose Administration) : The observat ion peri od for subjects in 
the dose -exploration cohort (Q4W) was added.
Secti on 5.1 (Schedul e of Study  Procedures): Table 5.1 -2 was added to describe the schedule 
of study  procedures for Q4W dosing. Reference to Table 5.1 -2 for Q4W dosing was added.
Secti on 5.1.3 (End of Treatment): Sentence removed because it was left in error when the 
procedure descriptions were removed in Amendment 5.
Secti on 5.2.7.2 (Tum or Bi opsies): A descript ion of when tumor biopsies will be co llected for 
dose-explorati on was added for clarificat ion.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 164of 220 Template 14.1Secti on 5.2.8 (Patient -reported Outcomes Assessments): A statement was added the subjects 
in the dose -explorat ion cohort will not complete PROs.
Secti on 5.2.9 (Estimate of Volume of Blood to be Collected): A subsect ion was a dded to 
describe the blood volume for the dose -exploration cohort.
Secti on 7.3.1 (Primary  Endpoints): The primary  endpoints for the Q4W dosing schedule were 
added.
Secti on 7.6 (Sam ple Si ze and Power Calculations): Section updated to add dose -exploration 
cohort.
Appendix 13 (Schedule of Study  Procedures for Subjects in Retreatment of MEDI4736): For 
Table 15- 1, footn ote “c” was added to PBMC collection for even numbered doses starting 
after Dose 2.
Appendix 14 (Schedule of Study  Procedures in Follow -up for Su bjects Who Have 
Discontinued MEDI4736 Treatment Due to Confirmed Progressive Disease): For Table 
15.1.1 -1, Day 14 and Month 2 samples were removed for PK and sPD -L1.
Protocol Administrative Change 3, 06Oct2014
The purpose of this administrative change is to change the medical mo nitors and to correct 
inadvertent errors created during the last protocol amendment. 
The fo llowing changes were made:
Cover Page –The m edical m onitor secti on was updated to add the PRA medical mo nitors, to 
change the sponsor’s medi cal monitor from Naimish Pandya to Dominic Lai, and to remove 
the back -up m edical m onitor.
Secti on 5.1 (Schedul e of Study  Procedures) –A sentence was removed that was left in error. 
A sentence was added to point to the retreatment schedule. The locat ion of the study  
procedures table for subject with progressive disease was corrected from Appendix 13 to 
Appendix 14. For Table 5.1 -1, footnote “f” was added for PBMC samples in dose -expansio n 
cohorts.
Secti on 5.1.3 (End of Treatment) –A sentence describing th e end of treatment procedures 
that were removed in the last amendment was removed. The sentence referring to Appendix 
14 was m oved to Secti on 5.1 (see above).
Secti on 5.1.4 (Post -treatm ent Follow -up) –Secti on was fixed to correct ty pographi cal error.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 165of 220 Template 14.1Section 5.2.1 (Medical History  and Physical Examinat ion, Electrocardi ogram , Weight, and 
Vital Signs) –A typographical error in the abbreviation of ECG was corrected.
Appendix 13 (Schedule of Study  Procedures for Subjects in Retreatment of MEDI4736), 
Table 15-1 – Footnote “c” was added for PBMC samples for even numbered doses after 
Dose 2.
Appendix 14 (Schedule of Study  Procedures: Follo w-up for Subjects Who 
Have Discontinued MEDI4736 Treatment Due to Confirmed Progressive Disease), 
Table 15.1.1 -1 –Samples for Day 14 and 2 m onths post dose were removed or PK and 
sPD-L1.
Protocol Amendment 7, 17Nov2014
The purpose of this amendment was to change tumoral PD- L1 requi rements f or future 
subjects being enro lled. In addit ion, the toxicit y management guidelines were up dated to 
discuss inflammatory  react ions attributed to local ant itumor response. In addit ion, wording 
was rem oved to allow French sites to enroll in the expanded NSCLC cohorts.
Study  Abstract: Updated to reflect changes in the body  of the protocol  amendment .
Secti on 1.2.3.1 (MEDI4736): Safet y, efficacy, and PK data were updated for Study  CD-ON-
MEDI4736-1108.
Secti on 1.5 (Benefit -risk and Ethical Assessment): Safet y date for Study  CD-ON-
MEDI4736-1108 was updated.
Secti on 3.1.3 (Dose Expansio n): Table 3.1- 1 wa s updated with recent data. Tumoral PD -L1 
status requirements were modified.
Secti on 4.2.1 (Incl usion Criteria): Tum oral PD-L1 requi rements were changed in inclusio n 
criterion #13.
Secti on 4.2.2 (Excl usion Criteria): Excl usion criterion #12 was m odified to remove untreated 
CNS m etastases.
Secti on 4.5.8 (Dose Modificat ion for Toxi city Management): Gui delines were added to 
discuss inflammatory  react ions attributed to local ant itumor response. Gui delines for infusio n 
related reacti ons were added for all grades to the table for clarit y.
Secti on 5.2.7.2 (Tum or Bi opsies): Tum oral PD-L1 status requi rements were changed.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 166of 220 Template 14.1Secti on 6.4.3.3 (Pregnancy): Reporting requirement for pregnancy in partners of male study  
subjects was added to align with glo bal safet y procedure s. 
Secti on 7.3.1 (Primary  Endpoint): The analysis for ORR by  line of therapy  and histol ogy in 
the NSCLC subpopulations with subjects who have tumoral PD -L1 expressio n was added.
Secti on 7.6 (Sam ple Si ze and Power Calculations): Sample size justificat ion for the 
requi rements on tum oral PD-L1 expressio n for NSCLC subjects is provided.
Protocol Amendment 8, 25Nov2015
The purpose of this amendment was to expand the UBC cohort in the dose -expansion phase 
to evaluate the ant itumor activit y of MEDI4736 in subject s with PD-L1-positive UBC and 
validate the potential for PD -L1 expressio n to predict response to MEDI4736 treatment. In 
addition, the toxi city management guidelines were updated to reflect the current version 
(02Oct2015), and they  were m oved from  the body  of the protocol (Section 4.5.8) to 
Appendix 15. Key changes are listed below.
1.Title page: as the sponsor’s medical mo nitor.
2.Study  Abstract: Updated to reflect changes in the body  of the protocol  amendment.
3.Secti on 1.2. 3 (Summary o f Clinical Experience): Updated to be consistent with the 
current MEDI4736 Investigator’s Brochure (version 8.0). In addit ion, data on the 
correl ation between MEDI4736 clinical act ivity and PD -L1 expressio n were added to 
support expansio n of th e UBC cohort.
4.Secti on 1.4 (Rati onale for Study  Conduct): Updated to reflect the assessment of a 
correl ation between PD -L1 expression and response to MEDI4736 treatment.
5.Secti on 1.5 (Benefit -risk and Ethical Assessment): Revised to reflect the updated data 
presented in Section 1.2.3 (Summary  of Clinical Experience) and to be consistent with 
the updated emerging safet y profile in the current MEDI4736 Investigator’s Brochure 
(versio n 8.0).
6.Secti on 2.1 (Primary  Object ive): Added a primary object ive for the dose -expansio n phase 
that will assess the antitumor activit y of MEDI4736 in subjects with PD- L1-positive 
UBC .
7.Secti on 2.2 (Secondary  Object ives): Updated this section to include secondary object ives 
for evaluat ion of the ant itumor activit y of MEDI4736 in UBC s ubjects by  PD-L1-
negat ive status, comparing PD -L1-positive and PD -L1-negat ive status, and regardless of 
PD-L1 status .
8.Secti on 3.1 (Overview of Study  Design): Updated to reflect expansio n of the UBC cohort 
in the dose -expansio n phase. In addit ion, updated t he number of subjects (by  tumor ty pe) 
enrolled into the dose -expansio n phase to show the most current enrollment status (based 
on data cutoff date of 20Nov2015).
9.Secti on 3.1.3 (Dose Expansio n) and Sect ion 3.4 (Rationale for Study  Design and Doses): 
Updated to reflect expansio n of the UBC cohort and rationale for the expansio n (ie, 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 167of 220 Template 14.1evaluat ion of the antitumor activit y of MEDI4736 in subjects with PD- L1-positive UBC 
and validat ion of the potential o f PD-L1 expressio n to predi ct response to treatment).
10.Secti on 4.2.1 (Incl usion Criteria): Revised the criteria to include the expanded UBC 
cohort. The following criteria were revised or added: 
◦ #5 (hi stology and pri or treatm ent)
◦#13d (tum or PD -L1 expression requirements)
◦#19a, b (measureable lesio ns)
◦#20 (archival tumor tissue)
◦#22 (l esion amenable to bi opsy )
◦#23 (consent for biopsy  samples)
11.Secti on 4.2.2 (Excl usion Criteria): Revised the criteria to include the expande d UBC 
cohort or other required updates. The fo llowing criteri a were revised or added:
◦#4 (pri or exposure to immunotherapy )
◦#13 (other invasive malignancy )
◦#25 (pri or parti cipation in studi es that include MEDI4736)
12.Secti on 4.5.8 (Dose Modificat ion for Toxi city Management): Revised to be consistent 
with the updated em erging safet y profile in the current MEDI4736 Invest igator’s 
Brochure (version 8.0). In addit ion, dose modificatio n and m anagement gui delines for 
MEDI4736 were updated to be consistent with the 0 2Oct2015 version, and the guidelines 
tables were m oved from  this secti on to Appendix 15.
13.Secti on 5.1 (Schedul e of Study  Procedures): Updated schedule of study  procedures tables 
to reflect expansio n of the UBC cohort.
14.Secti on 5.2.6 (Di sease Evaluat ion and M ethods): Updated to indicate that a modified 
RECIST m ay be used to discourage early discont inuation of MEDI4736 and provide a 
more com plete evaluat ion of ant itumor activit y than woul d be seen wi th conventi onal 
response criteria. In addit ion, disease assess ment by BICR was added.
15.Secti on 5.2.7 (Archival Tumor Samples and Tumor Biopsies): Updated to include 
requi rements for expanded UBC cohort.
16.Secti on 6.1.3 (Other Events of Special Interest): Added new AESI template language.
17.Secti on 6.5 (Safet y Management D uring the Study): Replaced reference to “MedImmune 
SMC (or equivalent)” with “internal safet y governance bodies”.
18.Secti on 7 (Statistical Considerat ions): Updated to reflect expansio n of the UBC cohort for 
evaluat ion of the antitumor activit y of MEDI4736 in subjects wi th PD-L1-positive UBC 
and validat ion of the potential correlat ion between PD -L1-positive expressio n and 
response to MEDI4736 treatment.
Protocol Amendment 9, 04
Feb2016
The purpose of this amendment was to update eligibilit y criteria and PD -L1 testing 
requi rements for the UBC cohort. In addit ion, clarificat ions were made to the analysis 
popul ation for the UBC cohort . Key  changes are listed below.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 168of 220 Template 14.11.Study  Abstract: Updated to align wit h changes made to the protocol body .
2.Secti on 1.5 (Benefit -risk and Ethical Assessment): Updated with rationale to lower the 
creatinine clearance requirement for UBC subjects to ≥ 30 mL/min . 
3.Secti on 3.1 (Overview of Study  Design): Updated subject enrollment numbers.
4.Secti on 3.1.3 (Dose Expansio n): Changed to update the PD-L1 requirements for subjects 
in the UBC cohort such that subjects with a non -evaluable tum or sam ple will  not be 
excluded. In addit ion, it was cl arified that tumor samples to be used for PD -L1 testing 
must be shipped to , and confirmed as received by, the Sponsor or designated central 
vendor prior to dosing. It i s estimated that approximately 10% of subjects will have 
tumors that are non -evaluable for PD -L1. As such, the sample size of the UBC cohort 
was increased by 10% from approximately  120 to approxim ately  132 subjects. Addit ional 
archival tumor tissue fro m beyond 6 m onths pri or to study  entry  is also required, if 
available.
5.Secti on 4.2.1 (Incl usion Criteria): Updated as follo ws:
a.Criterion 14.d was updated to reflect tumor tissue (fresh and/or recent w ithin 6 
months prior to study  entry ) for PD -L1 analysis must be shipped to the Sponsor or 
designated central vendor prior to the first dose of investigat ional product .However, 
subjects may  be dosed pri or to known PD -L1 results. Subjects in the UBC cohort 
must al so provi de addi tional older archival  tissue regardl ess of age, if available.
b.Criterion 19.f was updated to specify that UBC subjec ts wi th a creatinine clearance of 
≥ 30 mL/min will be eligible for study  entry . 
c.Criterion 21 was updated to indicate the addit ional tissue requirement for the UBC 
cohort, wi th reference to cri terion 14d.
d.Criteria 16 and 17 and Table 4.2.1- 1 were m odified to align contraceptive 
requi rements wi th other protocol s and wi th new template language.
6.Section 4.2.2 (Excl usion Criteria): Cri terion 13 was updated to clarify  incidental  
histol ogic findings of prostate cancer would include findings that, in the opinio n of the 
investigator, do not require active therapy  (eg, f ollowing cystoprostatecomy that is 
tumor/node/m etastasis stage ≤ pT2N0). Subjects wit h such findings may be enro lled 
pending discussio n and approval with the study  physician.
7.Secti on 4.4 (Blinding): Revised to remove formal blinding of PD- L1 status. However, 
exist ing procedures will be main tained to keep PD -L1 status for UBC subjects enrolled 
under Amendment 8 or above blinded fro m participating invest igators/site staff, subjects, 
and contract research organizat ion/Sponsor personnel who are involved in reviewing the 
clinical data. Detailed p rocedure to ensure the blinding will be specified under a separate 
study  docum ent.  
8.Table 5.1 -1 (Schedule of Study  Procedures: Screening and Treatment Period): Footnote i 
was m odified to indicate that addit ional o lder archival tissue is required of UBC su bjects 
if available. Footnote j was added to indicate that disease assessments performed as 
standard of care prior to signing of informed consent may be used for screening if 
obtained wit hin 28 days prior to first dose of investigat ional product.
9.Table 5.1 -2 (Q4W Schedule of Study  Procedures: Screening and Treatment Period): 
Footnote f was added to indicate that disease assessments performed as standard of care 
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 169of 220 Template 14.1prior to si gning of informed consent may  be used for screening if obtained wit hin 28 days 
prior to first dose of invest igational product.
10.Secti on 5.1.1 (Screening): Revised to clarify  that standard of care disease assessments
obtained wit hin 28 days prior to first dose of investigat ional product may be used for 
screening, even if obtained prior to sub jects signing informed consent. This change was 
made to avoid unnecessary repeated disease assessments. Footnote i was added to 
indicate that for subjects in the UBC cohort, a dditional  archival  tissue from > 6 m onths 
prior to study  entry  is also requi red,if available .
11.Secti on 5.2.7.1 (Archival Tumor Samples): For subjects in the UBC cohort who provide a 
fresh tumor biopsy  or an archived tum or specimen from  within 6 months prior to study  
entry  (ie, from subject si gning consent to participate in the study ) for PD-L1 IHC analysis 
during screening for PD -L1 IHC testing, addit ional archival tumor tissue from > 6 
months prior to study  entry  is also required, if available .
12. S ection 7.3.1 (Primary  Endpoints) and Section 7.5 (Interim Analysis): Updated to reflect 
the change in PD- L1 requi rements and clarify analysis populat ion for the UBC cohort. 
13.Secti on 7.6 (Sam ple Si ze and Power Calculations): Updated to increase number of 
additional enrolled UBC subjects to take into account that PD -L1 status for some enrolled 
UBC subjects will be not eval uable due to change on PD -L1 requirements. Addit ional 
updates were made to be consistent with the updates in Section 7.3.1 (Primary  
Endpoints).
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 170of 220 Template 14.1Appendix 1 Signatures
Sponsor Signatures
A Phase 1/2 Study  to Eval uate the Safet y, Tolerabi lity, and Pharmacokinet ics of MEDI4736 
in Subjects Wit h Advanced So lid Tumors
I agree to the terms of this protocol and all amendments/administrative changes.
Signature and date: Electronic signature is appended _______
Clinical Development Therapeutic Area Head
One MedImmune Way, Gait hersburg MD, 20878, USA 
Telephone number: 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 171of 220 Template 14.1Signature of Principal Investigator
A Phase 1/2 Study  to Eval uate the Safet y, Tolerabili ty, and Pharmac okinet ics of MEDI4736 
in Subjects Wit h Advanced So lid Tumors
I, the undersigned, have reviewed this protocol and all amendments, and I agree to conduct 
this protocol  in accordance with ethical principles that have their origin in the Declarat ion of 
Helsink i and are consistent with the International Conference on Harmonisat ion (ICH) 
guidelines on Good Clinical Practice (GCP), any  applicable laws and requirements, and any 
condi tions requi red by  a regul atory  authori ty and/or Insti tutional Review Board/Independ ent 
Ethics Co mmit tee (IRB/IEC).
I understand that the protocol may not be modified without written approval of the sponsor. 
All changes to the protocol must be submitted to the applicable regulatory  authori ty and 
IRB/IEC, and must be approved by  the IRB/IE C prior to implementation except when 
necessary  to eliminate immediate hazards to the subjects or when the change(s), as deemed 
by the sponsor, invo lves only logist ical or administrative changes. Documentation of 
IRB/IEC approval must be sent to the sponso r immediately upon receipt.
Signature and date: 
Nam e and ti tle:  
Address including postal code: 
  
Telephone number: 
Site/Center Number (if available)
This document contains confidential information , which should not be copied, referred to, released, or published 
without written approval from MedImmune or AstraZeneca. Investigators are cautioned that the information in 
this protocol may be subject to change and revision.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 172of 220 Template 14.1Appendix 2 Pain Questionnaire
Q1. On a scale ranging fro m 0 to 10, pl ease rate the severit y of your pain in the l ast 24 hours.
0 1 2 3 4 5 6 7 8 9 10
AbsentWorst 
imaginable
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 173of 220 Template 14.1Appendix 3 Patient- reported Outcome Questionnaire EORTC QLQ-
C30

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 174of 220 Template 14.1

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 175of 220 Template 14.1Appendix 4 Patient-reported Outcome Questionnaire EORTC QLQ -
BR23

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 176of 220 Template 14.1

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 177of 220 Template 14.1Appendix 5 Patient- reported Outcome Questionnaire EORTC QLQ-
LC13

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 178of 220 Template 14.1Appendix 6 Patient- reported Outcome Questionnaire EORTC QLQ-
STO22

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 179of 220 Template 14.1Appendix 7 Patient- reported Outcome Questionnaire EORTC QLQ-
PAN26

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 180of 220 Template 14.1

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 181of 220 Template 14.1Appendix 8 Patient- reported Outcome Questionnaire EORTC QLQ-
HCC18

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 182of 220 Template 14.1Appendix 9 Patient-reported Outcome Questionnaire EORTC QLQ-
H&N35
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 183of 220 Template 14.1

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 184of 220 Template 14.1

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 185of 220 Template 14.1Appendix 10 Patient-reported Outcome Questionnaire EORTC QLQ-
BN20

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 186of 220 Template 14.1Appendix 11 Patient-reported Outcome Questionnaire EORTC QLQ-
OV28

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 187of 220 Template 14.1

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 188of 220 Template 14.1Appendix 12 Patient-reported Outcome Questionnaire FA CT-BL
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 189of 220 Template 14.1

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 190of 220 Template 14.1

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 191of 220 Template 14.1

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 192of 220 Template 14.1Appendix 13 Schedule of Study Procedures for Subjects in 
Retreatment of MEDI4736
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 193of 220 Template 14.1Table 1 Schedule of Study Procedures: Rebaseline and Retreat ment Period
EvaluationRebaseline
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 
days)Odd -
numbered 
Doses 
(after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 6 
Weeks 
(Day 43 
± 7 days)After 12 Weeks and 16
Weeks (Days 85 and 
113) Then Every 8 
Weeks (± 7 days)Days Days
1 5 ±110 ± 1 1
Verify  discontinuation criteria 
not metX X
Medical history X
Hepatitis B and C; HIV X
Serum βhCG X
Urine hCG or serum βhCG X X X X
Kit assignment and 
MEDI4736 administrationX X X X
Protocol/Safety Evaluations
Physical examination X X X X X
Vital signs aX X X X X
Postinfusion observation X X X X
Weight X X X X X
AE/SAE assessment X X X X X X X
Concomitant medications X X X X X
ECOG performance status X X X X X
Laboratory Evaluations
Hepatitis B and C viral titers 
(only  HCC subjects with 
hepatitis B or C)X X
Serum chemistry X X X X X
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 194of 220 Template 14.1Table 1 Schedule of Study Procedures: Rebaseline and Retreat ment Period
EvaluationRebaseline
Day -28 to 
Day -1Treatment Period (12 Months)
Dose 1Dose 2 
(± 3 
days)Odd -
numbered 
Doses 
(after 
Dose 1; 
± 3 days)Even -
numbered 
Doses 
(after 
Dose 2; 
± 3 days)After 6 
Weeks 
(Day 43 
± 7 days)After 12 Weeks and 16
Weeks (Days 85 and 
113) Then Every 8 
Weeks (± 7 days)Days Days
1 5 ±110 ± 1 1
Thyroid functio n tests (TSH 
and free T3 and T4)X X X X X
Hematology X X X X X X
Urinaly sis X X X X X
Coagulation parameters X X X X
Flow cytometric analysis -
absolute cell counts, immune 
cell subsets, activation markersX X X X b
Circulating soluble factorscX X X X b
Disease Evaluations
Disease assessment X X X
Optional tumor biopsy (dose -
expansion phase only)c X X
AE = adverse event; βhCG = beta human chorionic gonadotropin; ECOG = Eastern Cooperative Oncology Group; HCC = hepatocellular carcinoma; hCG = 
human chorionic gonadotropin; HIV = human immunodeficiency virus; SAE = serious adverse event; TSH = thyroid -stimulating hormone; UBC = urothelial 
bladder cancer .  
aVital signs within an hour prior to the start of infusion, every 15 minutes (± 5 minutes) during MEDI4736 administration, at the end of infusion 
(+5minutes), and at 30 and 60 minutes (± 5 minutes) postinfusion, followed by a 3- hour (± 15 minutes) period of observation. For subsequent doses (at 
dose levels of 10 mg/kg or less), the 3 -hour observation period will not be required unless a subject experiences an infusion -related reaction or a higher 
dose level is being tested.
bSample collected at Dose 4 only.
cNot required for subjects in the UBC cohort.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 195of 220 Template 14.1Rebaseline
All rebaselining procedures must be performed within 28 days before the first retreatment 
dose of invest igational product (Day  -28 to Day  1), unless otherwise specified. The 
rebaseline evaluations may be carried out over more than one visit. If the subject has 
completed any  safety  laboratory  tests or ECOG assessment within 72 hours of Day  1, they  
will not need to be repeated.
Retreatment Period
If the subject has co mpleted any  safety laboratory  tests or ECOG assessment within 72 hours 
of Day  1, they  will not need to be repeated.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 196of 220 Template 14.1Appendix 14 Schedule of Study Procedures in Follow -up for 
Subjects Who Have Discontinued MEDI4736 Treatment 
Due to Confirmed Progressive Disease
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 197of 220 Template 14.1Table 1 Schedule of Study Procedures: Follow -up for Subjects Who Have Discontinued MEDI4736 
Treatment Due to Confirmed Progressive Disease
EvaluationEnd of 
TreatmentTime Since Last Dose of MEDI4736
Days
(± 3)Months (± 1 week)12 Months and 
Every 
3Months 
(±2 weeks)14 30 2 3 4 6 8 10
Protocol/Safety Evaluations
Pain questionnaire (dose -expansio n phase only) X X
EORTC QLQ -C30 and cancer -specific modules (dose -expansion 
phase only )X X
FACT -BL (UBC subjects only) X X
Physical examination X X
Vital signs X X
Weight X X
Electrocardiogram a,bX X
AE/SAE assessment X X X X X
Concomitant medications X X X
ECOG performance status X X
Subsequent anticancer therapy X X X X X X X
Survival status: phone contact with subjects who refuse to return for 
evaluations and agree to be contactedX X X X X X X
Laboratory Evaluations
Hepatitis B and C viral titers (only HCC subjects with 
hepatitis B or C)X X
Hematology X X
Serum chemistry X X
Thyroid functio n tests (TSH, and free T3 and T4) X X
Coagulation parameters X X
Urinaly sis X X
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 198of 220 Template 14.1Table 1 Schedule of Study Procedures: Follow -up for Subjects Who Have Discontinued MEDI4736 
Treatment Due to Confirmed Progressive Disease
EvaluationEnd of 
TreatmentTime Since Last Dose of MEDI4736
Days
(± 3)Months (± 1 week)12 Months and 
Every 
3Months 
(±2 weeks)14 30 2 3 4 6 8 10
Pharmacokinetic assessment XbXbX
Immunogenicity assessment XbXbX
sPD-L1 concentrationbX X
Flow cytometric analysis -absolute cell counts, immune cell subsets, 
activatio n markersb X
Circulating soluble factorsbX X
PBMC collection (immunodiversity, flow cytometry, or functional 
assessment)b X
Anticancer/testis antigen antibodiesbX
Circulating tumor cells (dose escalation and TNBC for dose 
expansion)X X
miRNA/mRNA analysisbX X
Disease Evaluation
Disease assessment X
AE = adverse event; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EORTC QLQ -C30 = European Organisation for Research and 
Treatment of Cancer quality -of-life questionnaire; FACT -BL = Functional Assessment of Chronic Illness Therapy -bladder; HCC = hepatocellular carcinoma; 
miRNA =micro ribonucleic acid; mRNA = messenger ribonucleic acid; PBMC = peripheral blood mononuclear cell; SAE = serious adverse ev ent; sPD -L1= 
soluble programmed death ligand 1; TNBC = triple negative breast cancer; TSH = thyroid -stimulating hormone; UBC = urothelial bladder cancer. 
aDigital ECGs will be collected at selected sites. All other sites will perform ECGs per their institution’s standard.
bNot required for subjects in the UBC cohort.
MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 199of 220 Template 14.1 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 200of 220 Template 14.1          
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 201of 220 Template 14.1          
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
  
 
 
  
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 202of 220 Template 14.1          
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
                                               
1ASCO Educational Book 2015. Michael Pestow, MD. “Managing Immune Checkpoint Blocking Antibo dy Side Effects”.

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 203of 220 Template 14.1          
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 204of 220 Template 14.1          
 
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               
2ASCO Educational Book 2015. Michael Pestow, MD. “Managing Immune Checkpoint Blocking Antibody Side Effects”.

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 205of 220 Template 14.1          
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
   

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 206of 220 Template 14.1          
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
                                               
 Educational Book 2015. Michael Pestow, MD. “Managing Immune Checkpoint Blocking Antibody Side Effects”.

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 207of 220 Template 14.1          
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 208of 220 Template 14.1          
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
  
 
 
 
                                               
4FDA Liver Guid ance Document 2009 Guidance for Industry: Drug Induced Liver Injury –Premarketing Clinical Evaluation.

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND          
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 210of 220 Template 14.1          
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 211of 220 Template 14.1          
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
testing 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 212of 220 Template 14.1          
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 213of 220 Template 14.1          
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
  
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 214of 220 Template 14.1          
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
or 
autonomic instability

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 215of 220 Template 14.1          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 216of 220 Template 14.1          
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 217of 220 Template 14.1          
 
  
 
 
 
 
 
 
 
 
 
 = acetylcholine esterase; AE = adverse event; ALP = alkaline phosphatase; ALT = alanine transaminase; ASCO = American Society of Clinical 
Oncology; AST = aspartate transaminase; BUN = blood urea nitrogen; CT = computed tomography; CTCAE = Common Terminology for A dverse Events; 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 218of 220 Template 14.1 
 
 
 
 
 
 
  
 
  
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 219of 220 Template 14.1Table 3  
 
 
 
 
 
 

MedImmune Protocol CD -ON-MEDI4736 -1108 Amendment 9
MEDI4736 04Feb2016 ;Final
CONFIDENTIAL AND PROPRIETARY 220of 220 Template 14.1